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ABSTRACT

inTroDucTion
Although GM-CSF and M-CSF contribute to both cell survival and proliferation, they exert distinct actions 
during macrophage development. The lack of M-CSF alters the development of various macrophage 
populations, whereas GM-CSF-deficient mice only exhibit altered maturation of alveolar macrophages. Along 
the same line, both cytokines promote the in vitro differentiation of macrophages with distinct morphology, 
pathogen susceptibility and inflammatory function. GM-CSF drives the generation of monocyte-derived 
macrophages that produce pro-inflammatory cytokines in response to LPS such as IL-12p40 or TNFα and 
display high antigen-presenting and tumoricidal capacity (M1-polarized macrophages). On the other hand, 
M-CSF yields macrophages that release IL-10 in response to pathogens and exhibit high phagocytic and pro-
tumoral activity (M2-polarized macrophages). Accordingly, and based on their respective cytokine and gene 
expression profiles, human macrophages generated in the presence of GM-CSF or M-CSF are considered as 
pro-inflammatory and anti-inflammatory, respectively.
Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from L-tryptophan via a rate-limiting reaction catalyzed 
by two tryptophan hydroxylases encoded by genes with a distinct pattern of expression (TPH1 in periphery, 
TPH2 in brain). Outside the central nervous system, 5-HT is synthesized and released into the circulation by 
enterochromafin cells, and is rapidly taken up and stored by platelets and, to a lesser extent, lymphocytes, 
monocytes and macrophages. Serotonin signals through seven different receptors (5-HTR
1-7
), six of which 
belong to the G protein-coupled superfamily of receptors (5-HTR
1
, 5-HTR2, 5-HTR4, 5-HTR5, 5-HTR6, 
5-RHT
7
). Outside the central nervous system, 5-HT play an important role as a growth factor and as a regulator 
of inflammation and tissue regeneration and repair, modulating cytokine production in a immune cell type-
dependent manner. 
Intravenous immunoglobulin (IVIg) is a preparation of polyclonal and polyspecific immunoglobulins (mostly 
IgG) derived from the plasma of thousands of healthy donors. IVIg exerts a potent immunomodulatory action 
in immunodeficiency syndromes, autoimmune diseases and infectious processes. Besides, previous studies 
have shown that IVIg impairs the metastatic spread of carcinomas in mice, and contributes to tumor regression 
in a number of cancer patients, leading to the proposal of IVIg as a potential anti-metastatic drug. However, 
the molecular basis for the IVIg immunomodulatory action and anti-tumoral effect remains to be completely 
clarified.
resulTs
Considering the importance of macrophage polarization plasticity for inflammatory responses and tissue repair, 
we evaluated whether 5-HT modulates human macrophage polarization. 5-HT inhibited the LPS-induced 
release of pro-inflammatory cytokines without affecting IL-10 production, upregulated the expression of M2 
polarization-associated genes (SERPINB2, THBS1, STAB1, COL23A1) and reduced the expression of M1-
associated genes (INHBA, CCR2, MMP12, SERPINE1, CD1B, ALDH1A2). Whereas only 5-HTR
7
 mediated 
the inhibitory action of 5-HT on the release of proinflammatory cytokines, both 5-HTR2B and 5-HTR7 receptors 
mediated the pro-M2 skewing effect of 5-HT. In fact, blockade of both receptors during in vitro monocyte-to-
macrophage differentiation preferentially modulated the acquisition of M2 polarization markers. 5-HTR2B and 
5-HTR
7
 were found to be preferentially expressed by anti-inflammatory M2 (M-CSF) macrophages and, in the 
case of 5-HTR2B, it was also detected in vivo in liver Kupffer cells and in Tumor-Associated Macrophages. 
Next, we undertook the identification of the 5HT-dependent gene expression profile in human macrophages. 
We report that the 5-HTR
7
-cAMP-PKA axis is responsible for the 5-HT-dependent expression of genes 
encoding growth factors (EREG), growth factor receptors (MET), cytokines (IL1B) and cell surface molecules 
involved in macrophage activation (TREM1), all of which might contribute to the growth-promoting and 
immunomodulatory functions of 5-HT. In addition, we have determined that 5-HT, via ligation of 5-HTR2B, 
regulates the expression of type I IFN-responsive genes (CXCL10, IFI2, IFIT3, TNFSF18), thus defining a 
novel link between 5-HT and the expression of genes that govern antiviral responses by human macrophages. 
Therefore, 5-HT modulates macrophage polarization and contributes to the maintenance of an anti-inflammatory 
state via 5-HTR2B and 5-HTR7, whose identification as functionally-relevant markers for anti-inflammatory/
homeostatic human M2 macrophages suggests their potential therapeutic value in inflammatory pathologies. 
The balance between polarization states contributes to inflammation resolution, and its alteration underlies 
inflammatory pathologies and cancer. Since Intravenous immunoglobulin (IVIg) exerts immunomodulatory 
actions and limits tumor growth and metastasis, we hypothesized that IVIg immunomodulatory activity might 
rely on its ability to alter macrophage polarization. We now demonstrate that IVIg abrogates GM-CSF- or 
M-CSF-driven monocyte polarization, and induces a CD16- and Syk-dependent transcriptional and functional 
polarization switch on monocyte-derived human macrophages. Likewise, the IVIg-promoted polarization switch 
is inhibited or prevented in Cd16-/- or Fcer1g-/- mouse macrophages. Besides, IVIg alters the polarization of 
tumor-associated CD11b+ cells in tumor mouse models, where it also impairs tumor progression in a Cd16- and 
Fcer1g-dependent manner. Therefore, IVIg halts monocyte polarization and exerts a potent M1 re-polarization 
ability on M2 macrophages. These observations link the anti-tumoral and macrophage re-polarization abilities 
of IVIg, and reveal that the IVIg immunomodulatory effects are dependent on the polarization state of the 
responding macrophages. This property of IVIg could be therapeutically useful in pathologies like cancer, 
where immunogenic and pro-inflammatory macrophage functions need to be promoted. 
conclusions
We here demonstrate that 5-HT-receptors 5-HTR2B and 5-HTR7 are preferentially expressed by in vitro M-CSF-
derived macrophages, and that 5-HTR2B is expressed by human macrophages in vivo, including Kupffer cells 
and Tumor Associated Macrophages (TAM). The ability of 5-HT to modulate macrophage polarization towards 
to an M2-like phenotype is mediated by 5-HTR2B and 5-HTR7, while its ability to inhibit the LPS-induced 
secretion of pro-inflammatory cytokines is via ligation of 5-HTR
7
. The gene expression profile observed in 
macrophages treated with 5-HT is dependent on the 5-HTR
7
/cAMP/PKA axis, while the activation of 5-HTR2B 
by BW723C86 promotes the expression of type I IFN-regulated genes.
In the case of IVIg, we demonstrate that IVIg reduces the LPS-induced secretion of pro-inflammatory cytokines 
from M1 macrophages without significantly affecting the transcriptomic polarization state. Meanwhile, on M2 
macrophages, IVIg switches the phenotypic and functional polarization of human and murine M2 macrophages 
towards the acquisition of an M1-like state. This switch is partly dependent on CD16 on human macrophages, 
and Fc receptor-mediated in murine macrophages. Since the M2-to-M1 switch might have an important role 
on inhibiting tumor progression, we demonstrate that IVIg treatment triggers an increase in pro-inflammatory 
gene markers (Such as Inhba, Ccr7, Egln3, Cd11c, Nos2) in intra-tumoral macrophages, as well as a change 
in the basal level of cytokines (such as Tnfa and Ccl2) in the peripheral blood of tumor-bearing animals. We 
further demonstrate that IVIg exerts an anti-tumoral activity in murine models of cancer, an effect that is 
dependent on macrophages.

RESUMEN

inTroDucción
Tanto el GM-CSF como el M-CSF contribuyen a la supervivencia y a la proliferación celular. Sin embargo, 
ejercen acciones diferentes durante la polarización de los macrófagos. La ausencia de M-CSF altera el desa-
rrollo de diversas poblaciones de macrófagos, mientras que en los ratones deficientes en GM-CSF sólo se ve 
afectada la maduración de los macrófagos alveolares. Ambas citoquinas promueven la diferenciación in vitro 
de macrófagos dando lugar a dos poblaciones con una morfología, respuesta a patógenos y función inflama-
toria distintas. Mientras que el GM-CSF promueve la generación de macrófagos “clásicos”, o M1 (que se 
caracterizan por ser productores de citoquinas pro-inflamatorias en respuesta a LPS, tales como IL - 12p40 o 
TNFα, además de por una alta capacidad presentadora de antígeno y actividad tumoricida), el M-CSF produce 
macrófagos “alternativos”, o M2, que liberan IL-10 en respuesta a agentes patógenos, poseen una alta capaci-
dad fagocítica y actividad pro-tumoral. De esta manera, y en base a sus respectivos perfiles de producción de 
citoquinas y la diferente expresión génica, los macrófagos humanos generados en presencia de GM-CSF (M1) 
o M-CSF (M2) se consideran pro- o anti-inflamatorios, respectivamente.
La serotonina (5-hidroxitriptamina, 5-HT) se sintetiza a partir de L-triptófano a través de una reacción cata-
lizada por dos triptófano-hidroxilasas (TPH) que se encuentran diferencialmente expresadas en el organismo 
(TPH1 en periferia, TPH2 en el cerebro). Fuera del sistema nervioso central, 5-HT se sintetiza y libera en la 
circulación por células enterocromafinas del intestino. Posteriormente sufre una rápida recaptura por las pla-
quetas, donde pasará a ser almacenada. En menor medida, linfocitos, monocitos y macrófagos también pueden 
almacenar y captar la serotonina circulante. Existen siete tipos de receptores de serotonina (5-HTR
1-7
), seis 
de los cuales pertenecen a la superfamilia de receptores acoplados a proteína G (5-HTR
1
, 5-HTR2, 5-HTR4, 
5-HTR5, 5-HTR6, 5-RHT7). Fuera del sistema nervioso central, 5-HT juega un papel importante como factor 
de crecimiento, así como de regeneración y reparación de tejidos. La 5-HT es capaz de actuar como un regu-
lador de la inflamación, modulando la producción de citoquinas en células del sistema inmune de una forma 
dependiente del tipo celular. 
Las inmunoglobulinas intravenosas (IVIg) constituyen una preparación de inmunoglobulinas policlonales y 
poliespecíficas (principalmente IgG) derivada a partir del plasma de miles de donantes sanos. IVIg ejerce una 
acción inmunomoduladora potente en síndromes de inmunodeficiencia, enfermedades autoinmunes y procesos 
infecciosos. Además, estudios anteriores han demostrado que IVIg inhibe la diseminación metastásica en car-
cinomas de ratón, y contribuye a la regresión tumoral en pacientes con cáncer, lo que ha llevado a proponer las 
inmunoglobulinas como un fármaco potencialmente anti-metastásico. A pesar de esto, las bases moleculares 
de la acción inmunomoduladora, así como el mecanismo de su efecto anti-tumoral, aún no se han aclarado por 
completo. 
resulTaDos
Dada la importancia de la plasticidad de polarización de los macrófagos para las respuestas inflamatorias, así 
como para la reparación de tejidos, evaluamos si 5-HT modula la polarización de macrófagos humanos. En 
este trabajo se muestra la presencia de los receptores 5-HTR2B y 5-HTR7 diferencialmente expresados en ma-
crófagos M2 generados in vitro. Además, 5-HTR2B fue detectado in vivo en células de Kupffer del hígado y en 
los macrófagos asociados a tumores (TAM).
También observamos que la 5-HT inhibió la liberación de citoquinas pro-inflamatorias (IL-12p40 y TNFα) en 
respuesta a LPS -sin afectar a la producción de IL-10- a través de la activación de 5-HTR
7
. Además, indujo un 
aumento en la expresión de genes asociados a polarización M2 (SERPINB2, THBS1, STAB1, COL23A1) y una 
reducción de expresión de genes asociados a estado de polarización M1 (INHBA, CCR2, MMP12, SERPINE1, 
CD1b, ALDH1A2) mediada por ambos receptores 5-HTR2B y 5-HTR7. De hecho, el bloqueo farmacológico de 
ambos receptores durante la diferenciación in vitro de monocitos a macrófagos en presencia de M-CSF provo-
có una alteración en la adquisición de genes marcadores de polarización M2. 
A continuación, se analizó el perfil de la expresión génica dependiente de 5-HT en los macrófagos humanos. 
En este informe describimos como el eje 5-HTR
7
 -AMPc-PKA es mayoritariamente responsable de la expre-
sión de genes dependientes de 5-HT entre los que se incluyen el factor de crecimiento (EREG) , receptores del 
factor de crecimiento de hepatocitos (MET) , citoquinas (IL1B) y moléculas de la superficie celular involucra-
das en la activación de macrófagos (TREM1), que podrían contribuir a la promoción del crecimiento y las fun-
ciones inmunomoduladoras de 5-HT. Además, hemos determinado que 5-HT, a través del receptor 5-HTR2B, 
regula la expresión de los genes sensibles a IFN de tipo I (CXCL10 , IFI2 , IFIT3 , TNFSF18 ) , definiendo 
de este modo un nuevo enlace entre la serotonina y la inducción de genes encargados de promover respuestas 
antivirales en los macrófagos humanos. Por lo tanto, 5-HT modula la polarización de macrófagos y contribuye 
al mantenimiento de un estado anti- inflamatorio a través de 5-HTR2B y 5-HTR7. La identificación de estos 
receptores como marcadores funcionalmente relevantes para macrófagos humanos M2 (anti-inflamatorios/
homeostáticos) les confiere un potencial valor terapéutico en patologías inflamatorias. 
El equilibrio entre los estados de polarización contribuye a la resolución de la inflamación, y alteraciones en 
este equiibrio pueden desembocar en patologías inflamatorias o cáncer. Puesto que IVIg ejerce acciones in-
munomoduladoras y limita el crecimiento tumoral y las metástasis, nuestra hipótesis fue que dichas acciones 
podrían deberse a cambios en el estado de polarización  de los macrófagos. En este trabajo demostramos cómo 
IVIg es capaz de inhibir ciertas actividades de los macrófagos M1, (como la secreción de citoquinas inflamato-
rias), mientras que en macrófagos M2, IVIg produce un cambio de polarización de un estado anti-inflamatorio 
(M2)  a uno pro-inflamatorio (M1), tanto a nivel funcional como génico. Esta re-polarización de macrófagos 
es mediada parcialmente en humanos por CD16 y SyK, mientras que en macrófagos de ratón es dependiente 
también de CD-16 y de Fcer1g. Además, IVIg inhibe el crecimiento tumoral en modelos de ratón y altera la 
polarización de las células CD11b+  asociadas a tumores, de manera dependiente de macrófagos y los recepto-
res CD16 /Fcer1g. 
conclusiones
Con este trabajo demostramos que los receptores de serotonina 5-HTR2B y 5-HTR7 se expresan preferen-
cialmente en macrófagos generados in vitro en presencia de M-CSF, y que el receptor 5-HTR2B se encuentra 
además en macrófagos humanos in vivo, incluyendo las células de Kupffer y macrófagos asociados a tumores 
(TAM). 
La capacidad de 5-HT para modular la polarización de macrófagos hacia un fenotipo M2 está mediada por 
5-HTR2B y 5-HTR7, mientras que su capacidad para inhibir la secreción de citoquinas pro-inflamatorias indu-
cida por LPS está regulada por 5-HTR
7
 . Además, el perfil de expresión génica observado en los macrófagos 
tratados con 5-HT es principalmente dependiente del eje 5-HTR
7
/cAMP/PKA, mientras que la activación de 
5-HTR2B por BW723C86 promueve la expresión de genes regulados de tipo I-IFN.
En el caso de IVIg, demostramos que reduce la secreción de citoquinas pro-inflamatorias inducida por LPS en 
los macrófagos M1, sin afectar significativamente el estado de polarización transcriptómica. Sin embargo, en 
los macrófagos M2, IVIg cambia las características fenotípicas y funcionales de los macrófagos (M2 humanos 
y murinos) hacia la adquisición de un estado tipo M1. Esta re-polarización es parcialmente dependiente de 
CD16 en macrófagos humanos, y de CD16 y otros receptores asociados a Fcer1g en los macrófagos de ratón. 
La re-polarización M2-a-M1 podría tener un papel importante en la inhibición de la progresión tumoral. De 
hecho, nuestros resultados demuestran que el tratamiento con IVIg provoca un aumento de marcadores génicos 
asociados a macrófagos M1, (pro-inflamatorios y anti-tumorales), (tales como INHBA, CCR7, EGLN3, CD11c, 
NOS2) en macrófagos intra-tumorales , así como un cambio en el nivel basal de citoquinas (tales como TNFa y 
Ccl2) en la sangre periférica de los animales en los que se les indujo un tumor. Además, demostramos que IVIg 
ejerce una actividad anti-tumoral en modelos de ratón de cáncer, un efecto que depende casi exclusivamente 
de los macrófagos.
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INTRODUCTION
1
2
1. Macrophages 
Macrophages are bone marrow-derived cells and, together with neutrophils, constitute the first line of 
resistance against pathogens, for which they provide a fast and unspecific response (innate immunity). 
Besides, and together with dendritic cells, macrophages are essential for the coordinated orchestration of 
innate and adaptive immune responses. Since the latest 1800, when Metchnikoff described the existence of 
phagocytes (1), numerous studies have addressed their developmental origin as well as their phenotypic and 
functional diversity (fig.1). Although still a matter of debate, macrophages can differentiate from peripheral 
blood monocytes and, once within tissues, become effector cells whose huge functional plasticity allows 
them to play essential roles in physio-pathological processes as diverse as pathogen clearance, tissue repair, 
angiogenesis and tumour progression and metastasis. (2). The functional plasticity of macrophages arises 
from their ability to respond to endogenous and non-self stimuli while adapting to the surrounding tissue 
environment (3-6), and explains both the existence of tissue-specific macrophages (microglia, osteoclasts, 
Kupffer cells, …) and the wide variety (continuum) of macrophage activation states (polarization).
Figure 1. Timeline: advances on macrophage biological research. Figure depicts some of the most relevant findings in the 
field.
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1.1 Macrophage polariZaTion
In response to microbe-derived factors, cytokines from Th1 cells (e.g. IFNγ) or other cytokines such as GM-
CSF or TNFα, macrophages acquire pro-inflammatory, bactericidal, tumor suppressive and immunogenic 
activities, in a process commonly referred to as “classic” or M1 polarization, and whose hallmark is the 
ability to release large amounts of IL-12/IL-23, reactive nitrogen and oxygen intermediates, and expression 
Figure 2. Different cytokines that induce macrophage polarization.
of Th1-cell attracting chemokines (2, 4) (fig.2). M1 macrophages also drive the polarization and recruitment 
of Th1 cells through the expression of cytokines and chemokines like IL-12, CXCL9 and CXCL10, thereby 
amplifying Type-1 immune responses (2). Conversely, Th2-derived cytokines like IL-4, IL-13, IL-10, TGFβ 
or M-CSF, as well as glucocorticoids, promote the acquisition of anti-inflammatory, scavenging, tumor-
promoting, tissue repair and pro-angiogenic functions, all of which are grouped under the terms “alternative” 
or M2 polarization, that endows them with the ability to produce high levels of IL-10 (2, 5-8) (fig.2). Therefore, 
the classical M1 and M2 macrophage polarization states are just two extremes of a wide range of functionally 
distinct macrophages activation states (3-6) (fig.3). 
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1.2 Macrophages in healTh anD Dissease
1.2.1 Macrophages in hoMeosTasis
Under homeostatic in vivo conditions, tissue-resident macrophages also exhibit a wide variety of polarization 
states, which are ultimately determined by the extracellular environment and the surrounding cell types. 
Thus, macrophages exhibit tissue-specific phenotypes and functions under homeostatic conditions. As 
representative examples, bone macrophages (osteoclasts) display potent bone-degrading functions, brain 
macrophages (microglia) (9) contribute to development of neural circuitry and modulation of angiogenesis and 
fluid balance in the brain (10), and liver macrophages (Kupffer cells) are primarily specialized in scavenging 
(11).  Due to their localization in liver sinusoids, Kupffer cells come in contact with antigens absorbed via the 
gastrointestinal tract and, therefore, play a crucial role in identifying and detoxifying bacteria, endotoxins 
(12), cell debris, apoptotic cells and immune complexes as well as toxic agents such as ethanol (13).
Regarding basal polarization, the existence of IL-10-producing (M2-polarized) macrophages has already been 
demonstrated in lungs (14) and gut (15, 16), tissues that are continuously exposed to exogenous and potentially 
damaging substances. Gut macrophages function in host defence through the recognition, phagocytosis, and 
killing of microorganisms (17, 18), and display a weak pro-inflammatory cytokine profile. The same applies for 
lung macrophages, that constitutively secrete IL-10 and whose ability for pro-inflammatory cytokine production 
is low (14). Other tissues also appear to preferentially contain M2-skewed macrophages in homeostasis. Brain 
Figure 3. Colour wheel of 
macrophage activation. Adapted 
from Mossser and Edwars  (3). 
On the top, linear scale of the 
two macrophage designations 
diferentation M1 and M2. On 
the bottom,  the color wheel 
that  shows the continum of 
macrophages polarization.
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microglia cells are dependent on M-CSFR signalling and also present an M2-like phenotype (9). In the case 
of liver, most Kupffer cells (80–90% of tissue macrophages of the body) (19) are also M-CSF-dependent (20), 
thus explaining their M2-skewed polarization state. Peritoneal fluid also contains large amounts of M-CSF 
(21), that ultimately results in peritoneal macrophages acquiring an M2-like phenotype (21, 22)  characterized 
by a low capacity for T-cell activation and high IL-10 secretion levels after stimulation (22). Taken together, 
these observations indicate that macrophages display M2-associated effectors functions in various tissues 
under basal conditions, implying that the control of macrophage polarization is of fundamental importance for 
tissue homeostasis. 
1.2.2 Macrophages in inFlaMMaTion, resoluTion anD Tissue repair
It is along an inflammatory response where the physio-pathological importance of fine-tuning macrophage 
polarization is most easily understood. Thus, M1-polarized macrophages predominate at the initial stages 
of an inflammatory response, when cytotoxic and tissue-damaging activities are more robust. Later, M2-
type macrophages increase in number, as a means to promote resolution of inflammation (by limiting Th1-
dependent responses and promoting Th2-cell recruitment and amplifying Th2-responses) (23). Therefore, a 
critical issue for inflammation resolution is a change in the polarization state (“polarization switch”) of the 
macrophages that are recruited towards inflamed tissues. Such a switch was elegantly demonstrated in the case 
of peritoneal infection by L. monocytogenes, where the initial influx of pro-inflammatory M1 monocytes is 
followed (after 6-8 hours) by a potent increase in “resolving” M2 monocytes (24). In fact, and in the resolution-
phase, macrophages express a unique mixed M1/M2 phenotype, with cAMP being essential to restrain M1 
activation (25). However, it remains to be determined whether pro-inflammatory macrophages within inflamed 
tissues are later converted into M2 macrophages. In this regard, it is generally accepted that such an M1-
to-M2 switch takes place during inflammation, and that the capture of apoptotic cells is the primary stimulus 
for such a polarization switch. This idea has gained considerable support after the studies of Brüne´s group, 
who demonstrated that apoptotic cell-derived Sphingosine-1-Phosphate (S1P) triggers the expression of Heme 
Oxygenase 1 (HO1) and pushes macrophages towards the M2/anti-inflammatory polarization state (26). 
Regardless of the polarization switch-triggering event, the sequential occurrence of both polarization states 
is required for adequate resolution of inflammation and return to tissue homeostasis. Some representative 
examples are commented below.
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In animal models of ischemic heart disease, the M1-to-M2 dynamic change in macrophage recruitment has 
been observed at an early inflammatory phase. After heart ischemia, macrophages primarily exhibit a “classical 
activation” (M1) phenotype, exemplified by their high expression of TNF-α, whereas their phenotype shifts 
into an “alternatively activated” phenotype (M2) (high Arginase 1 and 2 expression) during the transition 
from inflammation to scar tissue formation (27). Similarly, after spinal cord injury, activated microglia rapidly 
release pro-inflammatory cytokines, which contribute to the influx of neutrophils and macrophages from the 
circulation (28).  However, the resolution phase is characterized by the influx of macrophages that exhibit anti-
inflammatory and tissue-repair properties (M2), and whose injection promotes full recovery (29). 
All current evidences indicate that the misbalance of the M1/M2 polarization equilibrium, or an inadequate 
switch in the macrophage polarization state in inflamed tissues, invariably leads to chronic inflammatory 
pathologies that include tumor development, autoimmune diseases (multiple sclerosis), modulation of T cell–
mediated nervous system autoimmune disease (30), fat mass development, obesity-associated cardiovascular 
pathologies and insulin resistance (31-33). Human chronic venous ulcers (CVUs) represent a good example 
where macrophages fail to resolve a chronic inflammatory condition probably because of the failure to in 
the M1-to-M2 switch (34). In CVUs, iron overload appears to sustain M1 polarization, thus leading to ROS-
mediated DNA damage, fibroblast cellular senescence and defective tissue repair (34). Obesity-associated 
insulin resistance, diabetes and metabolic syndrome are also sustained by a chronic subclinical inflammation. 
In obesity, adipocytes release mediators such as CCL2, TNFα or free fatty acids that promote the recruitment 
and subsequent M1-like activation of Adipose Tissue Macrophages (ATM) (35). The activation of these 
macrophages by inflammatory cytokines and saturated fatty acids provokes the inhibition of the insulin 
signalling pathway by JNK, IKK and IRS, the activation of AP-1 and NF-κB (further increasing pro-
inflammatory cytokine secretion) and, consequently, leads to an insulin resistance(31, 36). ATMs from obese 
mice and human exhibit an M1-like profile, with up-regulation of TNFα and Nos2. In contrast, normal ATMs 
express high levels of M2-associated genes, including IL-10 and Arg1(32).
 
Tumor progression probably constitutes the paradigmatic example of the pathological consequences of de-
regulated macrophage polarization (37). Macrophages play a key role in cancer-related inflammation, and their 
presence usually correlates with a poor outcome. The link between infiltration by Tumor Associated Macrophages 
(TAMs) and a bad prognosis extends to the case of Classic Hodgkin’s Lymphoma (38), colon cancer (39), 
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breast cancer (40), hepatocellular carcinoma (41), melanoma (42) and many other tumors. In fact, the tumor 
environment has a key role in determining the immune suppressive capacity of TAMs (fig.4). Monocytes from 
peripheral blood are recruited into the tumor by M-CSF and chemokines like CCL2 and CXCL12. At the early 
stages of tumor-promoted inflammation, macrophages secrete pro-inflammatory cytokines (TNFα, IL-12, IL-1 
and IL-6), which might reduce tumour growth and progression (43, 44). However, this anti-tumoral behaviour 
turns immunosuppressive and pro-tumoral as cancer progresses (45). This is so because tumor and stromal 
cells contribute to the modulation of macrophage effector functions (polarization) by secreting M-CSF, IL-10, 
IL-6 and VEGF (46), all of which drive the acquisition of M2-associated properties. Tumor-recruited myeloid 
cells are also responsible for the expression of M2-promoting factors that commit TAMs to a pro-tumoral 
phenotype, with production of IL-4, IL-13 (mainly produced by tumour-infiltrating Th2 lymphocytes (40)), 
CCL2 and IL-6, all of which further favour tumor survival and M2 polarization within the tumour environment 
Figure 4. Factors that promote the polarization of TAMs towards a pro-tumor phenotype (a–c) can be subdivided into those 
derived from the immune system, actively produced by tumor cells, or resulting from tissue stress. These signals all direct the 
pro-tumor functions of TAMs (d–f) including immune suppression, tumor cell dissemination, and promoting angiogenesis. 
(Adapted from Ruffell et al. (51))
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(47). In this scenario, TAMs block cancer-induced immune responses, eliminate or switch M1 macrophages, 
limit innate immune responses by impairing NK cells and T cells activation, and display defective production 
of inflammatory cytokines. Moreover, they produce high levels of IL-10, that drives Treg generation (45, 
48-51). Therefore, macrophages are capable of destroying cancer cells and promoting anti-tumoral immune 
responses through their antigen-presentation capacity, but might also contribute to tumor progression via 
immune (37) and non-immune mechanisms (51) (promotion of angiogenesis (52), facilitation of tumor cell 
invasion and metastasis (53), protection of tumor cells from chemotherapy-induced apoptosis (54)) (fig.4). 
As a consequence, TAM polarization represents a critical process in tumor development, and has become the 
target for the development of anti-tumoral therapeutic strategies. 
1.3 Macrophage polariZaTion MarKers
A number of well-known markers are currently used to define the polarization state of mouse macrophages. 
Murine M1 “classically activated” (exposed to LPS and/or IFNγ) macrophages are usually identified by their 
high expression of NOS2, CD11c or CCR7 (55-57). On the other hand, the IL-4- dependent M2 macrophages 
polarization is usually defined through the expression of Arginase-1, macrophage mannose receptor (CD206), 
the chitinase-like Ym1 molecule, and Fizz-1 (found in inflammatory zone-1) (57). The opposite expression of 
NOS2 and Arginase-1 has become the paradigmatic best-established difference between classical and alternative 
mouse macrophages in terms of metabolism: while M1 macrophages use arginine to catabolize bactericidal 
nitric oxide through the stimulation of inducible nitric oxide synthase (NOS2), Arginase-1-expressing M2 
macrophages produce the polyamine precursors urea and ornithine, needed for collagen synthesis and cell 
proliferation, respectively (58). 
There are, however, other markers that distinguish M1 and M2 metabolism. Regarding lipid metabolism, 
M2 macrophages, but not M1 macrophages, show a significant up-regulation of fatty-acid uptake and fatty 
acid oxidation (58). This difference has been correlated with the opposite expression of COX-2 and COX-1, 
considered as M1 and M2 markers, respectively (59). In addition, iron metabolism is differentially regulated 
in M1 and M2 macrophages. M1 macrophages are set to an iron-retention phenotype defined as CD163Low 
(haemoglobin/haptoglobin receptor), FerritinHigh (involved in iron storage) and FerroportinLow (that mediates 
iron export), a profile that agrees with their bacteriostatic and tumoristatic activity. By contrast, M2 macrophages 
exhibit an opposite phenotype, as they are set to an iron-export mode that supports immune-regulation, matrix 
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remodelling and cell proliferation (60, 61). 
In the case of the glucose metabolism, M1 macrophages (activated with LPS or IFNγ) exhibit high expression 
of 6-Phospho-fructo-2-kinase (PKF2) and elevated glycolysis, probably to overcome their high-energy 
requirements and to override potentially hypoxic microenvironments 13,15. Along this line, chronic activation 
of bone marrow derived-macrophages increases intracellular succinate, that stabilizes HIF-1α and synergizes 
with Toll-like receptors for promoting an increment of glycolysis (62). On the contrary, M2-macrophages 
(activated with IL-4) display a stronger oxidative-glucose metabolism and a potent beta-oxidation in lipid 
metabolism 1,11. The contribution of the intrinsic glucose metabolism to macrophage polarization has been 
illustrated by the involvement of CARKL, an enzyme of the pentose phosphate pathway, in promotion of M2-
polarization (63). Therefore, glucose metabolism regulation is linked and determines macrophage polarization 
(62, 63).
The search for human macrophage polarization markers has revealed “difficulties of mouse-to-human 
extrapolation” (4). The comparison of human and mouse macrophages by in vitro studies demonstrated that 
only 26% of the polarization-associated genes are conserved between both species (56), claiming for the need 
of human macrophage polarization markers with potential diagnostic and therapeutic value. Numerous groups, 
including our own, have addressed the identification of such polarization markers in the last decade through 
transcriptional profiling of ex vivo-isolated macrophage populations and monocyte-derived macrophages 
generated in vitro under the influence of various M1 and M2-polarizing cytokines (IFNγ, GM-CSF, LPS, IL-4, 
M-CSF, IL-10, etc.) (3, 4, 37, 64). However, although the markers between human and mouse macrophages are 
not always comparable, the functions attributed to M1o M2 macrophages are usually common in both systems. 
A recent study by Hamilton´s group has reported the comparison of the gene expression profiles of human 
and murine M1 (GM-CSF) and M2 (M-CSF) macrophages generated from monocytes or bone marrow cells, 
respectively. Their study indicates that genes such as CCL1, CCL5, CCL22, CCR6, CSF1, FLT1 and ADORA1 
are more highly expressed in human M1 macrophages, while IL-10, THBS1, ALK, DLL1, IGF-1, ADRB2 and 
MSR1 are preferentially expressed by M2 macrophages (56). Moreover, other groups (including ours) have 
reported that CD163, LXR, CD200R, CD36, c-Myc, FRβ, HO1 and DC-SIGN are preferentially expressed by 
human anti-inflammatory M2 macrophages as well as by tumour-associated macrophages (TAM) (2, 64-70), 
and that CD80, Activin A, PHD3, IRF5 and IRF4 are preferentially expressed in human M1 macrophages (56, 
69, 71-73). 
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1.4 FacTors anD signaling paThWays ThaT unDerlie Macrophage 
polariZaTion
A network of signalling molecules, transcription factors, epigenetic mechanisms and post-transcriptional 
regulators underlies the existence of distinct M1 and M2 polarization/activation states (fig.5). 
Figure 5. Signalling pathways that underlie macrophage polarization
- NFκB signalling g pathway
In M1 polarization, macrophages respond to TLR ligands (like LPS) by activating the NF-κB transcription 
factor family (RelA/p65, c-Rel, RelB, p50 and p52) (74). By contrast, the NF-κB signalling pathway seems 
to be absent or defective in M2 polarization, where NF-κB p50 homodimers are enhanced (75-77). NFκB p50 
homodimers enhance IL-10 gene transcription, inhibit the NFκB-dependent production of IFNβ and negatively 
regulate STAT1 activity, whereas their absence leads to increased levels of TNFα and IL-12 (77, 78). Therefore, 
NFκB p50 homodimers impair M1 macrophage-mediated responses (75) and promote a defective expression 
of inflammatory NFκB-dependent cytokines and, consequently, an IL-10high/IL-12low M2-like profile (76, 
77).
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- Interferon-related pathways: IRF and STAT signalling 
The TRIF/IRF3/INFβ/STAT1 axis is also involved in macrophage polarization (35, 79). Stimulation of the 
IFNγ receptor triggers a JAK-mediated tyrosine phosphorylation and the subsequent dimerization of STAT1, 
which promotes the expression of “classical” M1 genes such as NOS2, MHC class II transactivator (CIITA), 
IL-12 and TNFα, among others (80). Although TAMs are considered to display an M2-skewed phenotype 
and present low expression of M1-asociated genes, high levels of expression and activation of IRF3 and 
STAT1 has been found in some TAMs (76), suggesting that the IRF3/STAT1 axis might exert a dual role in 
macrophage polarization. Several studies have also suggested that the expression of IL-10, which characterizes 
M2 macrophages and is required to avoid damage caused by an excess of pro-inflammatory cytokines, can 
be promoted in some settings by the TRIF/IRF3/INFβ/STAT1 pathway, thus highlighting the critical role of 
STAT1 in both initiating and limiting M1 macrophage polarization (76, 81). 
The contribution of IRF5 to human M1 polarization is somewhat controversial. Whereas Udalova´s group 
provided evidence for IRF5 as required for the acquisition of M1-associated genes and functions (73), others 
have found no evidence for such a role and propose that, instead, IRF4 might play that function (56). In fact, 
epigenetic studies have demonstrated the participation of the histone demethylase JMJD3 in the increased 
transcription of M2-associated genes triggered by IL-4, M-CSF or chitin, and that JMJD3 inhibits the IRF4-
mediated transcription of typical M1-associated genes (82). Recently, it has been demonstrated that SOCS are 
also essential controllers of macrophage polarization, and that SOCS proteins regulate inflammatory responses. 
The use of SOCS2- and SOCS3-deficient macrophages have led to the finding that SOCS2 depletion causes 
STAT1 activation and enrichment in M1-like macrophages. Conversely, the lack of SOCS3 leads to enhanced 
STAT6 phosphorylation and accumulation of M2-like macrophages (83). 
- IL-4Rα/ JAK-STAT6/ PPAR pathway
The role of IL-4 and IL-13-mediated signalling in M2 polarization is well established both in vivo and in vitro 
(84). IL-4Rα signals through a JAK-STAT6 pathway, and many of the M2-associated gene markers, such as 
Arg1 or Cd206, are regulated by this signalling route. Along the same line, the antagonism between STAT1 
and STAT6 has been described for the Th1 and Th2 cell polarization induced by INFγ and IL-4, respectively 
(35, 80).  STAT6 has been described to induce PPARδ in adipose tissue macrophages (ATM), driving them 
towards M2 polarization (85). Recent studies have shown that M2 macrophage polarization also appears to 
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be dependent on PPARγ  and that Pparg-deficient macrophages display insulin resistance (86, 87). PPARγ is a 
master regulator of lipid metabolism in macrophages, as it inhibits pro-inflammatory gene expression through 
several mechanism, including trans-repression of NF-κB (80). At present, the collaboration of STAT6 and 
PPARγ for M2 macrophage polarization in murine macrophages is widely accepted (88).
 - IL-10/ MAF and STAT3 pathway
Macrophage polarization in response to IL-10 is primarily dependent on c-MAF, STAT3 and the activation 
of NF-κB p50 homodimers. The expression of IL-10, a essential cytokine for resolution of inflammation, is 
regulated by PU-1, STAT3 and c-MAF 91,92. 
- CREB and C/EBP 
Other important factors involved in macrophage polarization are the CREB and C/EBP families of transcription 
factors. Both STAT6 and C/EBPβ are essential for Arg1 expression in macrophages in a stimulus-specific 
manner (Il-4/IL13 and TLR ligands, respectively). C/EBPβ also regulates the expression of M2-associated 
genes, since the CREB-dependent activation of the CEBPβ promoter is needed for the expression of M2 
markers like Arginase-1, IL-10 (89-91) and SERPINB2 (92). 
The identity of the signalling pathways implicated in the GM-CSF-promoted M1-polarization or the M-CSF-
mediated M2-like polarization are still currently unclear 6,7,39. Recent studies have demonstrated the 
implication of C/EBPδ in the GM-CSF-prompted M1-polarization on bone marrow derived macrophages, 
where it inhibits M2 polarization (93). In the case of the M-CSF-induced polarization, it has been propossed 
that CREB might play a role in the process, since it contributes to IL-10 expression and because M-CSF-
initiated signaling induces CREB phosphorylation (92). 
- Signalling pathways activated in TAM 
Like M2 macrophages, TAMs express high levels of M2-related genes such as CD163 (94-96). TAM 
polarization has been dissected at the transcriptional level in several models, including murine fibrosarcoma 
and human ovarian carcinoma (75). In those cases, TAMs display a defective M1 polarization caused by 
the nuclear accumulation of NF-κB p50 homodimers, which ultimately impair anti-tumoral responses and 
promote tumour growth (75, 76). On the other hand, murine fibrosarcoma-derived TAMs exhibit high levels of 
STAT1(76). In fact, STAT transcription factors are key players in the immunosuppressive phenotype of TAMs. 
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STAT6 appears to contribute to the pro-tumoral action of TAMs, since STAT6 KO macrophages display an 
M1 phenotype (97). STAT3 also importantly contributes to tumor survival and dissemination (98). In tumor-
associated myeloid cells, STAT3 exhibits a pro-tumoral action by inducing IL-10, IL-23/p19 and inhibiting 
IL12/p35 expression (98, 99). Altogether, these observations point to STAT3 as a potential therapeutic target 
in cancer, as demonstrated in the case of human squamous cell carcinoma (100) and animal models of glioma 
(101) and melanoma (102).
With all of these signalling pathways acting together, the stimulation of an M2-to-M1 switch in TAMs would 
be a desirable strategy to improve anti-tumoral therapies. Thus, it has been described that TLR9-mediated 
activation of NFκB in combination with anti-IL-10 treatment promotes a switch in the polarization state of 
TAMs in a mouse mammary carcinoma model (103). Moreover, the fact that the M1-to-M2 polarization in 
TAMs might be driven by apoptotic-derived molecules (like S1P) within the tumour environment (104, 105) 
is in agreement with the reduced tumor progression detected after prevention of apoptotic cell recognition by 
macrophages (106). These and other pathways that might control the M1-to-M2 switch in TAMs are indicated 
in Figure 4. 
An updated scheme illustrating all the factors whose involvement in macrophage polarization has been 
demonstrated or suggested is shown in Figure 6.
Figure 6.  Other factors involved on macrophage polarization
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2. seroTonin
The monoamine serotonin (5-hydroxytryptamine, 5-HT) has been known for more than a century (fig.7). 
However, although its role as neurotransmitter is well-established, evidences for its role in many fundamental 
aspects of physiology and behavior (mood, aggression, sleep, appetite, pain sensation, bone mass, tissue 
regeneration, platelet coagulation, gastrointestinal function and thermo-regulation) (107-110) are still being 
gathered. Approximately 2% of the tryptophan present in the diet is used for the synthesis of serotonin. 
Figure 7. Timeline: advances on serotonin discovery and research.
The rate-limiting enzyme involved in the synthesis of 5-HT is tryptophan hydroxylase (TPH), which converts 
L-Tryptophan to 5-hydroxy-1-Tryptophan (fig. 8) through oxidation at position 5 of the pyrrole ring. A later 
decarboxylation mediated by 5-OH-tryptamine decarboxylase leads to 5-HT. Importantly, there are two 
isoforms of TPH: TPH-1, which is expressed in the pineal gland and peripheral tissues, and TPH-2, which 
is exclusively expressed in the dorsal raphe nucleus of the brain (109). TPH-1 provides 5-HT to non-neural 
cells whereas TPH-2 supplies 5-HT to the brain and mesenteric plexus, thus establishing the existence of two 
independent serotonin systems (brain and periphery), and whose independency is further supported by the 
hydrophobic nature of the molecule, that impairs crossing of the blood-brain barrier (111). However, it is still 
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currently unclear whether these two serotonin systems (brain, periphery) are completely independent, and 
some evidences suggest a certain level of communication between them.
Figure 8. serotonin Synthesis
In the brain, 5-HT is one of the most widely distributed 
neurotransmitters. Serotoninergic fibers originate in 
the brain raphe nuclei and their synaptic connections, 
where 5-HT mediates circadian rhythms and endocrine-
related physiologic functions such as food intake, sleep, 
reproductive activity, cognition mood and anxiety (107). 
However, almost 95% of the whole body amounts of 
5-HT is present outside the central nervous system, as 
it is produced by enterochromaffin cells (EC) of the gut 
(107). Once released from EC, 5-HT is taken up and 
primarily stored by platelets, but also by other cells like 
lymphocytes, monocytes, macrophages, mast cells and 
pulmonary neuroendocrine cells (109-111).
2.1 seroTonin recepTors
Seven families of 5-HT receptors (5-HTR
1
 to 5-HTR
7
) have been described to mediate the physiological and 
pathological functions of 5HT. Up to 15 genes have been identified within these families, corresponding to a 
total of 20 subtypes with several alternative splicing variants (110). Differences in the tissue distribution of 
the 5-HTR subclasses appear associated with distinct activities and, probably, serve to fine-tune physiological 
and cellular responses to 5-HT. Thus, it has been suggested that each particular 5-HTR is probably linked to a 
specific biological response to 5-HT (110). 
At the molecular level, 5-HT receptors are G protein–coupled receptors (GPCRs) (except for the 5-HTR
3
 
receptor, that is a ligand-gated ion channel). Therefore, 5-HT receptors possess seven transmembrane spanning 
helices, three intracellular and three extracellular loops, an extracellular amino-terminus, and an intracellular 
carboxy-terminal region (110). Functionally, the extracellular regions serve to bind the ligands. The intracellular 
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domains couple these receptors to various intracellular signaling effectors, with the various receptors triggering 
different intracellular signaling cascades and, as consequence, distinct functional outcomes (fig.9) (110). Since 
5-HTR2B and 5-HTR7 receptors are the subject of study of a portion of this work, their most relevant roles in 
physiology and pathology are outlined below.  
Figure 9. Molecular pathways that underlie serotonin receptors activation
2.2 5-hT2b recepTor  
 
5-HTR2B was first described as a 5-HTR1-like receptor that mediated the 5HT-induced contraction of rat stomach 
fundus (112, 113). The human 5-HTR2B is homologous to 5-HTR2A and 5-HTR2C (45% and 42% identity, 
respectively). The 5-HTR2B-encoding gene is located at chromosomal position 2q36.3–2q37.1 and includes 
two introns (114). Pharmacologically, the receptor binding properties of human 5-HTR2B compare well with 
those of the 5-HTR2A and 5-HTR2C receptors, although 5-HTR2B is clearly distinct (115). For example, 5-HTR2B 
has low affinity for ritanserin but higher affinity for yohimbine than 5-HTR2A or 5-HTR2C. In the same line, 
SB 200646 and SB 206553 have high affinity for 5-HTR
2C/2B
 and lower affinity for 5-HTR2A, while spiperone 
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shows the opposite (116). Most importantly, a specific 5-HTR2B antagonist (SB206741, 20-to-60-fold more 
selective for 5-HTR2B than for other 5-HTR2 receptors) and agonist (BW723C86, with about 10-times higher 
selectivity for the 5-HTR2B versus 5-HTR2A/2C) have now become available (116).   
2.2.1 5-hTr2b : eXpression, signaling anD physiological role
5-HTR2B is strongly expressed during embryogenesis, mediating serotonin actions that are essential for normal 
development (117, 118). In adults, 5-HTR2B is mainly distributed in peripheral organs, but its expression has 
been also detected in some restricted areas of the brain (only at the mRNA level) (110). The activation of 
5-HTR2B leads to the stimulation of phospholipase C (PLC) pathway via the alpha subunit of the Gq GTP-
binding protein. 5-HTR2B stimulates ERK 1/2 (p42/44) and, in 5-HTR2B-expressing mouse fibroblasts, this 
activation is dependent on G protein and p21Ras(119). 5-HTR2B also activates the oncogenic cytoplasmic 
tyrosine kinase p60Src, which induces both cyclin D1 and cyclin E via MAPKs-dependent or -independent 
pathways, respectively (120). These cyclins lead to the induction of retinoblastoma protein (pRB) and the 
transcription factor E2F, which subsequently activates the transcription of genes involved in DNA replication. 
The activation of the 5-HTR2B downstream targets p21Ras and p60Rsc, together with the contribution of PDGFR 
and ErbB-2 growth factor receptors, seems to play a pivotal role in 5-HTR2B-induced mitosis (121). 5-HTR2B 
has also been proposed to display anti-apoptotic activity via MAPKs and PI3 Kinase (PI3K). Consequently, it 
is accepted that 5-HT2B receptors mediate cardiac development during embryogenesis, promoting proliferation 
and differentiation of cardiomyoblasts (121). In adult heart, some groups have proposed that 5-HTR2B is 
involved in the progression of myocardial hypertrophic remodelling (122), and activation of 5-HTR2B results in 
increased proliferation of interstitial cells of Cajal in vivo (123). Small intestinal neuroendocrine tumors (NET) 
also seem to exhibit 5-HTR2B-dependent mitosis (124). 5-HTR2B expression increases in maternal pancreatic 
islets during pregnancy, while blocking of 5-HTR2B signaling in pregnant mice limits beta cell expansion and 
causes glucose intolerance (125). Therefore, 5-HTR2B-dependent mitosis and its physiological implications are 
widely studied in many different patho-physiological settings.  
Interestingly, HTR2B
-/- mice present embryonic and neonatal lethality. Histological analysis of these embryos 
revealed increased apoptosis in the heart and decreased cell number in the ventricular trabeculae, as well as 
abnormal sarcomeric organization in the subepicardial layer (126, 127). Moreover, treatment with a 5-HT2 
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receptor inverse-agonist in developing mouse embryos induced apoptosis in other tissues such as cephalic 
region, neural tube and heart (121). These HTR2B
-/- mice have been also shown to display reduced bone density, 
thus confirming the involvement of the receptor in osteogenesis (128).  Altogether, these data have established 
a crucial role for 5-HT2B in development.
Finally, the role of 5-HTR2B in the nervous system has not been completely elucidated. Some studies implicated 
this receptor in the control of the respiratory network, because the local administration of a 5-HT2B specific 
agonist in the pre-Bötzinger complex increased respiratory frequency (129, 130). However, HTR2B
-/- mice 
respiratory activity appeared to be unaltered, thus indicating that 5-HTR2B is not the only serotonin receptor 
implicated in this process. In fact, 5-HTR2B is present in all respiratory nuclei and found to be co-expressed 
with lower levels of 5-HTR2A in many cells. Once the levels of circulating serotonin are higher than those 
required to activate 5-HTR2A, 5-HTR2B receptor might become activated to modulate the respiratory rhythm in 
a dose-dependent manner (130). 
2.2.2  5-hTr2b in paThology
In the 1980s and 1990s, the administration in the diet of the effective appetite suppressant fenfluramine was 
widely used until its use was linked to valvular heart disease (VHD) and Pulmonary arterial hypertension 
(PAH) (131, 132). Patients taking the drug combination fenfluramine/phentermine (Fen-Phen) for 1 to 28 
months developed heart valve abnormalities, with high myofibroblast proliferation (131). Later studies reveled 
that fenfluramine and its metabolite norfenfluramine were potent agonists of 5-HTR2B. Therefore, it was 
concluded that the activation of 5-HTR2B on heart valve interstitial cells leads to the formation of proliferative 
foci and subsequent changes that compromise tissue functions (e.g. increased extracellular matrix deposition 
and leukocyte infiltration) (133, 134).
Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder in humans that results from an 
increase in pulmonary blood pressure associated with abnormal vascular proliferation (135). Analysis of a 
chronic-hypoxic-mouse model demonstrated that hypoxia-dependent increase in pulmonary blood pressure 
and lung remodeling are associated with a serotonin- and 5-HTR2B-dependent increase in vascular proliferation, 
elastase activity and TGFβ levels (136-138). More recently, bone marrow progenitor cells have been implicated 
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in the etiology of PAH (139). Thus, it seems that 5-HT contributes to the pathogenesis of PAH by activating 
bone marrow progenitor through 5-HTR2B and ultimately leading to pulmonary vascular remodeling (140). 
Altogether, these observations point to 5-HTR2B receptors as key mediators of serotonin-induced proliferation, 
which leads to pathology in certain tissues.  
2.3 5-hTr7 recepTor
5-HTR
7
 was identified as a serotonin receptor by several independent laboratories in 1993 (141-143). Since 
its discovery, 5-HTR
7
 has been described in numerous species, including humans. 5-HTR
7
 is highly expressed 
in the brain, particularly in the neocortex, hippocampus, and hypothalamus, as well as in the suprachiasmatic 
nucleus (144). In periphery, 5-HTR
7
 has been detected predominantly in smooth muscle cells of the 
cardiovascular (138), gastrointestinal (145) and reproductive system (146, 147) , and in corneal epithelial cells 
(148). The 5-HTR
7
 gene is located on human chromosome 10q21–q24 and contains three introns. Alternative 
splicing only occurs at the second and third intron and gives rise to at least five splice variants in human, 
mouse, and rat, which differ in their C-terminal tail. So far, three splice variants have been identified in 
human (5-HTR
7A
, 5-HTR
7B
, and 5-HTR
7D
), three in mouse (5-HTR
7A
, 5-HTR
7B
, and 5-HTR
7C
), and four in rat 
(5-HTR
7A
, 5-HTR
7B
, 5-HTR
7C
, and 5-HTR
7E
) (144). The three human splice variants encode proteins of 448 
(5-HTR
7A
), 435 (5-HTR
7B
), and 479 (5-HTR
7D
) amino acids. In general, the 5-HTR
7A
 isoform is more widely 
expressed, followed by the 5-HTR
7B
 variant, while the 5-HTR
7C
 and the 5-HTR
7D
 isoforms frequency is low. 
Splicing variants do not seem to possess functional differences and are pharmacologically indistinguishable 
(144).  The availability of selective 5-HTR
7
 ligands has been the limiting factor for elucidating the functions 
of this receptor. It is well established that 5-Carboxamidotryptamine (5-CT) and 8-OH-DPAT act as agonists 
for 5-HTR
7
, but they can also activate other serotonin receptors. Fortunately, in the last years, 5-HTR
7
-specific 
agonists have been described, including LP-12 (149) and AS-19 (150).  On the other hand, selective antagonists 
of 5-HTR
7
, such as SB-258719 and SB-269970, have also allowed the analysis of the activity and functions of 
this receptor (110, 144). 
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2.3.1 5-hTr7 : eXpression, signaling anD physiological role 
As other serotonin receptors (5-HTR
4
 and 5-HTR6), 5-HTR7 is a G protein–coupled receptor that interacts 
with Gα12. Its activation leads to stimulation of adenylyl cyclase, resulting in the conversion of ATP to cyclic 
AMP (cAMP) (144), an ubiquitous intracellular messenger that interacts with numerous targets, including the 
phosphorylating enzyme protein kinase A (PKA) (151) and the exchange proteins activated by cAMP (Epac) 
(152). PKA phosphorylates cAMP-responsive transcription factors, such as the cAMP response element 
binding protein (CREB), thus affecting gene expression, whereas Epac activates Rap and Ras GTPases 
(110). It has been demonstrated that the activation of the 5-HTR
7
 Gα12 signalling pathway also leads to 
stimulation of Cdc42 and RhoA, resulting in serum response element-mediated gene transcription, which in 
turn induced filopodia formation and cell rounding (153). Ligation of 5-HTR
7
 also activates ERK1/2 but, in 
this case, the pathway differs depending on the cell system (151, 152). 5-HT induces a rapid 5-HT
7
–dependent 
phosphorylation of ERK and IκBα that result in increased early T-cell activation and proliferation (154). In the 
case of astrocytoma and microglial cell lines, the stimulation of 5-HT
7
 results in the expression of IL-6 via p38 
and PKC activation (155, 156).
The activation of 5-HTR
7
 in the central nervous system and in the periphery modifies different cellular 
functions. In periphery, 5-HTR
7
 activation mediates smooth muscle relaxation of the human colon (110, 157). 
A recent study has shown 5-HTR
7
 expression in hepatocytes, where it promotes IGF-1 synthesis via cAMP/
CREB/AKT (158) in response to elevated concentrations of 5-HT. In collaboration with the central nervous 
system, peripheral 5-HTR
7
 was also found to play a role in the regulation of the micturition reflex  (159, 
160), and also influences the resolution of gut inflammation, since the blockade of 5-HTR
7
 in dendritic cells 
improves the resolution of inflammation (161). In the central nervous system, studies with HTR
7
 -/- mice 
and selective antagonists (SB-269970) demonstrated that 5-HTR
7
 is involved in a number of functions. In 
depression conditions, HTR
7
 -/- mice exhibit a “antidepressant-like” phenotype (162), and in circadian rhythms 
and sleep, 5-HTR
7
 antagonists increase the time to onset of REM sleep and reduce the time spent in REM 
(163, 164). Antagonists of 5-HTR
7
 block 5-HT-induced hypothermia in both guinea pigs and rats. The role 
of 5-HTR
7
 in thermoregulation has been confirmed in HTR
7
 -/- mice, where 5-HT or 5-HTR
7
 agonists fail 
to produce hypothermia (165). Moreover, 5-HTR
7
 has been involved in anxiety, schizophrenia, nociception, 
epilepsy, and memory (144).
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2.4  seroTonin anD iMMune sysTeM
The determination of the role of 5-HT outside the central nervous system (CNS), and especially in immune 
cells, has been one of the recent aims when analyzing the neuro-immune connection. As mentioned above, 
90% of whole body serotonin is produced by enterochromaffin cells, and about 98% of the remaining 5-HT is 
found in platelets, whereas only 2% is located within CNS (108). In platelets, 5-HT is stored and constitutes 
a major secreted product. Under physiological conditions, the plasmatic and vascular concentrations of 5-HT 
are maintained at low levels by mechanisms like uptake, storage or monoamine oxidases-mediated degradation 
(107). Under inflammatory conditions like thrombosis and ischemia, activated platelets release 5-HT and 
increase its concentration around the inflamed area (108, 166).  Moreover, pro-inflammatory stimuli (LPS, 
IFNγ) directly induce platelet activation, which further enhances 5-HT levels (167, 168). 
2.4.1 cellular anD FuncTional eFFecTs oF seroTonin in iMMune cells
By acting through different receptors, 5-HT has an immunomodulatory role because of its stimulatory or 
inhibitory activities on B and T lymphocytes, NK cells and monocyte/macrophages/dendritic cells (fig.10). 
5-HT induces adhesion and chemotaxis in mouse and human mast cells, promoting their migration towards 
inflammatory sites through 5-HTR
1A
 (169). The infiltration and migration of eosinophils also seems to be 
5-HTR2A-dependent (170, 171), as the lack of 5-HTR2A diminishes allergen-induced pulmonary eosinophilia in 
allergic asthma (171). Furthermore, 5-HT enhances the cytolitic function of NKs in vitro (172), and long-term 
treatment with serotonin reuptake inhibitors increases NK cell proliferation (173). It has also been shown that 
5-HT is shuttled from dendritic cells to T lymphocytes as a means to modulate activation, proliferation, and 
differentiation through 5-HTR
7
 (154), and that 5-HT might be necessary for optimal macrophage accessory 
function (174). 
5-HT, acting through 5-HTR
1
 and 5-HTR2 receptor families, induces chemotaxis in immature human DCs and 
enhances the migration of pulmonary DCs to draining lymph nodes in mice (175). In the case of macrophages, 
physiological concentrations of 5-HT suppress IFNγ–induced MHC class II expression and phagocytosis in 
murine macrophages (176-178). In the context of inflammatory pathologies, 5-HT regulates macrophage-
mediated angiogenesis by reducing MMP12 expression in tumor-infiltrating macrophages (179). 5-HT can also 
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Figure 10. Serotonin receptors present on immune cells. 
modulate the production of chemotactic factors and cytokines from various immune cells (180). Therefore, 
5-HT participates in the control of numerous events during inflammatory processes. 
2.4.2 5-hT anD cyToKine release
The balance between pro-inflammatory and anti-inflammatory cytokines is crucial in the control of inflammatory 
responses. As described above, the presence of 5-HT at inflammatory sites suggests its possible involvement 
in the control of the inflammation promotion/resolution equilibrium. The effect of 5-HT on immune cells has 
been studied in different cell models and most in vitro results have been obtained in the presence of fetal bovine 
serum. A potential experimental problem with previously published information, only recently appreciated, is 
the presence of considerable amounts of 5-HT in culture media, primarily derived from serum or from 5-HT 
producing cells. Indeed, 10% of heat-inactivated foetal bovine serum contains 300 nM 5-HT as detected by 
ELISA (109). These levels of 5-HT, assuming that immunoreactive 5-HT is bioactive, are sufficient to activate 
many 5-HT receptors. Thus, there is real danger that contaminating 5-HT may have altered experimental 
results published in the past.
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In the case of NK cells, 5-HT increases the production of IFNγ in the presence of monocytes through the 
activation of 5-HTR
1A
 (181), but suppresses the production of this cytokine in whole blood cells (182). In 
whole blood, 5-HT decreases TNF-α and IL-6 production and has no effect on the LPS-induced production of 
IL-10 (183, 184). Along this line, human CD14+ monocytes respond to 5-HT by increasing the production of 
LPS-stimulated IL-1β and IL-8, and by decreasing that of TNF-α (185). 
Several studies have also revealed a role for 5-HT in DC cytokine secretion. Thus, 5-HT alters the cytokine 
profile of DCs, enhancing IL-1β, IL-8, IL-6 and IL-10, and decreasing IL-12 and TNF-α (175, 186). It has also 
been demonstrated that 5-HT impairs GM-CSF/IL-4–driven human monocyte-derived dendritic cell (MDDC) 
differentiation by reducing co-stimulatory molecule and CD1a expression and Mixed Lymphocyte Response 
stimulatory activity, and by increasing CD14 levels and IL-10 production through 5-HTR
1
 or 5-HTR
7
 (187). In 
addition, 5-HT-treated DCs increase their production of the Th2 attracting chemokine CCL22 while decreasing 
that of the Th1 chemokine CXCL10 (175). Thus, DCs treated with 5-HT induce Th2 polarization in naïve CD4 
T cells (175). However, recent studies have shown that gut DC produce IL-12 in response to 5-HT and LPS 
(188), and that the lack of 5-HTR
7
 ameliorates mucosal inflammation (161).
Regarding macrophages, 5-HT modulates many of their effector functions, including enhancement of 
phagocytosis (189). 5-HT decreases the LPS-evoked production of TNF-α and IL-6 in murine peritoneal 
macrophages (190) and, in 5-HTR2C–expressing alveolar macrophages, upregulates the expression of CCL2 
(191). In human alveolar macrophages and macrophage-like synovial cells, 5-HT stimulation leads to 
overexpression of PGE2 (192, 193), enhances LPS-stimulated IL-10 production and decreases LPS-induced 
TNF-α secretion (193). Therefore, and as a whole, 5HT exhibits a plethora of effectors functions on immune 
cells, and especially on cells within the myeloid lineage. The effects that 5-HT receptor ligation exerts on 
human macrophage polarization constitutes a major topic of the present thesis.
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3. inTravenous iMMunoglobolins (ivig)
Intravenous immunoglobulin (IVIg) is a polyclonal IgG fraction pooled from the sera of thousands of healthy 
donors. Both poly-reactive natural antibodies and antibodies with specificities for allotypic antigens are present 
in the pool. IVIg is used as a replacement therapy in immunodeficient individuals, who are unable to mount their 
own effective immune responses. Less intuitively, IVIg can also be used to suppress the pathological immune 
responses that occur in patients with autoimmunity, thus exerting a potent immunomodulatory action. IVIg 
therapy is FDA-approved for a limited number of pathologies and it is beneficial in other several pathologies 
(194, 195) (Table 1). Most experimental systems have provided evidences that the active immunomodulatory 
component of IVIg resides within the Fc domain-containing fractions rather than the F(ab´)2 fractions, thus 
implicating Fc receptors in the therapeutic benefits of IVIg. Although monomeric IgG is the major constituent, 
IVIg contains small percentages of dimeric and polymeric IgG, and even immunocomplexes (196). Moreover, 
it has been also shown that a small fraction of IgG in IVIg contains Fc-bound sialic acid and that this small 
fraction plays a critical roll in IVIg-mediated responses (194, 197-199). So far, all these reactive parts have 
been claimed to contribute to the IVIg immune-modulatory ability (200, 201). Importantly, previous studies 
have shown that IVIg impairs the metastatic spread of various carcinomas in mice, and contributes to tumor 
regression in a number of cancer patients, leading to the proposal of IVIg as a potential anti-metastatic drug 
(202, 203). 
Table 1. Pathologies for wich IVIg is FDA-approved
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3.1 ivig : MechanisM oF acTion
The mechanisms of action of IVIg are still poorly defined. Even more, many of the diseases that respond 
to IVIg show pathologic profiles that differ from one another. These circumstances have precluded so far 
the identification of a single common IVIg mechanistic pathway that might apply to every clinical scenario. 
Consequently, many distinct and not-mutually exclusive mechanisms of action of IVIg have been proposed 
(204). In fact, it is possible that the benefits of IVIg cannot be explained by a unique and common mechanism. 
Indeed, pleiotropic effects of IVIg might be responsible for the success of IVIg therapy to treat many different 
inflammatory and autoimmune diseases (204). As an example, administered IVIg has been shown to exert 
both anti-inflammatory and pro-inflammatory actions (204). In general, anti-inflammatory activities have been 
observed when IVIg is administered at high doses, whereas pro-inflammatory effects can be seen with low 
IVIg doses. This last effect involves complement activation and FcγR (204, 205). What follows is a concise 
compendium of the mechanisms of action of IVIg described so far, emphasizing only those with a more 
obvious relationship to the present work.
Fab-mediated activities (Fab: antigen-binding fragment of IgG) of IVIg
Since IVIg includes many antibodies from different donors and with very distinct specificities, one possible 
explanation of its therapeutic benefits may rely on the fact that the Fab portion binds to a wide spectrum of 
proteins or cell-surface receptors. In this regard, IVIg has been shown to exert several Fab-mediated activities 
(fig.11):
1. Suppression or neutralization of autoantibodies and cytokines (206).
2. Neutralization of activated complement components (206). IgG binds to potentially damaging complement 
fragments and blocks deposition of these fragments on target tissues. Thus, IVIg can prevent immune damage 
that arises from cell destruction or inflammation.
3. Restoration of idiotypic/anti-idiotypic networks (207). IVIg contains an array of anti-idiotypic antibodies 
that can target B lymphocytes expressing these idiotypes, thus downregulating or eliminating autoreactive 
clones.
4. Blockade of leukocyte adhesion molecules (204).
5. Targeting of specific immune cell-surface receptors (204).
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Fc-dependent activities (Fc: crystallizable fragment of IgG) of IVIg
1. Blockade of the FcRn (neonatal Fc receptor). FcRn localizes in many tissues and is highly expressed on 
vascular endothelial cells. This receptor is critical to modulate IgG levels, since it attenuates the catabolism 
of IgG by preventing lysosomal degradation and allowing intact IgG return to the circulation(208). Indeed, 
it is possible that IVIg intercepts the interaction of autoantibodies to this receptor, so eliminating them from 
circulation more rapidly and reducing target-cell damage (204).
2. Blockade of activating FcγR (receptor for the Fc portion of IgG). This explanation is one of the most obvious, 
since FcγR receptors are involved in many antibody-directed functions and its blockade can directly affect the 
pathology associated to immune system deregulation (197).  Nevertheless, it is important to consider that FcγR 
in humans tend to be low-affinity receptors, so they would present a low ability to interact with monomeric IgG 
Figure 11. IVIg mechanisms of action.
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(the main component of IVIg). In fact, IVIg preparations that contain dimeric or multimeric IgG could be more 
anti-inflammatory (196). However, the regulation of these receptors by IVIg can be indirect. IgG antibodies 
in IVIg preparations interact with their respective antigens creating a big pool of immune-complexes. These 
complexes might compete with autoantibody-antigen complexes, blocking their access to FcγR receptors and, 
consequently, modulating autoimmune responses (200). 
3. Modulation of maturation and function of dendritic cells. It has been demonstrate DCs primed ex vivo with 
IVIG and then trans¬ferred into mice were able to ameliorate (immunothrombocytopenia) ITP to a similar 
extent to IVIG injection (209). Interestingly, IVIG-primed FcγRIII-deficient DCs were not able to suppress 
ITP (209). However, in other studies, in which FcγRIII-deficient mice were used in models of nephro¬toxic 
nephritis and ITP, IVIG activity was not impaired, indicating that additional pathways may be operative in vivo 
(210, 211).
4. Up-regulation of inhibitory FcγRIIB. Different experimental systems have demonstrated that IVIg increases 
expression of the inhibitory receptor FcγRIIB on effector macrophages. As it happens with the low-affinitty 
activating FcγR, a direct interaction between IVIg and FcγRIIB (also a low-affinitty receptor) is unlikely. 
However, the fact that IVIg modulates the activity of macrophages through the up-regulation of inhibitory 
FcγRIIB can explain part of the blockade of pro-inflammatory responses by IVIg (198, 212, 213).
5. Immunomodulation by sialylated IgG. One of the remaining questions to explain its anti-inflammatory action 
is why high doses of IVIg are required to promote anti-inflammatory actions. The observation that different 
patterns of IgG glycosylation can be found in animal models of inflammation and autoimmune disease patients 
shed light on a potential IVIg mechanism that would be dependent on unique and rare IgG glycoforms (214). 
Indeed, IVIg contains a small portion of sialylated Fc-containing IgG that was found to mediate the IVIg 
anti-inflammatory action in a mouse model of arthritis (215). In fact, deglycosylated IVIg was unable to 
exert an anti-inflammatory action (198, 216). This hypothesis is likely to support the presence of a novel 
receptor on regulatory macrophages that would specifically recognize sialic acid-rich IgG and promote an 
anti-inflammatory environment (199, 206, 217). To exert its anti-inflammatory action, sialylated Fc fragments 
appeared to require a specific lectin expressed on macrophages, SIGN-R1 in mice or DC-SIGN (dendritic-cell-
specific ICAM 3-grabbing non-integrin) in humans (218). This lectin-dependent anti-inflammatory activity 
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of IVIg has been described to depend on two different macrophage populations: IVIg would first bind DC-
SIGN or SIGN-R1 in an M-CSF-dependent macrophage subset, which subsequently secretes IL-33 to activate 
basophiles. These basophiles would then increase the levels of IL-4, leading to the activation of effectors 
macrophages that would up-regulate FcγRIIB and inhibit inflammation as described above (217). In spite of all 
these evidences, recent studies have suggest that the proposed molecular interaction between terminal Fc sialic 
acid and DC-SIGN is not the primary recognition event responsible for triggering the IVIg anti-inflammatory 
effect (219). Therefore, it seems that the contribution of the sialylated motifs of IVIg and their mechanism of 
action should be re-evaluated (219).
In the present work we have addressed the potential role of IVIg on human and murine macrophage polarization, 
and its effects on a pathological setting where macrophage polarization plays a relevant role (tumor growth 
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and metastasis).
aiMs oF The Thesis
The principal aim of this Thesis was to analyze whether serotonin (5-HT) and Intravenous Immunoglobulin 
(IVIg) modify macrophage polarization at the phenotypic and functional level.  For this purpose, the following 
objectives were addressed:
1. Identification of 5-HT receptors expressed by human monocyte-derived macrophages at different 
polarization states.
2. Analysis of the transcriptomic and functional effects of 5-HT on human macrophages.
3. Determination of the phenotypic and functional effects of IVIg on pro- and anti-inflammatory macrophages, 
both in vitro and in vivo.
objeTivos
El  principal objetivo de esta Tesis Doctoral fue analizar cómo la serotonina (5-HT) y las Inmunoglobulinas 
Intravenosas (IVIg) son capaces de modificar la polarización de macrófagos a nivel fenotípico y funcional. 
Para esto, se abordaron los siguientes objetivos:
1. Identificación de los receptores de serotonina presentes en macrófagos derivados de monocitos humanos.
2. Análisis de los efectos de la serotonina sobre macrófagos a nivel trascriptómico y funcional.
3. Determinación del efecto de IVIg, tanto in vitro como in vivo, de los cambios fenotípicos y funcionales que 
provoca en macrófagos pro- y anti-inflamatorios. 
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RESULTS
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The following results are presented in paper format, in wich the next scientific articles are included:
1. Serotonin skews human macrophage polarization through HTR2B and HTR7. J Immunol. 2013 Mar 
1;190(5):2301-10. doi: 10.4049/jimmunol.1201133. Epub 2013 Jan 25.
2. Serotonin-dependent gene expression profile in human macrophages. Forthcoming.
3. Intravenous immunoglobulin promotes anti-tumor responses by modulating macrophage polarization. 
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The Journal of Immunology
Serotonin Skews Human Macrophage Polarization through
HTR2B and HTR7
Mateo de las Casas-Engel,* Angeles Domı´nguez-Soto,* Elena Sierra-Filardi,*
Rafael Bragado,† Concha Nieto,* Amaya Puig-Kroger,‡ Rafael Samaniego,‡ Mabel Loza,x
Marı´a Teresa Corcuera,{ Fernando Go´mez-Aguado,{ Matilde Bustos,‖
Paloma Sa´nchez-Mateos,‡ and Angel L. Corbı´*
Besides its role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5HT) regulates inflammation and tissue repair via a set of
receptors (5HT1–7) whose pattern of expression varies among cell lineages. Considering the importance of macrophage polariza-
tion plasticity for inflammatory responses and tissue repair, we evaluated whether 5HT modulates human macrophage polariza-
tion. 5HT inhibited the LPS-induced release of proinflammatory cytokines without affecting IL-10 production, upregulated the
expression of M2 polarization–associated genes (SERPINB2, THBS1, STAB1, COL23A1), and reduced the expression of M1-
associated genes (INHBA, CCR2, MMP12, SERPINE1, CD1B, ALDH1A2). Whereas only 5HT7 mediated the inhibitory action
of 5HT on the release of proinflammatory cytokines, both 5HT2B and 5HT7 receptors mediated the pro-M2 skewing effect of 5HT.
In fact, blockade of both receptors during in vitro monocyte-to-macrophage differentiation preferentially modulated the acqui-
sition of M2 polarization markers. 5HT2B was found to be preferentially expressed by anti-inflammatory M2(M-CSF) macro-
phages and was detected in vivo in liver Kupffer cells and in tumor-associated macrophages. Therefore, 5HT modulates
macrophage polarization and contributes to the maintenance of an anti-inflammatory state via 5HT2B and 5HT7, whose identi-
fication as functionally relevant markers for anti-inflammatory/homeostatic human M2 macrophages suggests their potential
therapeutic value in inflammatory pathologies. The Journal of Immunology, 2013, 190: 2301–2310.
A
lthough GM-CSF and M-CSF contribute to both cell
survival and proliferation, they exert distinct actions
during macrophage development. The lack of M-CSF
alters the development of various macrophage populations (1),
whereas GM-CSF–deficient mice only exhibit altered maturation
of alveolar macrophages (2). Along the same line, both cytokines
promote the in vitro differentiation of macrophages with distinct
morphology, pathogen susceptibility, and inflammatory function
(3–5). GM-CSF drives the generation of monocyte-derived mac-
rophages that produce proinflammatory cytokines in response to
LPS and display high Ag-presenting and tumoricidal capacity
(M1-polarized macrophages). Alternatively, M-CSF yields mac-
rophages that release IL-10 in response to pathogens and exhibit
high phagocytic and protumoral activity (M2-polarized macro-
phages) (3, 6). Accordingly, and based on their respective cytokine
and gene expression profiles, human macrophages generated in
the presence of GM-CSF or M-CSF are considered as proinflam-
matory and anti-inflammatory, respectively (3, 7, 8), and the ac-
quisition of their gene expression profiles is critically dependent
on activin A and the ALK/Smad signaling axis (3, 7, 8).
Serotonin (5-hydroxytryptamine, 5HT) is synthesized from
L-tryptophan via a rate-limiting reaction catalyzed by two trypto-
phan hydroxylases encoded by genes with a distinct pattern of ex-
pression (TPH1 in periphery, TPH2 in brain) (9). Outside the
CNS, 5HT is synthesized and released into the circulation by en-
terochromaffin cells and is rapidly taken up and stored by pla-
telets and, to a lesser extent, lymphocytes, monocytes, and mac-
rophages (9). Serotonin signals through seven types of receptors
(5HT1–7), six of which belong to the G protein–coupled super-
family of receptors (5HT1, 5HT2, 5HT4, 5HT5, 5HT6, 5HT7) and
include ERK1/2 activation as a downstream signal (9, 10). As a
neurotransmitter, 5HT regulates mood and behavior as well as
many cardiovascular and gastrointestinal functions (9). However,
5HT is also a growth factor, and it exhibits mitogenic properties
on smooth muscle cells (11), hepatocytes (12), and endothelial
cells (13), mainly through activation of 5HT2 receptors.
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Additionally, 5HT functions as a regulator of inflammation and
tissue regeneration and repair (14), and it modulates cytokine
production in a cell type–dependent manner. In peripheral blood,
serotonin is released from platelets and lymphocytes/monocytes
following stimulation by LPS and IFN-g (15), and it modulates
cytokine production by myeloid cells (16). Physiologic concen-
trations of 5HT suppress IFN-g–induced MHC class II expression
and phagocytosis in murine macrophages (17, 18) and inhibit the
LPS-induced IL-1b, IL-6, IL-8, IL-12p40, and TNF-a production
by human monocytes and PBMCs (19–21). In human alveolar
macrophages, serotonin inhibits IL-12 and TNF-a release, but it
increases IL-10, NO, and PGE2 production via 5HT2 receptors
(22). In the case of dendritic cells, 5HT impairs GM-CSF/IL-4–
driven human monocyte-derived dendritic cell (MDDC) differ-
entiation by reducing costimulatory molecule and CD1a expres-
sion as well as MLR stimulatory activity while increasing CD14
levels (23) and IL-10 production through 5HT1 or 5HT7 receptors
(23). Others have shown that 5HT is shuttled from dendritic cells
to naive T lymphocytes as a means to modulate T cell activation,
proliferation, and differentiation (24), and that it might be nec-
essary for optimal macrophage accessory function (25). In the
context of inflammatory pathologies, 5HT regulates macrophage-
mediated angiogenesis by reducing matrix metalloproteinase 12
(MMP12) expression in tumor-infiltrating macrophages (26), and
its contribution to the development of pulmonary arterial hyper-
tension depends on 5HT2B receptor expression on bone marrow
progenitors (27). Thus, 5HT modulates myeloid cell functions in a
variable manner, and its effects are dependent on the profile of 5HT
receptors expressed by each macrophage subtype. In this regard,
previous studies have reported mRNA for 5HT1E, 5HT2A, 5HT3,
5HT4, and 5HT7 in human monocytes (21), 5HT1B, 5HT1E, and
5HT2B in immature MDDC, 5HT4 and 5HT7 in mature MDDC
(28), and 5HT2C in murine alveolar macrophages (29).
The differential expression of 5HT receptors in macrophages
at distinct states of functional polarization prompted an evaluation
of the contribution of 5HT to macrophage polarization. We now
report that 5HT stimulates human macrophage polarization toward
the acquisition of an M2-like phenotype, and that this effect is
mediated by 5HT2B and 5HT7, which are preferentially expressed
by anti-inflammatory M2 macrophages. These findings point to
serotonin as a potential target for modulating macrophage polar-
ization under physiological and pathological settings.
Materials and Methods
Generation of human monocyte-derived macrophages and cell
isolation and culture
Human PBMC were isolated from buffy coats from normal donors over
a Lymphoprep (Nycomed Pharma, Oslo, Norway) gradient according to
standard procedures.Monocytes were purified from PBMC bymagnetic cell
sorting using CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Monocytes (.95% CD14+ cells) were cultured at 0.5 3 106
cells/ml for 7 d in RPMI 1640 supplemented with 10% FCS (completed
medium) at 37˚C in a humidified atmosphere with 5% CO2, and containing
GM-CSF (1000 U/ml) or M-CSF (10 ng/ml) (both from ImmunoTools,
Friesoythe, Germany) to generate M1(GM-CSF) and M2(M-CSF)
monocyte-derived macrophages, respectively. Cytokines were added ev-
ery 2 d. As previously described (3, 7, 8) (Gene Expression Omnibus,
accession no. GSE27792; http://www.ncbi.nlm.nih.gov/geo/), the resulting
macrophage populations exhibited a differential expression of the STAB1,
HTR2B, SERPINB2, COL23A1, THBS1, SERPINE1, MMP12, INHBA,
CCR2, CD1B, and ALDH1A2 genes (Supplemental Fig. 1A) and differed
in the protein levels of FOLR2, EGLN3, and DC-SIGN (30–32) (Sup-
plemental Fig. 1B, 1C). Before treatment with 5HT, M2(M-CSF) macro-
phages were maintained in serum-free medium for 48 h, without a
significant change in the level of expression of the polarization markers
FOLR2, EGLN3, and DC-SIGN (Supplemental Fig. 1B, 1C). Macrophage
activation was accomplished with LPS (Escherichia coli 055:B5, 10
ng/ml) for 24 h. For determination of LPS-induced cytokine expression,
different doses of 5HT or the 5HT2B agonist BW723C86 (Sigma-Aldrich)
were added immediately before the addition of LPS. When receptor
antagonists were used (SB204741, 1 mM; SB269970, 1 mM), they were
added 1 h before 5HT and LPS addition.
RNA from human liver cells was obtained as previously described (33).
Murine Kupffer cells, liver sinusoidal endothelial cells (LSEC), hepa-
tocytes, and hepatic stellate cells (Ito cells) were isolated from 12-wk-old
C57BL/6 mice using sequential pronase/collagenase digestion and a
Nycodenz density-gradient centrifugation as described (34). Briefly, after
perfusion via portal vein with 20 ml MEM (Life Technologies BRL), liver
was digested with 10 ml DMEM/F-12 (Life Technologies BRL) containing
pronase (0.5 mg/g body weight; Roche Diagnostics), followed by 10 ml of
DMEM/F-12 containing 7 mg collagenase (Liberase Blendzymes; Roche
Diagnostics). Digested liver was mashed ex vivo and incubated at 37˚C for
25 min in 50 ml DMEM/F-12 solution containing 0.05% pronase and 20
mg/ml DNase I (Roche Diagnostics). The resulting suspension was filtered
through a filter (mesh size 70 mm) and centrifuged over a 7.5% Nycodenz
(Axis-Shield, Oslo, Norway) cushion at 14003 g for 15 min. The Ito cell–
enriched fraction was recovered from the upper whitish layer. Kupffer and
LSEC were simultaneously collected from the interface, and each cell type
was further purified using anti-CD146 (for LSEC) and anti-CD11b (for
Kupffer cells) microbeads (Miltenyi Biotec) according to the manu-
facturer’s protocol. Purity of Ito cell preparations was assessed by auto-
fluorescence 1 d after isolation. LPS (E. coli 055:B5) was purchased from
Sigma-Aldrich, and IL-10 and IL-4 were obtained from BioLegend (San
Diego, CA) and used at 50 ng/ml. The monoclonal anti-human IL-10
(R&D Systems, Abingdon, U.K.) blocking Ab was added at a final con-
centration of 2.5 mg/ml. The 5HT2B receptor agonist BW723C86 and the
antagonists SB204741 (for 5HT2B) and SB269970 (for 5HT7) were pur-
chased from Sigma-Aldrich. Where indicated, SB204741 (1 mM) and
SB269970 (1 mM) were added every 24 h during the process of in vitro
macrophage generation using DMSO as a negative control.
ELISA
Macrophage supernatants were tested for the presence of cytokines and
growth factors using commercially available ELISA for TNF-a, IL-10 (both
from ImmunoTools), and IL-12p40 (OptEIA IL-12p40 set; BD Pharmin-
gen, San Diego, CA), following the protocols supplied by the manu-
facturers.
Reporter gene assays
The luciferase-based plasmids CRE-Luc (containing 21 cAMP-response
elements), SRE-Luc (containing three serum-response elements from the
c-FOS promoter), and TRE-Luc (containing four copies of the canonical
AP-1–binding site) were provided by Dr. W. Born (Departments of Or-
thopedic Surgery and Medicine, University of Zurich, Zurich, Switzerland).
The TATA-pXP2 plasmid was derived from the promoterless pXP2 plasmid
by insertion of the TATA-like sequence 59-AGGGTATATAATGGAAG-39
immediately upstream of the luciferase gene. The C/EBP-Luc plasmid,
which contains four copies of the consensus C/EBP-binding element, was
provided by Dr. Daniel G. Tenen (Beth Israel Deaconess Medical Center,
HarvardMedical School, Boston, MA). CHO-K1 cells stably expressing the
5HT2B receptor (ValiScreen; PerkinElmer, Boston, MA) were cultured in
DMEM/F-12 with 1% dialyzed FCS and transiently transfected with 2 mg
each reporter gene using SuperFect (Qiagen). After transfection, cells were
cultured overnight and replated before exposure to 5HT (1025 M) or
BW723C86 (1025 M) for 24 h. To normalize transfection efficiency, cells
were cotransfected with an SV40 promoter-based b-galactosidase expres-
sion plasmid (RSV-bgal). Measurement of relative luciferase units and
b-galactosidase activity were performed using a luciferase assay system
(Promega) and a Galacto-Ligth kit (Tropix), respectively.
Quantitative real-time RT-PCR
Oligonucleotides for selected genes were designed according to the Uni-
versal ProbeLibrary system (Roche Diagnostics) for quantitative real-time
PCR (qRT-PCR). Total RNA was extracted using an RNeasy kit (Qiagen),
retrotranscribed, and amplified in triplicates. Results were expressed rel-
ative to the expression level of GAPDH RNA (human samples). When in-
dicated, results were expressed relative to the mean of the expression
levels of GAPDH, TBP, HPRT1, and SDHA RNA and normalized to the
values obtained in untreated cells. In the case of RNA from murine sam-
ples, qRT-PCR was done using SYBR Green I detection for quantification
of the level of expression of Htr2B (using oligonucleotides 59-TGCCCT-
CTTGACAATCATGT-39 and 59-AGGGAAATGGCACAGAGATG-39) and
Emr1 (59-CCTGGACGAATCCTGTGAAG-39 and 59-GGTGGGACCAC-
AGAGAGTTG-39), as well as with Tbp gene levels (59-GGGGAGCTGT-
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GATGTGAAGT-39 and 59-CCAGGAAATAATTCTGGCTCA-39) as a ref-
erence.
Western blot
Western blot was carried out on 10–100 mg cell lysates using standard
procedures. Affinity-purified rabbit mAbs from Cell Signaling Technology
(Danvers, MA) were used to detect phospho-ERK1/2 and phospho-MSK1.
Detection of 5HT2B was accomplished using a rabbit polyclonal antiserum
(sc-25647; Santa Cruz Biotechonology), and protein loading control was
done using mouse mAbs against human a-tubulin (B-7, sc-5286; Santa
Cruz Biotechonology) or human vinculin (hVIN-1; Sigma-Aldrich).
Confocal microscopy and immunohistochemistry
Human melanoma tissues (s.c. tissue, lymph node, and lung metastasis)
were obtained from patients with primary or metastatic lesions undergoing
surgical treatment. Liver biopsies were obtained from patients undergoing
surgery. In all cases, samples were obtained after written informed consent
and following Medical Ethics Committee procedures. Thick sections (4 mm
in depth) of cryopreserved tissue were first blocked for 10 min with 1%
human Igs and then incubated for 1 h with either a rabbit polyclonal an-
tiserum against human 5HT2B (Santa Cruz Biotechnology), anti-CD163,
anti–VE-cadherin or anti–HMB-45 mAbs, or isotype-matched control Abs.
All primary Abs were used at 1–5 mg/ml, followed by incubation with
FITC-labeled anti-mouse and Texas Red–labeled anti-rabbit secondary
Abs. Samples were imaged with the 363 PL-APO (numerical aperture,
1.3) immersion objective of a confocal scanning inverted AOBS/SP2 mi-
croscope (Leica Microsystems). Image processing and colocalization
analyses (scatterplots) were assessed with Leica confocal software LCS-
15.37. Normal human tissue microarrays were obtained from RayBiotech
(Norcross, GA) and processed according to the manufacturer’s recom-
mendations using a Prestige affinity-purified polyclonal Ab against 5HT2B
(Sigma-Aldrich) and an anti-CD68 mAb (clone PG-M1, 1/100 dilution;
DakoCytomation).
Statistical analysis
Statistical significance was assessed at the 0.05 level using a paired Student
t test. Where indicated, a one-way ANOVA with Newman–Keuls for mul-
tiple comparison test was done.
Results
5HT receptors are differentially expressed by M1(GM-CSF)
and M2(M-CSF) macrophages
HTR2B and HTR7 genes code for the 5HT receptors 5HT2B and
5HT7, respectively. Gene expression profiling on proinflammatory
M1(GM-CSF) and anti-inflammatory M2(M-CSF) macrophages
(GSE27792) (8) revealed that HTR2B and HTR7 mRNA are
preferentially expressed by M2(M-CSF) macrophages (Fig. 1A,
1B), and that HTR7 is the only serotonin receptor–encoding gene
expressed above background levels in M1(GM-CSF) macrophages
(Fig. 1A, 1B). Analysis of five independent samples confirmed
that HTR2B is expressed at significantly much higher levels in M2
FIGURE 1. Preferential expression and cytokine responsiveness of HTR2B mRNA in human M2(M-CSF) macrophages. (A) Relative expression of
the genes encoding serotonin receptors in M1(GM-CSF) and M2(M-CSF) macrophages, as determined by microarray DNA analysis (GSE27792).
Shown data indicate the quantile-normalized fluorescence intensity of each probe. (B) Heat map representation of the data shown in (A). (C) HTR2B
mRNA expression levels in M1(GM-CSF) and M2(M-CSF) macrophages as determined by qRT-PCR (n = 5). **p , 0.005). (D) HTR2B mRNA
expression levels along M2(M-CSF) macrophage polarization, as determined by qRT-PCR (n = 3). *p , 0.05 compared with the level detected in
monocytes (t = 0). (E) HTR2B mRNA expression levels in M2(M-CSF) macrophages after replacement of the culture supernatant with fresh complete
medium containing either M-CSF or GM-CSF for 48 h (n = 4). *p , 0.05. (F) HTR2B mRNA expression in monocytes exposed for 72 h to the indicated
stimuli, as determined by qRT-PCR (n = 3). *p , 0.05 compared with the level detected in monocytes maintained in RPMI 1640 (2). (G) HTR2B
mRNA expression in M2(M-CSF) macrophages exposed for 24 h to the indicated stimuli, as determined by qRT-PCR (n = 3). *p , 0.05 compared with
the level detected in nonstimulated macrophages (2). (H) HTR2B mRNA expression in M2(M-CSF) macrophages exposed for 24 h to LPS in the
presence of either a blocking anti–IL-10 or an isotype-matched (IgG) Ab, as determined by qRT-PCR (n = 5). *p , 0.05, **p , 0.005 after one-way
ANOVA with Newman–Keuls multiple comparison test. In (C)–(H), results are presented as relative expression, which indicates HTR2B mRNA levels
relative to GAPDH mRNA levels, and mean and SD are shown.
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(M-CSF) than in M1(GM-CSF) macrophages (.500-fold) (Fig.
1C). Kinetic analysis showed that high HTR2B mRNA levels are
first observed 48 h along M-CSF–driven polarization, reaching
maximal levels after 96 h (Fig. 1D). Moreover, cytokine re-
placement experiments revealed that GM-CSF almost abrogated
HTR2B mRNA levels from M2(M-CSF) macrophages (Fig. 1E).
This inhibitory effect of GM-CSF prompted us to identify the
cytokines affecting HTR2B expression at early time points. As
shown in Fig. 1F, monocytes exposed to M-CSF for 72 h showed
significantly higher levels of HTR2B mRNA than did non-
stimulated monocytes, whereas other M2-polarizing cytokines
(IL-4, IL-10) did not promote HTR2B mRNA expression but
impaired the positive effects of M-CSF on the acquisition of
HTR2B mRNA by monocytes. In fact, exposure of M2(M-CSF)
macrophages to IL-4 or IL-10 for only 24 h led to a dramatic
reduction in HTR2B mRNA levels, an effect also seen upon LPS
stimulation (Fig. 1G). Because M2(M-CSF) macrophages respond
to LPS by releasing large amounts of IL-10 (3, 8), we evaluated
whether IL-10 mediated the LPS-induced downregulation of
HTR2B mRNA expression. As shown in Fig. 1H, addition of a
blocking anti–IL-10 Ab partly inhibited the action of LPS, indi-
cating that IL-10 contributes to the inhibitory effect of LPS on
HTR2B expression. Therefore, M2(M-CSF) macrophages are
characterized by the presence of HTR2B mRNA, whose restricted
expression is promoted by M-CSF. Moreover, M1(GM-CSF)
macrophages generated in the presence of the Smad signaling
inhibitor ALK4/5/7 exhibited an enhanced expression of HTR2B
mRNA (data not shown), a result that agrees with the inhibitory
action of the activin A/Smad signaling pathway on M2(M-CSF)
macrophage polarization (8). Collectively, these results imply that
HTR2B expression is upregulated by M-CSF but impaired by ei-
ther IL-4, IL-10, GM-CSF, or ligands of ALK4/5/7.
5HT2B is expressed by M2-skewed tissue macrophages
To extend the above results, HTR2B gene expression in macro-
phages was assessed at the protein level. Immunocytochemical
analysis confirmed the expression of 5HT2B in M2(M-CSF) (Fig.
2A), and the differential expression of 5HT2B was also seen by
Western blot, which revealed a considerably higher expression in
M2(M-CSF) than in M1(GM-CSF) macrophages (Fig. 2B). Next,
we evaluated 5HT2B expression in macrophages from normal and
pathological tissues with a predominance of M2-skewed macro-
FIGURE 2. Expression of 5HT2B and HTR2B mRNA in M2(M-CSF) and tissue-resident human macrophages. (A) Immunofluorescence analysis on M2
(M-CSF) macrophages, as determined by confocal microscopy (original magnification 320) using a 5HT2B-specific rabbit polyclonal antiserum or non-
specific rabbit antiserum (IgG). Nuclei were counterstained with DAPI (blue). The experiment was done on one preparation of in vitro–generated M2
macrophages. (B) Immunoblot analysis of 5HT2B in lysates of 5HT2B-transfected CHO-K1 cells and M1(GM-CSF) and M2(M-CSF) macrophages.
Vinculin protein levels were determined as a loading control. The light gray arrow indicates a nonspecific band, whereas the black arrow indicates the band
corresponding to 5HT2B. One representative experiment out of three different donors and experiments is shown. (C) Confocal sections of human liver after
double immunofluorescence analysis for 5HT2B (green), a control rabbit antiserum (IgG, green), or the macrophage-specific marker CD163 (red). In the
first two panels, nuclei were counterstained with DAPI (blue). The right panel shows a higher magnification of the macrophage indicated by an arrow in the
second panel. Shown is a representative result of one out of three different sections from a human liver sample. (D) HTR2B mRNA expression in human
sinusoidal endothelial cells (HSEC), Ito cells, Kupffer cells, and hepatocytes as determined by qRT-PCR. Results are expressed as relative expression,
which indicates HTR2B the mRNA levels relative to GAPDH mRNA levels. As a reference, HTR2B mRNA levels in in vitro–generated human M2(M-CSF)
macrophages were measured in parallel. Determinations were done in triplicate, and mean and SD are shown. (E) Left panel, Htr2b mRNA expression in
murine sinusoidal endothelial cells (mSEC), Ito cells, Kupffer cells, and hepatocytes as determined by qRT-PCR. As a reference, Emr1 (murine F4/80)
mRNA levels were evaluated in the same populations (right panel). Results are expressed as relative expression, which indicates Htr2b or Emr1 mRNA
levels relative to the levels of Tbp mRNA, and mean and SD are shown (n = 3). *p , 0.05 compared with the level detected in Kupffer cells.
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phages. Immunohistochemical analysis indicated the colocaliza-
tion of 5HT2B and the M2-associated marker CD163 in human
liver Kupffer cells (Fig. 2C). Along the same line, the 5HT2B
reactivity in lung and colon tissue greatly resembled that of the
macrophage marker CD68, further supporting the expression of
this serotonin receptor in tissue-resident macrophages (Supple-
mental Fig. 2). In line with protein data, HTR2B mRNA was
detected in isolated liver Kupffer cells, with expression levels
similar to those found in in vitro–generated M2(M-CSF) macro-
phages (Fig. 2D), whereas Htr2b mRNA expression was prefer-
entially found in murine Kupffer cells, which showed the highest
expression of the myeloid marker Emr1 (F4/80) (Fig. 2E). Taken
together, these results demonstrate the expression of the 5HT2B-
coding HTR2B gene in tissue-resident macrophages with anti-
inflammatory ability (alveolar, colonic macrophages) (35, 36) or
whose development is dependent on M-CSF (Kupffer cells) (37).
For evaluation of the 5HT2B expression in macrophages from
a pathological setting, we analyzed tumor-associated macrophages
(TAM), whose M2-skewed polarization is well established (38,
39). Analysis of cutaneous primary melanomas revealed that
5HT2B colocalizes with CD163, a macrophage marker preferen-
tially found in M2-polarized macrophages (30, 40), and it showed
a distribution pattern different from the melanoma-specific marker
HMB45 (Fig. 3A, 3B). Most 5HT2B-positive macrophages were
found in the proximity of VE-cadherin–positive endothelial cells
(Fig. 3B). To confirm these results, the presence of HTR2B mRNA
was analyzed in TAM isolated from carcinomas of various origins.
Although to a lower extent than in vitro–generated M2(M-CSF)
macrophages, HTR2B mRNA was detected in ex vivo–isolated
TAM from gastric carcinoma, breast carcinoma, and melanoma
(Fig. 3C). Therefore, and in agreement with its expression in M2
(M-CSF) macrophages, 5HT2B constitutes a marker for macro-
phages exhibiting an M2-skewed polarization both in homeostatic
and pathological conditions.
5HT and 5HT2B receptor engagement trigger intracellular
signaling and gene expression changes in M2(M-CSF)
macrophages
To assess the functional expression of the 5HT2B receptor in M2
(M-CSF) macrophages, we next evaluated the intracellular signals
triggered in response to either 5HT stimulation or 5HT2B en-
gagement by the BW723C86 agonist. Screening of the activation
state of 46 kinases revealed that ERK1/2 and its downstream
targets MSK1/2 are phosphorylated in M2(M-CSF) macrophages
in response to either 5HT stimulation or 5HT2B ligation (data not
shown). Kinetic analysis confirmed that both stimuli promote
transient phosphorylation of ERK1/2 and MSK1 that peak at 10
min and diminished thereafter (Fig. 4A, 4B). Therefore, 5HT and
BW723C86 activate ERK1/2 in M2(M-CSF) macrophages, con-
firming the presence of functional 5HT2B receptors on their cell
surface. These results are in agreement with previous results
showing that ligation of the 5HT2B receptor leads to ERK1/2
FIGURE 3. Expression of 5HT2B in TAM from human melanoma. (A and B) Confocal sections of macrophages infiltrating a s.c. primary melanoma, as
determined by immunofluorescence analysis of 5HT2B (red), the macrophage marker CD163 (green), and either the melanoma marker HMB45 (white) (A)
or the endothelial marker VE-cadherin (white) (B). Magnification of a 5HT2B/CD163 colocalizing area (indicated by the white rectangle) is shown in the
right panels. In the leftmost panel in (B), nuclei were counterstained with DAPI (blue). In (A) and (B), representative results of one out of seven independent
melanoma samples are shown. Scale bars, 50 mm. (C) HTR2B mRNA expression in ex vivo CD14+ TAM isolated from one gastric carcinoma, one breast
carcinoma, and one melanoma, as determined by qRT-PCR. For comparative purposes, HTR2B mRNA expression in a representative M2(M-CSF) mac-
rophage preparation is shown. Results are expressed as relative expression, which indicates HTR2B mRNA levels relative to GAPDH mRNA levels.
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activation in cardiomyocytes and hepatic stellate cells (41, 42),
and they also fit with the ability of 5HT and BW723C86 to in-
crease the activity of ERK1/2-regulated transcription factors that
control macrophage activation and polarization (AP-1, C/EBP,
SRF) (Supplemental Fig. 3).
The signaling capability of the 5HT2B receptor in macrophages
led us to explore whether 5HT or 5HT2B ligation could modulate
macrophage polarization. To that end, the expression of polarization-
specific markers (8) was monitored in M2(M-CSF) macrophages
that had been exposed to either 5HT or BW723C86 for 24 h. The
expression of the M1(GM-CSF) polarization markers ALDH1A2,
CD1B, and MMP12 was significantly reduced by either 5HT or
BW723C86 (Fig. 4C, Supplemental Fig. 4), whereas both agents
enhanced the expression of the M2(M-CSF)–specific markers
SERPINB2,COL23A1, THBS1, and STAB1 (Fig. 4C). Besides, 5HT,
but not the agonist, reduced the expression of the M1(GM-CSF)–
specific markers INHBA,CCR2, and SERPINE1 (Supplemental Fig.
4). These results are in agreement with the reported ability of 5HT to
reduce the expression of MMP12 in murine macrophages (26), and
they demonstrate that both 5HTand the 5HT2B agonist BW723C86
influence the phenotypic macrophage polarization.
Because the defining difference between M1(GM-CSF) and
M2(M-CSF) macrophages is their opposite cytokine profile upon
stimulation, we next analyzed whether 5HT2B ligation influenced
the macrophage cytokine profile. To that end, M2(M-CSF) mac-
rophages that had been maintained for 48 h in serum-free medium
were exposed to LPS in the presence of 5HT and/or the 5HT2B
agonist. 5HT greatly reduced the LPS-stimulated production of
TNF-a and IL-12p40, but it did not modify the LPS-stimulated
production of IL-10 (Fig. 4D). In contrast, the presence of the
5HT2B agonist BW723C86 had no significant effect on the LPS-
stimulated release of TNFa, IL-12p40, or IL-10 (Fig. 4D). These
results imply that 5HT modulates the functional polarization of
human macrophages by limiting the production of proinflamma-
tory cytokines, and that such a modulatory action is not mediated
by the 5HT2B receptor.
5HT7 and 5HT2B mediate the 5HT-dependent modulation of the
macrophage gene expression profile
The distinct effects of 5HT and BW723C86 on gene expression
(INHBA, CCR2, SERPINE1) (Supplemental Fig. 4) and on the
LPS-stimulated cytokine profile (Fig. 4D) led us to evaluate
FIGURE 4. Effects of 5HT and the 5HT2B agonist BW723C86 on intracellular signaling, polarization marker expression, and cytokine production. (A)
ERK1/2 phosphorylation in lysates of untreated (2), 1025 M 5HT-treated, or 1025 M BW723C86-treated M2(M-CSF) macrophages, as determined by
Western blot using Abs specific for total or phosphorylated ERK1/2 (upper panels). The relative level of phosphorylated ERK1/2 was determined after
densitometric analysis and normalization with a-tubulin levels and is referred to the level of ERK1/2 phosphorylation in untreated cells (2) (lower panel).
One representative experiment out of three different donors and experiments is shown. (B) MSK1 phosphorylation in lysates of untreated (2), 1025 M 5HT-
treated, or 1025 M BW723C86-treated M2(M-CSF) macrophages, as determined by Western blot using Abs specific for phosphorylated MSK1 (upper
panels). The relative level of phosphorylated MSK1 was determined after densitometric analysis and normalization with a-tubulin levels and is referred to
the level of MSK1 phosphorylation in untreated cells (2) (lower panel). One representative experiment out of two different donors and experiments is
shown. (C) ALDH1A2, COL23A1, STAB1, SERPINB2, and THBS1 mRNA expression levels in M2(M-CSF) macrophages exposed to either 5HT or
BW723C86 (1025 M) for 24 h, as determined by qRT-PCR. Results are expressed as relative expression (relative to TBP, HPRT1, SDHA, and GAPDH
RNA levels) and are referred to the expression level observed in the absence of stimulation (2). Mean and SD of triplicate determinations on 10 (for 5HT)
or 13 independent samples (for BW723C86) are shown. *p, 0.05, **p, 0.005. (D) ELISA determination of TNF-a, IL-12p40, and IL-10 levels in culture
supernatants of M2(M-CSF) macrophages untreated or stimulated with LPS (10 ng/ml) for 24 h in the absence or presence of the indicated concentrations
of 5HTor the 5HT2B agonist BW723C86. Each determination was performed in triplicate on six independent samples, and means and SD are shown (n = 6).
*p , 0.05 compared with the cytokine levels in LPS-treated macrophages.
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whether additional 5HT receptors might contribute to the macro-
phage polarization skewing ability of 5HT. As predicted from the
gene expression profiling data (Fig. 1A, 1B), M2(M-CSF) mac-
rophages also contained higher levels of HTR7 mRNA than did
M1(GM-CSF) macrophages (Fig. 5A). Similar to HTR2B, HTR7
mRNA expression was detected at early time points (Fig. 5B) and
inhibited by GM-CSF (Fig. 5C), IL-4, or LPS (Fig. 5D, 5E).
However, and unlike HTR2B, HTR7 mRNA expression was not
significantly affected by M-CSF, IL-10 (Fig. 5D, 5E), or inhibition
of the M-CSF–dependent ERK1/2 activation (data not shown).
Therefore, we next determined whether 5HT7 contributed to
the modulation of gene expression and cytokine profile promoted
by 5HT. To that end, and owing to the lack of specific 5HT7 ago-
nists, 5HT-mediated changes were monitored in the presence of the
5HT7 receptor–specific antagonist SB269970 and using the 5HT2B-
specific antagonist SB204741 as a control. Whereas the 5HT7 an-
tagonist SB269970 prevented the 5HT-induced upregulation of
STAB1, SERPINB2, THBS1, and COL23A1 gene expression (Fig.
6A), the 5HT2B antagonist SB204741 only inhibited the positive
effect of 5HTon STAB1 and SERPINB2 gene expression (Fig. 6A).
Therefore, the modulation of the macrophage polarization pheno-
type caused by 5HT in M2(M-CSF) macrophages is mediated by
5HT2B and 5HT7.
5HT abrogates proinflammatory cytokine production in
macrophages through 5HT7
Because 5HT2B did not mediate the inhibitory action of 5HTon the
LPS-stimulated release of IL-12p40 and TNF-a from M2(M-CSF)
macrophages (Fig. 4D), the potential role of 5HT7 was tested. The
presence of the 5HT7 antagonist SB269970 significantly reverted
the inhibitory effect of 5HT on the LPS-stimulated production
of both TNF-a and IL-12p40 (Fig. 6B). Conversely, in agreement
with the results observed with the 5HT2B agonist BW723C86, the
5HT2B antagonist SB204741 did not affect the inhibitory effect of
5HT on the LPS-stimulated production of TNF-a and IL-12p40
from M2(M-CSF) macrophages that had been maintained for
48 h in serum-free medium (Fig. 6B). Because none of the antag-
onists modified the basal level of cytokine production (Fig. 6B),
these results indicated that 5HT modulates the cytokine profile
of LPS-stimulated human M2(M-CSF) macrophages primarily
through interaction with the 5HT7 receptor.
5HT influences macrophage polarization
Given the ability of 5HT to alter phenotypic and functional mac-
rophage polarization, we hypothesized that it might also contribute
to the cytokine-dependent polarization of monocytes. To test this
hypothesis, monocytes were subjected to M-CSF–driven polari-
zation in the presence or absence of 5HT2B or 5HT7 antagonists,
and the expression of M1- and M2-specific markers was measured
in the resulting monocyte-derived macrophage populations. Re-
garding M2(M-CSF) markers, the expression of SERPINB2 and
HTR2B mRNA was significantly diminished in the presence of
the 5HT2B antagonist SB204741, whereas STAB1 and THBS1 ex-
pression was significantly reduced in the presence of the 5HT7
antagonist SB269970 (Fig. 7A). Moreover, the simultaneous pres-
ence of both inhibitors limited the expression of COL23A1 (Fig.
7A). Alternatively, the 5HT2B antagonist SB204741 alone im-
paired the expression of the M1(GM-CSF) markers ALDH1A2
and CCR2 mRNA, whereas the combined presence of SB204741
and SB269970 reduced the expression of MMP12 and enhanced
that of CD1B mRNA (Fig. 7B). Collectively, these results dem-
onstrate that antagonizing 5HT2B or 5HT7 along the monocyte-to-
macrophage differentiation process alters the pattern of expression
of polarization markers, thus demonstrating that serotonin con-
tributes to the acquisition of macrophage polarization markers
during the M-CSF–driven monocyte-to-macrophage transition.
FIGURE 5. Regulated expression of HTR7 mRNA in human M2(M-CSF) macrophages. (A) HTR7 mRNA expression levels in M1(GM-CSF) and M2
(M-CSF) macrophages as determined by qRT-PCR (n = 5). *p , 0.05. (B) HTR7 mRNA expression levels along M2(M-CSF) macrophage polarization, as
determined by qRT-PCR (n = 3). *p , 0.05 compared with the level detected in monocytes (t = 0). (C) HTR7 mRNA expression levels in M2(M-CSF)
macrophages after replacement of the culture supernatant with fresh complete medium containing either M-CSF or GM-CSF for 48 h (n = 4). *p , 0.05.
(D) HTR7 mRNA expression in M2(M-CSF) macrophages exposed for 24 h to the indicated stimuli, as determined by qRT-PCR (n = 3). *p , 0.05
compared with the level detected in nonstimulated macrophages (2). (E) HTR7 mRNA expression in monocytes exposed for 72 h to the indicated stimuli,
as determined by qRT-PCR (n = 3). *p , 0.05 compared with the level detected in monocytes maintained in RPMI (2). In (A)–(E), results are presented as
relative expression, which indicates HTR2B mRNA levels relative to GAPDH mRNA levels, and mean and SD are shown.
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Discussion
Although 5HT controls important functions in the CNS, recent
advances have now shown that 5HT functions as a regulator of
cell proliferation as well as inflammation, tissue regeneration, and
repair (12, 42, 43). The importance of macrophage polarization for
an adequate regulation of these latter processes justifies the pres-
ence of functional 5HT receptors on their cell membrane and the
5HT ability to modulate macrophage effector functions. However,
5HT effects on the immune system are pleiotropic and incom-
pletely understood (14). In the case of myeloid cells, 5HT variably
affects the production of proinflammatory and anti-inflammatory
cytokines from monocytes, macrophages, and dendritic cells,
mainly because of the existence of a large set of 5HT receptor
subtypes that exhibit cell- and tissue-specific patterns of expression
(44). In the present study we provide evidence for the preferential
expression of 5HT2B in anti-inflammatory macrophages and liver
Kupffer cells, demonstrate the effects of 5HTon the phenotypic and
functional human macrophage polarization, and identify 5HT2B
and 5HT7 as the serotonin receptors that mediate the polarization
skewing action of 5HT at the gene expression (5HT2B and 5HT7)
and functional (5HT7) levels.
Kupffer cells represent .50% of resident macrophages in the
whole body, and their development and maturation are dependent
on M-CSF (37). Because of their location in the liver sinusoids,
Kupffer cells are continuously exposed to the 5HT levels found
in peripheral blood after its release from either enterochromaffin
cells (under physiological conditions) or platelets (after degranu-
lation events). Therefore, it is conceivable that 5HT2B might
contribute to adjusting the activation state of Kupffer cells to
extracellular 5HT levels. Additionally, because 5HT2A and 5HT2B
mediate serotonin-dependent liver regeneration (12), a process
where Kupffer cell–derived cytokines also participate (45), it is
tempting to speculate that the presence of 5HT2B on Kupffer cells
has a direct impact on liver regeneration. In this regard, the ability
of the 5HT2B agonist BW723C86 to favor the in vitro maintenance
of the M2 macrophage polarization state, characterized by its
tissue repair– and cell growth–promoting properties, supports such
a hypothesis.
Besides Kupffer cells, we have identified 5HT2B expression in
TAM, which display a tumor-promoting and immunosuppressive
M2-like polarization (46). A link between 5HTand macrophages in
cancer progression has been already established, as 5HT enhances
angiogenesis in murine colon cancer allografts via the 5HT-
dependent reduction of MMP12 expression by tumor-infiltrating
macrophages (26). Our results on the phenotypic changes in-
duced by 5HT and BW723C86 on human macrophages are com-
patible with these findings because: 1) both stimuli inhibitMMP12
mRNA expression (Supplemental Fig. 4), thus suggesting 5HT2B as
a mediator of inhibitory effect of 5HT on MMP12 expression; and
2) both stimuli skew macrophages toward M2 polarization, which
is associated with potent proangiogenic activity (46). Therefore,
our results suggest that 5HT2B is a relevant receptor whose ex-
FIGURE 6. Effects of 5HT receptor antagonists on the 5HT-dependent
changes in the gene expression and LPS-induced cytokine profile of M2
(M-CSF) macrophages. (A) STAB1, SERPINB2, COL23A1, THBS1, and
ALDH1A2 mRNA expression levels in M2(M-CSF) macrophages exposed
for 24 h to 5HT (1025 M) in the absence or in the presence of SB269970
(SB-7), SB204741 (SB-2B), or both, as determined by qRT-PCR. Results
are expressed as relative expression and are referred to the expression level
of each gene in the presence of 5HT. Mean and SD of triplicate deter-
minations on three independent samples are shown. *p , 0.05, **p ,
0.005 compared with the level of expression detected in the absence of
antagonists. (B) ELISA determination of TNF-a, IL-12p40, and IL-10
levels in culture supernatants of M2(M-CSF) macrophages untreated or
stimulated with LPS (10 ng/ml) for 24 h in the absence or presence of 5HT,
or 5HT plus the 5HT7 antagonist SB269970 (SB-7), the 5HT2B antagonist
SB204741 (SB-2B), or both antagonists. Each determination was per-
formed in triplicate on five independent samples, and mean and SD are
shown. *p , 0.05, **p , 0.005 compared with the level of each cytokine
in macrophages exposed to LPS plus 5HT.
FIGURE 7. The presence of 5HT2B or 5HT7 antag-
onists during the monocyte-to-macrophage differentia-
tion process impairs the acquisition of macrophage
polarization markers. Expression levels are shown of
STAB1, SERPINB2, COL23A1, THBS1, and HTR2B
(A) and ALDH1A2, SERPINE1, MMP12, INHBA,
CCR2, and CD1B (B) mRNA in M2(M-CSF) macro-
phages generated in the continuous presence of DMSO,
SB269970 (SB7), SB204741 (SB2B), or both, as de-
termined by qRT-PCR. Results are expressed as relative
expression (relative to GAPDH RNA levels) and are
referred to the expression level of each gene in the
presence of DMSO. Mean and SD of triplicate deter-
minations on three independent samples are shown.
*p , 0.05 compared with the level of expression de-
tected in the absence of antagonists.
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pression on human macrophages might mediate the proprolifer-
ative and tissue repair activity of 5HT in peripheral tissues.
Alternatively, the location of 5HT2B-expressing TAM in the
proximity of VE-cadherin–positive endothelial cells (Fig. 3) might
be also of significance considering the link between 5HT2B ex-
pression and pulmonary arterial hypertension (PAH) (47). PAH is
characterized by vascular remodeling secondary to abnormal cell
proliferation and extracellular matrix deposition, with the latter
two activities commonly linked to M2 macrophage polarization.
Thus, the presence of 5HT2B in lung macrophages, as well as its
expression in human TAM, which promote tumor cell growth and
dissemination, raises the question of whether 5HT2B-positive
macrophages might contribute to PAH by enhancing proliferation
of other cell types (endothelium, smooth muscle) or through ex-
acerbated extracellular matrix deposition. This possibility is com-
patible with the recent finding that PAH development requires the
expression of the murine 5HT2B receptor in bone marrow–derived
progenitor cells (27).
Previous reports have documented the ability of 5HT to mod-
ulate the production of numerous cytokines in mononuclear cells,
monocytes, monocyte-derived dendritic cells, and ex vivo–isolated
macrophages (14, 48). Whereas the inhibition of TNF-a produc-
tion is a general finding, the effects of 5HT on other proin-
flammatory cytokines and IL-10 are variable, and they appear to
be cell type–dependent. Interestingly, most previous studies have
evaluated 5HT on myeloid cells in medium containing serum,
where 5HT concentration is as high as 1–2 mM, thus potentially
leading to an underestimation of the influence of 5HT. Alterna-
tively, the presence of serum factors could modulate or synergize
with 5HT, and it might have caused an overestimation of the 5HT
influence. In an effort to avoid these potentially confounding
issues, we have carried out all experiments on macrophages
maintained in serum-free medium for 48 h. Thus, apart from the
cell type–specific nature of 5HT actions, the distinct medium used
for assaying 5HT might explain the discrepancy between the lack
of effect of 5HT on IL-10 release seen in our experiments and
those of others (20, 49) and the positive action of 5HT in IL-10
production described in human alveolar cells and monocyte-
derived dendritic cells (22, 23). Despite these discrepancies, our
results are in agreement with the lack of effect of 5HT2 agonists
on the LPS-induced monocyte cytokine production (21).
The results presented in this study reveal that the modulation
of the phenotypic and functional macrophage polarization by 5HT
is mediated by both 5HT2B and 5HT7 receptors. At the functional
level, our results point to 5HT7 as the critical receptor mediating
the effect of 5HT on macrophage cytokine production. Within the
myeloid cell lineage, HTR7 mRNA has been identified in human
monocytes (21) and mature MDDC (28), and, similar to the case
of M2(M-CSF) macrophages, 5HT7 has been shown to negatively
regulate the secretion of TNF-a from mature MDDC (28) and
LPS-activated monocytes (21). Whereas 5HT7 agonists also en-
hance the release of IL-1b and IL-8 from MDDC (28) and
monocytes (21), opposite activities on IL-12 have been reported in
both cell types. Our results extend those previous findings to the
case of anti-inflammatory macrophages and, to our knowledge,
also provide the first evidence that 5HT7 directly contributes to the
gene expression changes provoked by 5HT in human macro-
phages.
The ability of 5HT to promote the maintenance of the M2
phenotype and to impair the release of proinflammatory cytokines
is in agreement with the recent finding that platelet-derived 5HT
delays activated virus-specific CD8+ T cell infiltration in a murine
model of noncytopathic lymphocytic choriomeningitis viral in-
fection (50), and suggests that tissue macrophages might over-
come the action of peripheral 5HT to display their full range of
proinflammatory activities. In fact, note that 5HT is released from
enterochromaffin cells along the gut, where macrophages mostly
release anti-inflammatory molecules (including IL-10) upon
stimulation (36). 5HT might therefore contribute to the mainte-
nance of the anti-inflammatory profile of lamina propria macro-
phages, an effect that could be mediated by 5HT2B on intestinal
macrophages (Supplemental Fig. 2). This possibility, combined
with the functions of 5HT in the hepato-gastrointestinal tract (9),
should prompt further investigation on the role of the macrophage
5HT2B and 5HT7 receptors in liver and gut physiopathology.
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Supplementary Figure 1.- A.- Relative mRNA expression levels of the indicated genes in four independent M1(GM-CSF) and M2(M-
CSF) macrophage samples, as determined by qRT-PCR. Results are shown as the log of the ratio between the expression of each 
mRNA in M2(M-CSF) and M1(GM-CSF) macrophages. B,C.- Expression of FOLR2 (B), DC-SIGN (C) and EGLN3 (C) in M1(GM-
CSF), M2(M-CSF) and M2(M-CSF) macrophages that had been maintained under serum-free conditions for 48 hours (M2*), as 
determined by flow cytometry with a FOLR2-specific polyclonal antiserum (B) or Western blot using polyclonal antisera specific for 
either DC-SIGN or human PHD3 (C). In C, and for loading control purposes, the levels of GAPDH were determined with a 
monoclonal antibody against GAPDH (sc-32233; Santa Cruz Biotechnology, Santa Cruz, CA). In B-C, shown are the representative 
results of one out of two independent experiments.
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Supplementary Figure 2.- Expression of 5-HT2B in human tissues, as determined by immunohistochemistry on lung (a,b), colon (c,d) 
and liver (e,f) tissue sections. Shown are light microscopy images (40X magnification) of the indicated tissues after staining with a 
anti-5-HT2B antibody rabbit polyclonal (a,c,e) or an anti-CD68 murine monoclonal antibody (b,d,f). Similar results were obtained on 
two independent samples of each tissue, and one of them is shown.
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Supplementary Figure 3
Supplementary Figure 3.- Activity of the indicated reporter constructs in CHO-K1 
(5-HT2B) stable transfectants either unstimulated (-) or exposed to 5-HT or 
BW723C86 (10-5 M). For normalization, cells were co-transfected with the RSV-�-
gal expression plasmid, and results are presented as Relative Promoter Activity, that 
indicates the units of luciferase activity per unit of �-galactosidase activity for each 
assay condition. Three independent experiments were done, and evaluation of 
luciferase activity was done in triplicate. Shown are the mean and standard 
deviations of the three experiments (*, p < 0.05). 
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Supplementary Figure 4
Supplementary Figure 4.- Effects of 5-HT and BW723C86 on polarization 
marker expression.- SERPINE1, MMP12, INHBA, CCR2 and CD1B mRNA 
expression levels in M2(M-CSF) macrophages exposed to either 5-HT or 
BW723C86 (10-5 M) for 24 hours, as determined by qRT-PCR. Results are 
expressed as Relative Expression (relative to TBP, HPRT1, SDHA and GAPDH 
RNA levels) and referred to the expression level observed in the absence of 
stimulation (-). Mean and standard deviation of triplicate determinations on ten 
(for 5-HT) or thirteen independent samples (for BW723C86) are shown (*, p < 
0.05; **, p < 0.005).
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absTracT
Serotonin (5-hydroxytryptamine, 5HT) is a monoamine neurotransmitter that regulates mood, appetite and 
sleep within the nervous system. In periphery, however, 5HT acts as a growth factor and a regulator of wound 
healing and inflammation. Since 5HT skews human macrophage polarization via engagement of 5-HT2B and 
5-HT
7  
receptors, we undertook the identification of the 5HT-dependent gene expression profile in human ma-
crophages. We now report that the 5-HT
7
-cAMP-PKA axis is responsible for the 5HT-dependent expression 
of genes encoding growth factors (EREG), growth factor receptors (MET), cytokines (IL1B) and cell surface 
molecules involved in macrophage activation (TREM1), all of which might contribute to the growth-promoting 
and immunomodulatory functions of 5HT. In addition, we have determined that 5HT, via ligation of 5-HT2B, 
regulates the expression of type I IFN-responsive genes (CXCL10, IFI2, IFIT3, TNFSF18), thus defining a 
novel link between 5HT and the expression of genes that govern antiviral responses by human macrophages. 
inTroDucTion
Serotonin (5-hydroxytryptamine, 5HT) is a monoamine neurotransmitter derived from L-tryptophan via a 
rate-limiting reaction catalyzed by two tryptophan hydroxylases (TPH1, THP2) with different expression pat-
terns (TPH1 in periphery, TPH2 in brain) (1). Serotonergic neurons regulate mood, appetite, sleep, memory 
and learning, and modulation of 5HT at synapses is a major mechanism of action of several pharmacological 
antidepressants (2-4). However, ninety per cent of the human body’s 5HT is synthesized and secreted by the 
enterochromaffin cells in the gastrointestinal tract, where 5HT controls intestinal movements. Enterochromaf-
fin cell-derived 5HT is actively taken up by blood platelets that, upon activation, release it to exert a vasocons-
trictor and growth factor function on smooth muscle cells (5), hepatocytes (6) and endothelial cells (7), thus 
contributing wound healing. 5HT also functions as a regulator of inflammation (8), as it modulates cytokine 
production in a cell type-dependent manner (9-11). In human alveolar macrophages, 5HT inhibits IL-12 and 
TNFα release, but increases IL-10, NO and PGE2 production (12), whereas it is capable of modulating T-
cell activation, proliferation and differentiation (13). Regarding inflammatory pathologies, 5HT regulates ma-
crophage-mediated angiogenesis by reducing MMP12 expression (14), and contributes to Pulmonary Arterial 
Hypertension (PAH) via 5-HT2B receptor engagement on bone-marrow progenitors (15). 5HT signals through 
seven types of receptors (5-HT
1-7
), six of which belong to the G protein-coupled superfamily of receptors (5-
HT
1
, 5-HT2, 5-HT4, 5-HT5, 5-HT6, 5-HT7).
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GM-CSF and M-CSF promote the in vitro differentiation of macrophages with distinct morphology, pathogen 
susceptibility and inflammatory function (16-18). GM-CSF drives the generation of monocyte-derived ma-
crophages that produce pro-inflammatory cytokines in response to LPS and display high antigen-presenting 
and tumoricidal capacity (M1-polarized macrophages). Conversely, M-CSF yields macrophages that release 
IL-10 in response to pathogens and exhibit high phagocytic and pro-tumoral activity (M2-polarized macropha-
ges) (16,19). We have previously demonstrated that the complement of 5HT receptors is different between 
pro-inflammatory (M1) and anti-inflammatory (M2) human macrophages, and that the presence of 5-HT2B and 
5-HT
7
 shapes the phenotype and effector functions of monocyte-derived macrophages (20). We now report 
the identification of the 5HT-dependent gene expression profile of human macrophages, demonstrate that the 
5-HT
7
-cAMP-PKA signaling axis is critical for the 5HT-dependent acquisition of anti-inflammatory functions, 
and provide evidences for the ability of 5HT to alter the expression of IFN-responsive genes via engagement 
of 5-HT2B. Our findings establish 5HT-initiated signaling cascades as critical modulators of macrophage pola-
rization and potential targets for modulating inflammatory responses.
MaTerials anD MeThoDs
Generation of human monocyte-derived macrophages and cell isolation and culture.- Human peripheral 
blood mononuclear cells (PBMC) were isolated from buffy coats from normal donors over a Lymphoprep 
(Nycomed Pharma, Oslo, Norway) gradient according to standard procedures. Monocytes were purified from 
PBMC by magnetic cell sorting using CD14 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). 
Monocytes (>95% CD14+ cells) were cultured at 0.5 x 106 cells/ml for 7 days in RPMI supplemented with 
10% fetal calf serum (FCS) (completed medium), at 37ºC in a humidified atmosphere with 5% CO2, and con-
taining GM-CSF (1000U/ml) or M-CSF (10 ng/ml) (both from ImmunoTools GmbH, Friesoythe, Germany) 
to generate M1(GM-CSF) (hereafter termed M1) and M2(M-CSF) (hereafter termed M2) monocyte-derived 
macrophages, respectively. Cytokines were added every two days. Before treatment with 5HT, M2 macropha-
ges were maintained in serum-free medium for 48 hours, without a significant change in the level of expression 
of M2 polarization-specific markers. Macrophage activation was accomplished with LPS (E. coli 055:B5, 10 
ng/ml) for 24 hours. Receptor antagonists SB204741 (for 5-HT2B) and SB269970 (for 5-HT7) were purchased 
from Sigma, used at 1 μM, and added 1 hour before 5HT treatment. 5HT Receptor-specific agonists included 
BW723C86 (5-HT2B) and LP12 (5-HT7) where used at 10-5M and 10-6M respectively. In the case of cAMP 
analogs the concentration used was 200 μM for Br-cAMP, 50μM for dBR-cAMP, and 10 μM in the case of 
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forskolin. The PKA-specific activator 6-BNZ-cAMP and the Epac-specific activator 8-pCPT-2′-O-Me-cAMP 
were obtained from Sigma Aldrich and used at 200 μM and 100 μM, respectively. The PKA-specific inhibitor 
RP-8-CPT-cAMPS was obtained from Biolog and was used at 1 μM.
ELISA.-  Macrophage supernatants were tested for the presence of cytokines and growth factors using com-
mercially available ELISA for TNF-α, IL-10, IL1B (all from Biolegend), IL-12 p40 (OptEIATM IL-12 p40 set, 
BD Pharmingen, San Diego, CA) and EREG (USCN life science Inc.), following the protocols supplied by the 
manufacturers. 
Quantitative real-time RT-PCR.-  Oligonucleotides for selected genes were designed according to the Uni-
versal Probe Roche library system (Roche Diagnostics) for quantitative real time PCR (qRT-PCR). Total RNA 
was extracted using the RNeasy kit (Qiagen), retrotranscribed, and amplified in triplicates. Results were ex-
pressed relative to the expression level of GAPDH RNA to the values obtained in untreated cells.
Microarray analysis.- RNA was isolated from three independent preparations of macrophages exposed to 
5HT, BW723C86 or DMSO for 6 hours by using AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Labeled 
RNA was used as a hybridization probe on Whole Human Genome Microarrays (Agilent Technologies, Palo 
Alto, CA). Gene expression data were filtered eliminating any non probe-gene and probes with low signals and 
questionable quality.  A total of 36232 useful probes were obtained for subsequent analysis, and quantiles were 
normalized. For the detection of differentially expressed genes, a linear model was fitted to the data and em-
pirical Bayes moderated statistics were calculated using the limma package from Bioconductor (Smyth, G. K. 
(2005). Limma: linear models for microarray data. In: ‘Bioinformatics and Computational Biology Solutions 
using R and Bioconductor’. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (eds), Springer, New 
York, pages 397-420). All computations were done using R statistical software.
Statistical analysis.- Statistical significance was assessed at the 0.05 level using a paired Student t-test. 
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resulTs
Serotonin inhibits proinflammatory cytokine production in human macrophages.- We have previously de-
monstrated that 5HT inhibits the LPS-induced production of IL-12p40 and TNFα and had no effect on IL-10 
production when both stimuli (5HT and LPS) are added simultaneously. However, it remained to be deter-
mined whether 5HT-pretreated macrophages exhibited an altered proinflammatory cytokine release. To that 
end, macrophages were pretreated with 5HT and exposed to LPS after 6 hours. As seen in Figure 1A, 5HT 
pretreatment led to a significant reduction in the LPS-induced production of IL-12p40 and TNFα, whereas it 
had no effect on IL-10 production. Therefore, 5HT conditions macrophages for diminished production of pro-
inflammatory cytokines upon exposure to a pathogenic stimulus. 
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Figure 1.- Serotonin shapes the cytokine and gene expression profile of human macrophages.- A. Determination of TNFα, 
IL-12p40 and IL-10 levels in culture supernatants of non-treated (-) or 5HT-treated (6 h) macrophages, after stimulation with LPS 
(10 ng/ml) for 18 hours. Each determination was performed in triplicate on three independent macrophage samples, and means and 
standard deviations are shown (n=4, *, p < 0.05 compared to the cytokine levels in LPS-treated macrophages (LPS)). B. Schematic 
representation of the profiling experiments, with indication of the treatment and time points for sample collection. C.  Quantifica-
tion of the number of genes whose expression is significantly upregulated or downregulated (adjusted p<0.05) after treatment with 
5HT for 6 hours. D. Relative expression of the indicated genes in non-treated (-) or 5HT-treated (6 h) macrophages. Results are ex-
pressed as Relative Expression that indicates the expression of the corresponding mRNA relative to the GAPDH mRNA levels in 
each sample. Three independent experiments were performed and mean and standard deviations are shown (*, p<0.05; **, p<0.01). 
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Identification of the 5HT-dependent gene expression profile in human macrophages.- As a mean to deter-
mine the 5HT-dependent transcriptome in human macrophages, cells were exposed to 5HT and global gene 
expression changes analyzed after 6 hours (Figure 1B). Transcriptional profiling revealed that the expression 
of 361 genes was significantly altered upon exposure to 5HT, with a roughly similar amount of upregulated and 
downregulated genes (Figure 1C). Analysis of 5HT-responsive genes revealed the presence of numerous genes 
associated with macrophage activation, including IL1B and TREM1, as well as genes that code for proteins 
that control intracellular cAMP levels like PDE2A and PDE7B (Table I). To validate the microarray transcrip-
tomic data, 5HT-dependent gene expression was evaluated in independent macrophage samples. As shown in 
Figure 1D, 5HT significantly upregulated the expression of genes like PDE2A, PDE7B, EREG, ILIB, TREM1, 
THBS1 and MET. Assessment of the functional activity of 5HT-regulated genes indicated their involvement in 
modulation of cAMP-mediated signalling, VDR/RXR Activation, Docosahexaenoic Acid (DHA) Signalling, 
Clathrin-mediated Endocytosis Signalling and mTOR Signalling (Supplementary Figure 1), and predicted 
forskolin and PGE2 as their putative upstream regulators (Supplementary Figure 2). As a whole, these results 
confirmed the ability of 5HT to modulate the expression of genes directly involved in macrophage activation. 
Top 5HT regulated genes Top BW723C86 regulated genes 
Gene symbol 5HT/C p Gene symbol 5HT/C p Gene symbol BW/C p Gene symbol BW/C p 
PDE2A 13.20 2.9844E-05 BNIPL -2.08 0.00529128 EIF5B 6.51 0.0037544 HEPACAM -2.20 0.00293896 
PDE7B 5.99 0.00130597 TPTE2P1 -2.08 0.04562586 CISH 4.80 0.00227339 PLAC1 -2.25 0.01054164 
EIF5B 4.98 0.01414957 MAP2 -2.12 0.00786528 REXO1L1 4.64 0.01407177 KAZALD1 -2.25 0.00587898 
MET 4.91 0.00497563 ECEL1 -2.12 0.04486986 DDX6 4.52 0.00636526 IGSF10 -2.27 0.00786169 
TREM1 4.42 0.00122957 CDC20B -2.12 0.00667189 RSAD2 4.48 0.00732694 GCNT4 -2.27 0.01770033 
PLAT 4.34 0.01510161 SPRR1A -2.13 0.00620383 IFIT2 4.45 0.00132356 LALBA -2.34 0.04010939 
AZI2 4.06 0.00547121 GRIA1 -2.17 0.03452025 RPL21 4.33 0.01810706 CDC20B -2.34 0.00573081 
STAT4 3.95 0.00074132 NEK7 -2.19 0.00973714 NDUFA6 4.18 0.00598053 RSPH4A -2.35 0.00249602 
EREG 3.27 0.01377387 PLEKHG7 -2.19 0.00708648 AZI2 3.89 0.00627127 KPNA7 -2.44 0.00157983 
SIPA1L1 3.04 0.00128322 KLK13 -2.21 0.02991914 CDC42 3.82 0.00284724 FAM135B -2.44 0.00864682 
SIDT1 3.03 0.00232599 MCHR2 -2.25 0.01261128 IMPACT 3.82 0.01943155 OR4K2 -2.46 0.02915229 
HOXB3 2.99 0.02514732 HDAC9 -2.25 0.02328635 OASL 3.69 0.00083665 TMPRSS15 -2.49 0.01953383 
SEMA5A 2.91 0.0015864 TEX9 -2.27 0.04291463 CST5 3.68 0.02976087 ADAM12 -2.52 0.00303682 
ST6GALNAC3 2.90 0.00018912 H2BFWT -2.31 0.00196815 RGS4 3.62 0.00263792 ANKRD56 -2.57 0.00216008 
SYT14 2.79 0.03301681 TMPRSS15 -2.32 0.00292369 EIF4B 3.58 0.01384987 YJEFN3 -2.59 0.00951135 
CDC42 2.75 0.01927368 KPNA7 -2.35 0.00462084 PCDH9 3.33 0.00714172 TTN -2.62 0.00385423 
BTBD11 2.65 0.00058571 ADAMTSL1 -2.46 0.03811199 SLC9A3 3.26 0.04843774 WT1 -2.63 0.00024227 
CREM 2.65 0.00642774 RASGRF2 -2.53 0.01111136 LEP 3.25 0.0183936 S1PR5 -2.71 0.01573084 
SMOX 2.64 0.00017096 PRDM9 -2.58 0.04165992 PRR23A 3.23 0.01742533 KLK13 -2.71 0.01390964 
CPNE6 2.57 0.04621476 CCDC114 -2.63 0.03379949 QKI 3.22 0.00353718 TNFSF18 -2.81 0.00487245 
SEMA6B 2.55 0.00260665 ADAM12 -2.70 0.03898422 SULT1A2 3.22 0.00099811 SERPIND1 -3.00 0.01405119 
SULT1A2 2.55 0.00626473 DEFB106B -2.74 0.0011248 CCZ1 3.05 0.02813603 FBXW12 -3.14 0.00090772 
PKIB 2.55 0.00883159 PLAC1 -2.86 0.01341949 RPS23 2.98 0.00267266 ECEL1 -3.14 0.00283073 
CDKN1C 2.51 0.00093617 OR6Q1 -2.98 0.03886197 IFIT1 2.90 0.00998218 KRT75 -3.65 0.00128444 
SMPDL3A 2.47 0.02190835 OR4K2 -3.12 0.00603715 MPPED2 2.74 0.01068319 HBG1 -3.75 0.00854594 
CLEC4D 2.43 0.02927023 WT1 -3.33 0.00064773 MET 2.73 0.00975211 TEX9 -4.40 0.00035768 
MOB3B 2.43 0.00027666 GARNL3 -3.44 0.04430381 CYP1B1 2.63 9.4237E-05 EFCAB8 -7.56 0.00893481 
Table I 
Top Serotonin- and 5HT2B-dependent genes 
Table 1. Top Serotonin- and 5-HT2B dependent genes
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5HT-dependent gene expression in macrophages is mainly mediated by the 5-HT7 - cAMP-PKA signaling 
axis.-  To dissect the process of gene upregulation in response to 5HT, kinetic analysis was performed by de-
termining the changes in gene expression after 2, 4, 6 and 12 hours of exposure to 5HT. Surprisingly, EREG, 
IL1B, and TREM1 gene expression was significantly upregulated after 2 hours of exposure to 5HT (Figure 2), 
whereas those of PDE2A, PDE7B, THBS1 and MET were only observed after 4 and 6 hours, and only PDE2A 
expression remained significantly elevated after 12 hours (Figure 2). The heterogeneity of responsiveness to 
5HT suggested the existence of different pathways that mediate the 5HT-dependent upregulation of gene ex-
pression in macrophages. As we have previously demonstrated that 5HT alters the expression of macrophage 
polarization markers via engagement of 5-HT2B and 5-HT7 receptors (20), we hypothesized that 5-HT7 might 
mediate most of the observed 5HT-induced gene expression changes. To address this issue, macrophages 
were treated with a 5-HT
7
 specific agonist (LP12), or exposed to 5HT in the presence of a 5-HT7 antagonist 
(SB269970). The presence of the 5-HT
7
 antagonist SB269970 abrogated the 5HT-triggered upregulation of 
EREG, PDE2A, PDE7B and TREM1 (Figure 3A). Moreover, these genes, together with THBS1 and MET, were 
significantly upregulated upon exposure of macrophages to the 5-HT
7
 agonist LP12 (Figure 3B). In the same 
line, 6 hours LP-12-treatment lead to a reduction LPS-induced TNFα and IL-12p40 production, whereas it had 
no effect on IL-10 levels (Figure 3C).  Therefore, these experiments allowed us to conclude that a significant 
proportion of the 5HT-dependent gene expression changes in human macrophages are dependent on 5-HT
7
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Figure 2.- Influence of 5HT 
and the 5HT2B agonist 
BW723C86 on the gene ex-
pression profile of human ma-
crophages.- Relative expres-
sion of the indicated genes in 
macrophages either untreated 
(-) or treated with 5HT or the 
5-HT2B agonist BW723C86 
(BW) for 2, 4, 6 and 12 hours. 
Results are expressed as Relati-
ve Expression, which indicates 
the expression of the corres-
ponding mRNA relative to the 
GAPDH mRNA levels in each 
sample. Three independent ex-
periments were performed and 
mean and standard deviations 
are shown. (*, p<0.05).
Upon ligand binding, 5-HT
7
 augments cAMP (21), whose targets include PKA and exchange factor directly 
activated by cAMP (Epac) (22). Since a number of 5HT-regulated genes were related to the cAMP signalling 
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pathway (Supplementary Figures 1 and 2), and were directly induced by a 5-HT
7
 receptor agonist (Figure 
3B), we assessed the ability of cAMP analogs to upregulate the expression of 5HT-regulated genes. Br-cAMP 
and dBr-cAMP significantly upregulated the expression of genes significantly altered by the 5-HT
7
 receptor 
agonist (Figure 4A, B). Furthermore, all of them were significantly upregulated by either forskolin or the PKA-
specific activator 6-Bnz-cAMP, but not by the specific Epac activator cAMP analog 8-(4-chlorophenylthio)-2′-
O-methyl-cAMP (8-pCPT) (Figure 4A, B). 
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Figure 3.- Influence of the 5HT7 receptor on the gene expression profile of human macrophages.- A. 
Relative expression of the indicated genes in macrophages either untreated (-) or treated with 5HT (6 h) in the 
absence (-) or the presence of an antagonist of the 5-HT7 receptor. Results are expressed as Relative Expression, 
which indicates the expression of the corresponding mRNA relative to the GAPDH mRNA levels in each 
sample. Three independent experiments were performed and mean and standard deviations are shown. (*, 
p<0.05). B.  Relative expression of the indicated genes in macrophages either untreated (-) or treated (6 h) 
with 5HT or the -HT7 receptor agonist LP12. Results are expressed as Relative Expression, that indicates the 
expression of the corresponding mRNA relative to the GAPDH mRNA levels in each sample. Three independent 
experiments were performed and mean and standard deviations are shown. (*, p<0.05). C. Determination of 
TNFα, IL-12p40 and IL-10 levels in culture supernatants of non-treated (-) or LP12-treated (6 h) macrophages, 
after stimulation with LPS (10 ng/ml) for 18 hours. Each determination was performed in triplicate on three 
independent macrophage samples, and means and standard deviations are shown (n=4, *, p < 0.05 compared to 
the cytokine levels in LPS-treated macrophages (LPS)) 
To definitively establish the involvement of the 5-HT
7
-cAMP-PKA axis in the 5HT-dependent upregulation of 
the aforementioned genes, macrophages were exposed to the 5-HT
7
 agonist LP12 in the presence of the PKA 
inhibitor RP-8-CPT-cAMPS. As expected, the upregulation of EREG, PDE2A, TREM1, THBS1 and MET 
by LP12 was significantly reduced in the presence of the PKA inhibitor RP-8-CPT-cAMPS (Figure 4A, B). 
Therefore, the 5HT-initiated upregulation of PDE2A, PDE7B, EREG, TREM1, THBS1 and MET is mediated 
by 5-HT7 and the subsequent cAMP-dependent activation of PKA, without a significant contribution of Epac. 
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Figure 4.- Influence of the cAMP-dependent signaling pathways on the gene expression profile of human 
macrophages.- A,B. Relative expression of the indicated genes in macrophages either untreated (-) or treated (6 h) 
with Br-cAMP, dBr-cAMP, Forskolin, 6-Bnz-cAMP (6Bnz) or 8-(4-chlorophenylthio)-2′-O-methyl-cAMP (8cPT). 
Right panels: Relative expression of the indicated genes in macrophages either untreated (-) or treated (6 h) with 5HT 
or the 5-HT7 receptor agonist LP12 and either in the absence or the presence of the PKA inhibitor RP-8-CPT-cAMPS 
(RP-8). In all cases, results are expressed as Relative Expression, that indicates the expression of the corresponding 
mRNA relative to the GAPDH mRNA levels in each sample. Three independent experiments were performed and 
mean and standard deviations are shown. (*, p<0.05; **, p<0.01).
The functional relevance of the 5HT-dependent gene expression changes was corroborated through evaluation 
of changes at the protein level. To that end, the release of IL1β and Epiregulin, the proteins encoded by IL1B 
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Figure 5.- Effect of 5HT on the production of Epiregu-
lin and IL-1β.- A,B. Determination of Epiregulin (A) and IL-
1β (B) in the culture supernatants of macrophages either non-
treated (-) or exposed to 5HT, BW723C86 or LP12 for 4 and 6 
hours, as determined by ELISA.  Each determination was per-
formed in triplicate on 4 independent macrophage samples, 
and means and standard deviations are shown (n=4, *, p < 0.05 
compared to the cytokine levels in untreated macrophages). 
and EREG respectively, was measured in macrophages exposed to 5HT. As shown in Figure 5, epiregulin 
was detected at detectable levels in macrophages treated with 5HT or even the 5-HT2B agonist (Figure 5A). 
Conversely, no IL1β was found in the supernatant of 5HT-treated macrophages (Figure 5B). 
The 5-HT2B receptor also contributes to the serotonin-dependent gene expression in macrophages.- We 
have previously shown that the 5-HT2B receptor constitutes a marker for M2 macrophage polarization in vitro 
and in vivo, and that 5-HT2B influences macrophage polarization (20). As a mean to determine whether 5-HT2B 
also contributed to the 5HT-dependent gene expression profile in macrophages, transcriptional profiling was 
done on macrophages that had been exposed to the 5-HT2B agonist BW723C86 for 6 hours (Figure 6A). 
More than 400 genes were regulated upon exposure to BW723C86 (Figure 6B). Microarray data were verified 
on independent macrophage samples, and BW723C86 was found to regulate the expression of IL1B, IFIT1, 
IFIT2, RSAD2, CXCL10, ETV7 and TNFSF18 (Figures 2 and 6C). Except for the case of IL1B and TNFSF18, 
none of these genes were significantly affected by 5HT (Figure 2 and 6C), thus suggesting a predominance of 
5-HT
7
 receptor in the 5HT-dependent gene profile in human macrophages. In fact, comparison of the 5HT- and 
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BW723C86-dependent profiles revealed that only a gene subset was regulated by both agents (Figure 6D and 
Table I). Altogether, these results illustrate that 5HT modifies the macrophage gene expression through more 
than one receptor (at least 5-HT
7 
and 5-HT2B), an explanation that is compatible with our previous report on the 
modulation of macrophage polarization by both receptors (20). 
Identification of a 5-HT
2B
-mediated link between 5HT and IFN signaling.- Gene ontology analysis indicated 
that BW723C86 affects the expression of genes associated with Coagulation, Interferon Signaling, Aryl 
Hydrocarbon Receptor Signaling, Chemokine Signaling and EIF2 Signaling (Supplementary Figure 1), 
whereas Ingenuity Pathway Analysis revealed a significant link between BW723C86-upregulated genes and 
the IFN type I signaling pathway (Supplementary Figure 2). Besides, SOCS1 (p=6.04 x 10-6) and Interferon 
(p=2.07 x 10-5) were predicted as Upstream Regulators of BW723C86-regulated genes (Supplementary Figure 
2). Therefore, we searched for interferon (IFN)-regulated genes within the 5-HT2B receptor-regulated genes. 
Interestingly, 16% of the 177 genes upregulated by BW723C86, but not 5HT, turned out to be regulated by 
IFN (http://www.interferome.org). Along the same line, 18% of the genes upregulated by either BW723C86 or 
5HT have been previously identified as IFN-responsive (http://www.interferome.org). Importantly, the specific 
involvement of 5-HT2B receptor in the gene changes observed upon BW723C86 treatment was demonstrated 
through the use of the 5-HT2B receptor antagonist SB204741,  which inhibited the BW723C86-mediated 
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 Figure 6.- Determination of the 5-HT2B-dependent gene 
expression profile in human macrophages.- A.  Schematic re-
presentation of the profiling experiments, with indication of the 
treatment and time points for sample collection. B.  Quantifi-
cation of the number of genes whose expression is significantly 
upregulated or downregulated (adjusted p<0.05) after treatment 
with BW723C86 for 6 hours. C. Relative expression of the indi-
cated genes in non-treated macrophages (-) or macrophages ex-
posed to 5HT or BW723C86 for 2, 4, 6 or 12 hours. Results are 
expressed as Relative Expression, that indicates the expression of 
the corresponding mRNA relative to the GAPDH mRNA levels in 
each sample. Three independent experiments were performed and 
mean and standard deviations are shown. (*, p<0.05).  D. Compa-
rison of the number of genes whose expression in macrophages is 
significantly (adjusted p<0.05) regulated, upregulated or downre-
gulated after treatment (6 hours) with either 5HT or BW723C86. 
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regulation of IFIT1, IFIT2, CXCL10, RSAD2 and TNFSF18 genes (Figure 7A). These findings support the 
existence of a potential link between 5HT and interferon signaling. Moreover, the ability of BW723C86 to 
upregulate the expression of paradigmatic IFN-regulated genes like IFIT1, IFIT2, RSAD2, OASL, CXCL10 
and ETV7 (Table I and Figure 6C) and basal levels of CXCL10 protein (Figure 7B) suggests that such a link is 
primarily 5-HT2B-dependent. 
Discussion 
We have previously reported that 5HT skews macrophage polarization (20). The data in the present manuscript 
further extends this finding, as we have determined the whole range of polarization-associated markers 
specifically affected by 5HT. Comparison of the 5HT- and BW723C86-dependent gene expression profiles 
with those of proinflammatory M1 and anti-inflammatory M2 macrophages (23) indicates that 5HT modulates 
a higher number of M2-specific genes (including MS4A7, TTYH2, ISG20, RGS2, OLFML2B, HMOX1, S1PR1 
and NAMPT) (Supplementary Figure 3). The ability of 5HT to alter the expression of HMOX1 (that encodes 
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 Figure 7.- The 5-HT2B receptor mediates the gene expression changes induced by BW723C86 
on macrophages.- A. Relative expression of the indicated genes in non-treated macrophages (-), 
macrophages exposed for 6 hours to BW723C86 in the presence or in the absence or the 5-HT2B 
antagonist SB SB204741 (SB2B), or macrophages exposed solely to the 5-HT2B antagonist. Re-
sults are expressed as Relative Expression, that indicates the expression of the corresponding 
mRNA relative to the GAPDH mRNA levels in each sample. Three independent experiments were 
performed and mean and standard deviations are shown. (*, p<0.05).  B. Determination of CXCL10 
levels in culture supernatants of non-treated (-) or 5-HT-treated or BW723C86 (6 h) macrophages, 
after stimulation with LPS (10 ng/ml) for 18 hours. Each determination was performed in triplicate 
on two independent macrophage samples, and means and standard deviations are shown (n=2). 
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Heme-Oxygenase 1) and S1PR1 (that codes for the sphingosine-1-phosphate (S1P) receptor 1) is of special 
interest because the S1PR1 agonist FTY720 increases the expression of Heme-Oxygenase 1, that exhibits 
anti-apoptotic and anti-inflammatory activity, and because Heme-Oxygenase 1 favors the acquisition of an 
anti-inflammatory phenotype in macrophages exposed to S1P-containing apoptotic cell supernatants (24,25). 
Therefore, it is conceivable that 5HT participates in the M1-to-M2 macrophage polarization switch that takes 
place in the presence of apoptotic cells and apoptotic cell-derived products. 
In peripheral tissues, 5HT regulates cell proliferation, inflammation and tissue repair (6,26,27). 5-HT
7
 is 
primarily expressed in smooth muscle cells of blood vessels (28)  and the gastrointestinal tract (29), and also 
detected in kidney, liver, pancreas and spleen. Interestingly, the physiological processes regulated by 5HT (cell 
proliferation, tissue repair, inflammation) are also critically modulated by tissue macrophages in a polarization-
dependent manner (30). However, and in spite of its potential in vivo significance, the role of 5HT on innate 
immune cells is not yet completely understood (8). Within the immune system, 5-HT
7
 has been found to be 
expressed by naive T cells (13), monocytes (31) and dendritic cells (32-35). We previously showed that the 
modulation of the phenotypic and functional macrophage polarization by 5-HT is mediated by both 5-HT2B and 
5-HT
7
 receptors (20). In the present report we describe the identification of the 5HT-dependent gene expression 
profile on human macrophages, and demonstrate that most transcriptional effects of 5HT on macrophages are 
mediated by the 5-HT
7
-PKA signaling axis because 5-HT
7
 agonists and antagonists reproduce or neutralize 
the majority of 5HT-mediated gene expression changes. In addition, we provide evidences for the involvement 
of 5-HT2B on the 5HT effects on human macrophages, and illustrate the existence of a link between 5-HT2B-
initiated signals and the type I IFN signaling pathway. The identity of the genes specifically regulated after 
5HT binding to 5-HT
7
 and/or 5-HT2B sheds new light on the ability of 5HT to modulate cell proliferation (by 
promoting the expression of growth factors and growth factor receptors) and to influence macrophage effector 
functions (by modulating the expression of genes that control macrophage activation). Thus, our results place 
5-HT
7
 as a potentially relevant molecule for modulation of macrophage effector functions under physiological 
and pathological settings. 
In the case of the central nervous system, 5-HT
7
 mRNA has found in thalamus, hypothalamus, cerebral cortex, 
hippocampus and amygdala (36-38). In line with the control of various cerebral functions by 5HT, 5-HT
7
 
regulates circadian rhythms, thermoregulation, learning and memory (2,3,38-42), affects depression and 
activation of rapid-eye-movement (REM) sleep (2-4), and is a potential therapeutic target for pain and migraine, 
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schizophrenia, anxiety, cognitive disturbances, and inflammation (2). Our results on human macrophages are 
in line with these previous findings, because the signaling ability of 5-HT
7
 is compatible with the receptor 
exerting a modulatory action on the process of macrophage activation. In fact, given the expression of 5-HT
7
 in 
microglia cells (43), it is tempting to speculate that 5-HT
7
-expressing microglia could participate in the above 
mentioned physio-pathological processes. This hypothesis would be also compatible with recent evidences for 
the implication of alternatively IL-4-activated macrophages in maintaining adaptive thermo-genesis (44) and 
improving learning and memory (45-47), two processes that are directly controlled by 5-HT
7
. 
The predicted upstream regulators of 5-HT
7
–regulated genes that we have identified in human macrophages also 
fit well with 5-HT
7
-initiated signalling pathways in other cell types. 5-HT
7
 stimulation affects gene expression 
via activation of ERK1/2, PKA (48), Akt (49), p38 MAPK and protein kinase Cε (PKCε) (50), and stimulation 
of Cdc42 and RhoA GTPases (51). 5-HT
7
 couples positively to adenylate cyclase (AC) through activating 
Gαs, resulting in increased of cAMP levels and activation of PKA and Epac1/2 (22). In fact, the activation of 
Cdc42 and RhoA occurs via 5-HT
7
-Gα12 coupling and regulates the transcription of serum response factor 
(SRF)-regulated genes (51). Probably in a PKA- (48,52) or Epac-dependent manner (53), 5-HT
7
  engagement 
also triggers ERK1/2 activation in naive T cells (13,54), and monocytes (31), where it also prevents apoptosis 
(31). In addition, 5-HT
7
 activates NF-κB in naive T cells, monocytes and dendritic cells (13,31,35). Our results 
indicate the predominance of the 5-HT
7
-AC-PKA pathway in human macrophages exposed to 5HT, as most 
5HT-regulated genes could be induced by PKA activators and their 5HT-responsiveness is blocked by PKA 
inhibitors. Furthermore, this result would indicate that, like in other cell types (51) (and our unpublished 
results), 5HT would activate CREB in macrophages. If so, considering that CREB activation favours the 
acquisition of an M2 polarization state (55), the 5HT-dependent macrophage polarization shift towards M2 
that we have previously reported (20) would be dependent on such a 5-HT
7
-AC-PKA-CREB signaling axis. In 
addition, and taking into account the importance of cAMP-initiated signaling for limiting the effector functions 
of pro-inflammatory stimuli (56,57), the 5-HT
7
-AC-PKA-CREB pathway could play a role in inflammation 
resolution in cases where platelet de-granulation takes place. This issue deserves additional investigation 
because we have observed that 5HT also increases mRNA levels for various phosphodiesterases, which limit 
cAMP availability. 
Regarding target genes, 5-HT
7
 ligation augments pro-inflammatory cytokine production (IL-12p40, IL-1β, and 
IL-6) in CD11c+ dendritic cells, probably via NF-kB activation (35), enhances IL-6 synthesis in astrocytoma 
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and human microglia cells (43,50), and increases cAMP and secretion of IL-1β, IL-6, IL-12p40 and CXCL8, 
but lowers LPS-induced TNF-α release, in monocytes (11). Since 5-HT
7
-induced increased IL-6 synthesis 
peaks at 4 and 24 h after 5HT stimulation, the existence of two independent 5-HT
7
-initiated signal transduction 
pathways has been hypothesized. However, it is also possible that 5HT might trigger the production of a factor 
promoting IL-6 release (50).  Our results suggest that the 5-HT
7
-AC-PKA-CREB signaling pathway might 
contribute to the latter mechanism, as it mediates the positive effect of 5HT onthe gene (IL1B) encoding IL-1β, 
a potent inducer of IL-6 synthesis. 
Although to a lower extent than 5-HT
7
, our results indicate that 5HT also modulates macrophage gene expression 
via 5-HT2B (Figure 8). This is specially relevant from a pathologic point of view, because 5-HT2B mediates the 
deleterious effect of 5HT in diseases like pulmonary arterial hypertension (PAH) and fibrosis (15,58), liver 
fibrosis (59) and cardiac hypertrophy (60). Besides, 5-HT2B controls bone mass via osteoblast proliferation (61), 
and modulates hepatocyte proliferation in chronic liver disease (62). The pathological link between 5-HT2B and 
cell proliferation/fibrosis is supported by its ability to stimulate the production of extra-cellular matrix proteins 
(63) and, in fact, targeting 5-HT2B has been proposed as an effective antiproliferative and antifibrotic strategy 
(64). Our gene expression profiling experiments have identified growth factors that might potentially mediate 
the cell growth-promoting action of 5-HT2B, as exposure of macrophages to either 5HT or an 5-HT2B agonist 
lead to enhanced expression of the EREG gene-encoded epiregulin growth factor. Epiregulin is a member of 
the epidermal growth factor family which binds to the epidermal growth factor receptor (EGFR) and most 
members of the ERBB family. Epiregulin is a growth factor involved in cancer development whose expression 
is regulated by cAMP (65). Importantly, epiregulin functions as a autocrine/paracrine factor for vascular 
smooth muscle cells (VSMC)(66), and contributes to vascular remodeling (67). Therefore, epiregulin might 
constitute a link between 5-HT2B on macrophages and the abnormal neomuscularization of small pulmonary 
arteries, adventitial proliferation and vascular remodelling that occurs in pulmonary arterial hypertension, 
whose development is dependent on bone marrow-derived cells (15). 
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Supplementary Figure 1 
Ingenuity Canonical Pathways -log(p-value) Ratio Molecules 
5HT-regulated genes 
cAMP-mediated signaling 3.12E00 5.02E-02 GRK4,PDE2A,RGS2, PDE7B,PKIB,CREM,PDE4A,S1PR1,FPR2,HTR1D,PKIG 
VDR/RXR Activation 2.77E00 7.41E-02 IFNG, WT1,FOXO1,RUNX2,THBD,HSD17B2 
Docosahexaenoic Acid (DHA) Signaling 2.44E00 8.16E-02 ALOX15,FOXO1,IL1B,PNPLA2 
Clathrin-mediated Endocytosis Signaling 1.97E00 4.1E-02 VEGFA,MET,CDC42,GAK,FGF8,FIGF,ITGB8,MYO1E 
mTOR Signaling 1.9E00 3.83E-02 VEGFA,HMOX1,DDIT4,FIGF,RPS6,RPS6KA5,EIF3C/EIF3CL,RPS23 
BW723C86-regulated genes 
Interferon Signaling 2.41E00 1.11E-01 IFIT3,IFIT1,IFNG ,IFNA21 
Coagulation System 2.36E00 1.05E-01 VWF,F7,PLAT,SERPIND1 
Aryl Hydrocarbon Receptor Signaling 2.31E00 5.03E-02 RB1,NQO1,MAPK8,TGFB3,IL1B,NFIB,ALDH3A1,CYP1B1 
Atherosclerosis Signaling 2.12E00 5.34E-02 COL1A2,ITGB2,PLA2G6,IFNG , CXCR4,IL1B,COL11A2 
Chemokine Signaling 1.99E00 6.85E-02 CALML5,CXCR4,MAPK8,PPP1R12B,CAMK2G 
MSP-RON Signaling Pathway 1.94E00 7.84E-02 ITGB2,IFNG, ACTB,NOS2 
EIF2 Signaling 1.57E00 3.96E-02 RPL21,RPL23A,RPS21,RPS3,RPS23,RPS27A,RPS12,RPL37 
Supplementary Figure 1.- Identification of the canonical signaling pathways that potentially control the 
expression of 5HT- and BW723C86-regulated genes, as determined by the Ingenuity Pathway Analysis, with 
indication of its statistical significance (adjusted p-value, p) and the molecules associated.
Upstream Regulator p-value 
5HT upregulated genes 
LY294002 2.24E-07 
beta-estradiol 6.28E-07 
Tgf beta 2.06E-06 
forskolin 3.17E-06 
lipopolysaccharide 4.26E-06 
HGF 6.43E-06 
prostaglandin E2 1.78E-05 
IL6 2.05E-05 
IL1B 4.15E-05 
SMAD7 7.04E-05 
BW723C86 upregulated genes 
TNF 2.07E-08 
IFNA2 5.09E-07 
SOCS1 1.73E-06 
lipopolysaccharide 4.26E-06 
IFNG 1.01E-05 
IFNA1/IFNA13 1.15E-05 
Interferon alpha 1.28E-05 
IFN TYPE 1 4.19E-05 
BACH1 5.78E-05 
IFN Beta 6.14E-05 
5HT & BW723C86  
Upregulated genes 
 
IL33 1.10E-04 
simvastatin 3.55E-04 
8-bromo-cAMP 3.72E-04 
CD200 4.73E-04 
NR1H3 4.87E-04 
thiazolidinedione 5.40E-04 
C5 9.43E-04 
IFN Beta 1.01E-03 
SMAD7 1.56E-03 
Supplementary Figure 2 
Supplementary Figure 2.- Identification of the potential 
upstream regulators of the expression of 5HT- and BW723C86-
upregulated genes, as determined by the Ingenuity Pathway 
Analysis, with indication of its statistical significance (adjusted 
p-value, p).
. 
   5HT    
BW723C86        M1 
M2 
Supplementary Figure 3 
Supplementary Figure 3.- Quantification of the 5HT- and 
BW723C86-regulated genes whose expression significantly 
differs in M1(GM-CSF) (M1) and M2(M-CSF) (M2) 
macrophages (> 2-fold; adjusted p<0.05). 
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absTracT
Intravenous immunoglobulins (IVIg) therapy is widely used as an immunomodulatory strategy in inflammatory 
pathologies, and is suggested to promote cancer regression. Since progression of tumors depends on their ability 
to re-direct the polarization state of tumor-associated macrophages (from M1/immunogenic/pro-inflammatory 
to M2/anti-inflammatory), we have evaluated whether IVIg limits tumor progression and dissemination 
through modulation of macrophage polarization. In vitro, IVIg inhibited proinflammatory cytokine production 
from M1 macrophages, and induced a M2-to-M1 polarization switch on human and murine M2 macrophages. 
In vivo, IVIg modified the polarization of tumor-associated myeloid cells in an Fcεr1γ-dependent manner, 
modulated cytokine blood levels in tumor-bearing animals, and impaired tumor progression via CD16 and 
FCεR1γ engagement, the latter two effects being macrophage-mediated. Therefore, IVIg immunomodulatory 
activity is dependent on the polarization state of the responding macrophages, and its ability to trigger a M2-
to-M1 macrophage polarization switch might be therapeutically useful in cancer, where pro-inflammatory or 
immunogenic functions should be promoted.
inTroDucTion
Macrophages exhibit a huge functional plasticity and, in response to endogenous and non-self stimuli, can 
acquire a continuum of polarization states (1-4). Microbe-derived factors, or cytokines like IFNγ, GM-CSF 
or TNFα, promote in macrophages the acquisition of pro-inflammatory, bactericidal, tumor suppressive 
and immunogenic activities, a process commonly referred to as “classic” or M1 polarization and whose 
hallmark is the ability to release large amounts of IL-12/IL-23 (2). Conversely, cytokines like IL-4, IL-10, 
TGFβ or M-CSF, promote anti-inflammatory, scavenging, tumor-promoting, tissue repair and pro-angiogenic 
functions, all of which are grouped under the terms “alternative” or M2 polarization that endows them with 
the ability to produce high levels of IL-10 (3-5). M1-polarized macrophages predominate at the initial stages 
of an inflammatory response, whereas M2-type macrophages drive resolution of inflammation, tissue repair 
after injury, and maintain tissue homeostasis (6). In vivo, the misbalance of macrophage polarization states 
underlies numerous pathophysiological processes, including tumor development, autoimmune diseases and 
chronic inflammatory pathologies (6-8). 
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The switch between M1 and M2 polarization states is especially relevant in tumor initiation, progression 
and dissemination, which are extremely reliant on the presence and polarization state of macrophages within 
the tumor stroma (Tumor-Associated Macrophages, TAM) (5). The contribution of macrophages to tumor 
development is inferred from the poor outcome associated with enhanced levels of M-CSF, the reduced 
metastasis observed in Csf1op/op mice (9, 10), and the positive correlation between high content of TAM and 
a bad prognosis (11). Depending on their polarization status, macrophages can either promote antitumor 
immune responses or contribute to tumor progression (12). In fact, as tumor progresses, TAM develop an 
immunosuppressive and pro-tumoral phenotype which fuels tumor growth, metastasis and suppression of 
tumor-specific immune responses (13).
Intravenous immunoglobulin (IVIg) is a preparation of polyclonal and poly-specific immunoglobulins derived 
from the plasma of thousands of healthy donors. IVIg therapy is FDA-approved for primary immunodeficiencies, 
Immune Thrombocytopenic Purpura and Kawasaki s´ disease, and is beneficial for multiple sclerosis, 
rheumatoid arthritis and systemic lupus erythematosus (14, 15). Previous reports have evidenced that IVIg 
exerts potent immunomodulatory actions in immunodeficiency syndromes, autoimmune diseases and 
infectious processes (16). The molecular and cellular basis for the IVIg immunomodulatory action, including 
the identity of the biologically active constituents in IVIg and its specific cell surface receptors and targets 
cells, remains to be completely clarified (17-20). In the present report we demonstrate that IVIg promotes an 
M2-to-M1 macrophage polarization switch through ligation of activating Fc receptors in both human and 
mouse macrophages, and that Fcgr3 and Fcer1g mediate the IVIg-induced re-polarization of tumor-associated 
myeloid cells and inhibition of tumor progression and metastasis in vivo. 
MaTerials anD MeThoDs
Macrophage differentiation, cell culture and treatments.- Human peripheral blood mononuclear cells 
(PBMC) isolation was carried out as described previously (21). Human TAM were obtained from the pleural 
fluid of a metastatic breast adenocarcinoma patient, after obtaining written informed consent and following 
Medical Ethics committee procedures (Hospital General Universitario Gregorio Marañón), and using CD14 
microbeads as described (22). Human postnatal thymocytes were isolated from thymus fragments removed 
during corrective cardiac surgery of patients aged 1 month- 4 years, after providing informed consent in 
accordance with the Declaration of Helsinki. Thymocyte cell suspensions were enriched in non-T cells by 
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sheep erythrocyte rosetting as previously described (23). Intrathymic macrophages (>95% CD13+ CD11c+ 
CD14+) were obtained from the resulting cell fraction by positive selection using a PE-labeled anti-CD14 
monoclonal antibody and anti-PE microbeads (Miltenyi Biotec).  Bone marrow-derived macrophages (BMDM) 
were obtained as described previously (24,25). For activation, macrophages were treated with E.coli 055:B5 
lipopolysaccharide (LPS) (100 ng/ml for mouse macrophages, 10 ng/ml for human macrophages) for 24 hours. 
The B16F10 mouse melanoma cell line (C57BL/6 origin), the mouse MC38 colon carcinoma cancer line, and 
the highly invasive human BLM melanoma cell line (kindly provided by Dr. J. Teixidó, CIB/CSIC, Madrid, 
Spain), were maintained in RPMI (MC38) or DMEM (BLM, B16F10) medium supplemented with 10% FCS, 
at 37ºC in a humidified atmosphere with 5% CO2.  Fully polarized macrophages were exposed to 10 mg/ml 
IVIg (Privigen ®, CSL Behring) for 24 hours. For Syk inhibition assays, differentiated macrophages were 
treated with vehicle (H2O) or piceatannol (100 µM, Calbiochem) 1 hour before IVIg treatment. To determine 
the CD16 contribution, an anti-human CD16 F(ab)’2 monoclonal antibody (LSBio, clone 3G8), or an isotype-
control mouse IgG1 F(ab)’2, was used at 20 μg/ml before IVIg treatment. 
Quantitative real-time RT-PCR.- Total RNA was extracted using the RNeasy® Mini kit or AllPrep® DNA/
RNA/Protein Mini kit (Qiagen) following manufacturer’s guidelines. cDNA was synthesized using the Reverse 
Transcription System kit (Applied Biosystems). Oligonucleotides for selected genes were designed according 
to the Roche software (Universal Probe Roche library). Quantitative real-time PCR (qRT-PCR) was performed 
using custom-made panels (Roche Diagnostics) or standard plates on a LightCycler® 480 (Roche Diagnostics) 
or a iQTM5 (Biorad), respectively. An extensive battery of genes differentially expressed between M1 and M2 
macrophages were included in our assays (a total of 33 genes, out of which thirteen were previously identified 
as M1 marker genes and twenty as M2 marker genes) (21,26,27). Assays were made in triplicate and results 
normalized according to the expression level of GAPDH or to the mean of the expression level of endogenous 
reference genes HPRT, SDHA and TBP. Results were expressed using the ΔΔCT method for quantitation. 
ELISA.- Culture supernatants from LPS-treated (24h) human macrophages were assayed for the presence 
of cytokines using commercially available ELISA for TNF-α, IL-10, IL-6 (ImmunoTools GmbH), IL-12p40, 
CCL-2 (OptEIATM IL-12p40 set, BD Pharmingen) and Activin A (R&D Systems). LPS-treated mouse 
macrophage supernatants were tested for Il-10, Tnf-α and Ccl-2 using available ELISA  (BioLegend). ELISA 
were performed following the protocols supplied by the manufacturers. 
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Cell Proliferation Assays.- BLM cells were plated (5×103 cells/well), allowed to adhere for 24 h, and exposed 
to culture supernatants from untreated or IVIg-treated human macrophages for 48 h. Cell proliferation was 
evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma). Complete 
media was used as control to determine the basal BLM cell proliferation.
Mouse tumoral models.- For the pulmonary metastasis animal model, 6-to-8-week-old wild-type C57BL/6, 
Fcgr3-/- and Fcer1g-/- mice (kindly provided by Dr. Jordi Ochando, Mount Sinai School of Medicine, NY, USA) 
were used for all experiments. Mice were injected intravenously (i.v., tail vein) with 3 x 105 B16F10 melanoma 
cells in 0.1 ml of sterile PBS on day 0, and with 400 μl of IVIg (100 mg/ml) or PBS (control) 24 h before tumor 
cell injection (day -1) and on days 6 and 13. Mice were sacrificed on day 18, and lung surface metastases 
counted under a dissecting microscope as black nodules after bleaching in Fekete s´ solution. For xenograft 
studies, 2–3 months old BALB/c SCID or C57BL/6 mice were injected subcutaneously (lateral thoracic wall) 
with 2 x 106 BLM cells or 5 x 105 MC38 cells in 0.1 ml of PBS 0.1% glucose. IVIg (400 μl, 100 mg/ml) or 
PBS (400 μl) was injected intravenously on day -1, 7 y 14, and mice were killed 17-21 days after cell tumor 
inoculation. Mice were inspected daily and the tumor volume measured as width2 ×length / 2. All protocols 
were approved by the CIB-CSIC Ethics Committee.
Permanent middle cerebral artery occlusion (pMCAO) in mice.- The surgical procedure was a variant of that 
described by Chen et al. (1986) (28) and Liu et al. (1989) (29). Mice were anesthetized with isoflurane 1.5-2% in 
a mixture of 80% air/20% oxygen, and body temperature was maintained at physiological levels with a heating 
pad during the surgical procedure and anesthesia recovery. Mice were subjected to permanent focal cerebral 
ischemia through the distal occlusion of middle cerebral artery (MCA) by ligature of the trunk just before its 
bifurcation between the frontal and parietal branches with a 9-0 suture, in combination with the occlusion of 
the ipsilateral common carotid artery. Physiological parameters were not significantly different among the 
different groups studied. Following surgery, individual animals were returned to their cages with free access 
to water and food. All the groups were performed and quantified in a randomized fashion by investigators 
blinded to treatment groups. IVIg (400 μl, 100 mg/ml) or PBS (400 μl) were injected by vein tail 10 min after 
MCAO. 48h after pMCAO mice were killed by an overdose of sodium pentobarbital and brain was removed, 
cut into 1-mm thick coronal slices and stained with 2,3,5-triphenyl tetrazolium chloride (TTC; 1% in 0.1M 
phosphate buffer). Infarct volumes were calculated sampling each side of the coronal sections with a digital 
camera (Nikon Coolpix 990), and the images were analyzed using ImageJ 1.33u (National Institutes of Health). 
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To exclude the brain edema effects, infarct area was corrected by the ratio of the entire area of the ipsilateral 
hemisphere to that of the contralateral.
LPS-Induced Endotoxin Shock model mice.- Mice received i.p. injections of 350 µg of LPS per 25 g of body 
weight one hour after or PBS injection. LPS was dissolved prior to injection in phosphate-buffered saline at a 
concentration of 10 mg/ml. Injected animals were monitored for a 7 days.
Statistical analysis.- Differences between the experimental groups in in vivo experiments were analyzed by 
a non-paired Student t-test. In the case of CD11b+ isolated cells, qPCR data were analyzed with the REST-
2009 software from Qiagen using 5000 permutations. Statistical significance of in vitro generated data was 
evaluated using a paired Student t-test. In all cases, p<0.05 was considered as statistically significant.
resulTs
M1 and M2 macrophages are differentially affected by IVIg.- Since IVIg is used off-label for chronic 
inflammatory diseases (30), where M1 macrophages critically contribute to pathology, we first investigated 
whether IVIg modulates the effector functions of pro-inflammatory M1 macrophages. A 24-hour exposure 
to IVIg led to a significant reduction in the LPS-stimulated release of TNFα, IL-12p40 and CCL2 from M1 
macrophages (Fig. 1A), without affecting their tumor cell growth inhibitory ability (Fig. 1C, upper panel). 
IVIg did not overtly alter the gene expression profile of M1 macrophages, as most M1 polarization-specific 
markers were only weakly modulated in response to the treatment (Fig. 1D, upper panel). The functional 
modulation induced by IVIg on M1 macrophages is, therefore, compatible with the previously reported anti-
inflammatory activity of IVIg, and might help explaining the clinical improvement of chronic inflammatory 
diseases by IVIg treatment (14,17,19,31). 
The effects of IVIg on macrophages under homeostatic conditions, or in M2-associated patho-physiological 
processes, had not been addressed before. Unlike M1 macrophages, treatment of M2-polarized macrophages 
with IVIg for 24 hours led to a significant reduction in the LPS-induced CCL2 and IL-10 release, and a 
concomitant enhancement of the LPS-induced production of TNFα and IL-12p40 (Fig. 1B). Moreover, IVIg-
treated M2 macrophage supernatants, like M1 macrophage-conditioned media, inhibited the growth of BLM 
melanoma cells (Fig. 1C, lower panel), whose proliferation was not affected by IVIg itself. Along the same 
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line, IVIg provoked a dramatic transcriptomic switch in M2 macrophages, as it reduced the expression of M2-
specific markers (between 5- and 100-times) and increased the expression of M1-specific markers (10-to-100-
fold) (Fig. 1D, lower panel). Kinetic analysis revealed that the polarization switch of M2 macrophages is already 
evident 12 hours after IVIg addition (Supplementary Fig. S1). Unsupervised hierarchical clustering confirmed 
that the gene expression profile of IVIg-treated M2 macrophages resembles that of pro-inflammatory M1 
macrophages (Fig. 1E). These results indicated that IVIg differentially affects the functional and transcriptomic 
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Fig. 1. Effect of IVIg on human macrophage polarization. M1 (A) and M2 (B) macrophages were cultured with (+) or 
without (-) IVIg (10 mg/ml, 24 hours), stimulated with LPS (10 ng/ml, 24 hours), and supernatants assayed for the indicated 
cytokines. Shown are the mean ± SD of four to seven independent experiments (*, p<0.05; **, p<0.01; ***, p<0.001). (C) BLM 
melanoma cell-growth inhibitory ability of IVIg-treated M1 and M2 macrophage supernatants, relative to the proliferation 
of untreated BLM cells (CNT) (n=3; *, p<0.05). (D) Polarization marker expression in M1 and M2 macrophages exposed to 
IVIg (24 hours), as determined by qRT-PCR (n=2 for M1, n=3 for M2 macrophages). Relative Expression (log scale) indicates 
the expression of each marker in the presence of IVIg relative to its expression in the absence of IVIg (*, p<0.05; #, p<0.01; $, 
p<0.001). (E) Non-supervised hirarchical clustering (Genesis software, http://genome.tugraz.at/genesisclient/genesisclient_
description.shtml) on the mean expression level of each polarization marker under the indicated culture conditions. 
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polarization of M1 and M2 macrophages, as it inhibits the production of pro-inflammatory cytokines by 
M1 macrophages while promotes the acquisition of a pro-inflammatory profile in M2 macrophages. Further 
supporting these results, IVIg increased the expression of most M1-specific markers, and downregulated the 
majority of M2-specific markers, on ex vivo isolated CD14+ human thymic macrophages (Supplementary Fig. 
S2), and reduced the constitutive and LPS-induced expression of IL-10, while potentiated that of TNFα, from 
CD14+ Tumor-Associated Macrophages (Supplementary Fig. S2). Altogether, these results demonstrate the 
ability of IVIg to promote an M2-to-M1 polarization switch in human macrophages. 
CD16 and Syk phosphorylation mediates the IVIg-induced switch in macrophage polarization.- To 
unravel the mechanisms underlying the IVIg effect on human macrophage polarization, we initially focused 
on activating Fcγ receptors, and specially on CD16, whose expression is significantly higher in M2 than in 
Fig. 2. CD16-Syk axis mediates the IVIg-induced M2-to-M1 human macrophage polarization switch. (A) Relative 
expression (log scale) of indicated FcR-encoding genes in M1 and M2 human macrophages, as determined by gene expression 
profiling (GSE27792, *, adjusted p<0.05). (B) CD16 and CD64 cell surface expression in M1 and M2 human macrophages, as 
determined by flow cytometry. (C) LPS-stimulated cytokine release from untreated or IVIg-treated M2 macrophages preincubated 
(30 minutes) with a blocking anti-CD16 Fab´2 antibody (αCD16 Fab´2) or an isotype-matched antibody (CNT Fab´2). Shown 
are the mean ± SD of three independent determinations (**, p<0.01). (D) M1 and M2 polarization marker expression in M2 
macrophages preincubated (30 minutes) with a blocking anti-CD16 Fab´2 antibody (αCD16 Fab´2) or an isotype-matched antibody 
(CNT Fab´2), and exposed to IVIg (24 hours). (E) M1 and M2 polarization marker expression in M2 macrophages preincubated 
with piceatannol and exposed to IVIg (24 hours). In D and E, Relative Expression indicates the expression of each marker in 
the presence of IVIg and relative to its expression in the absence of IVIg (indicated by a dotted line and arbitrarily set to 1). 
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M1 macrophages (Fig. 2A,B). The contribution of the CD16-encoding FCGR3A gene to the IVIg-mediated 
functional polarization switch was assessed by using the anti-CD16 3G8 blocking antibody. 3G8 mAb 
significantly reversed the IVIg-mediated change in cytokine profile, as it abrogated the IVIg-dependent increase 
in TNFα production and inhibited the IVIg-mediated reduction in IL-10 release (Fig. 2C). Moreover, anti-
CD16 impaired the IVIg-induced downregulation of M2-specific marker expressions as well as the increase 
of M1-specific markers (Fig. 2D). Taken together, these results demonstrate that CD16 is involved in the M2-
to-M1 phenotypic and functional polarization switch induced by IVIg. In agreement with the known CD16-
dependent Syk phosphorylation, IVIg triggered activation of Syk and its downstream targets Akt, ERK1/2, 
CREB and p38MAPK (Supplementary Fig. S3) (32,33), but had no effect on the phosphorylation state of 
SHIP1 (unpublished observation), a read-out for the engagement of the inhibitory CD32b Fcγ receptor (31). In 
fact, the IVIg-induced polarization switch was reverted by the Syk tyrosine kinase inhibitor piceatannol (Fig. 
2E and Supplementary Fig. S4). Thus, the CD16-Syk axis mediates the M2-to-M1 macrophage polarization 
switch induced by IVIg in human macrophages. 
IVIg modifies bone marrow-derived M2 mouse macrophage polarization via Fcer1g and Fcgr3.-  To 
determine the extent of the relevance of these findings, we next determined whether the IVIg-mediated 
polarization switch was also observed in mouse bone marrow-derived macrophages (BMDM). Like in the case 
of human macrophages, IVIg significantly enhanced the expression of the paradigmatic M1 markers Nos2, 
Tnfa and Cd11c, whereas it inhibited the expression of a large number of M2 polarization markers (Fig. 3A). At 
the functional level, the LPS-stimulated production of TNFα by mouse M2 BMDM was significantly enhanced 
by IVIg, without affecting IL-10 release (Fig. 3B). The IVIg-induced polarization switch took place via Fc 
receptors, because ablation of the Fcgr3 gene inhibited the increase of Nos2 and the decrease of Cbr2, Emr1 
and Cd206 triggered by IVIg (Fig. 3A), and because all the IVIg-triggered changes were blunted in Fcer1g-/- 
M2 macrophages (Fig. 3A). Regarding LPS-cytokine release, the absence of Fcεr1γ expression completely 
abolished the IVIg-induced increase in TNFα release from mouse M2 BMDM (Fig. 3B). Consequently, all the 
transcriptomic and functional changes triggered by IVIg on M2 BMDM are absent in Fcer1g-/- macrophages, 
whereas ablation of the Fcgr3 gene has only a partial influence on the polarization switch triggered by IVIg. 
Therefore, and like in the case of human macrophages, Fcγ activating receptors mediate the pro-inflammatory 
polarization of mouse macrophages by IVIg. 
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Fig. 3. Effect of IVIg on mouse macrophage polarization. (A) Polarization marker expression in untreated (CNT) or IVIg-treated 
(24 hours) M2 BMDM from wild type, Fcgr3-/- and Fcer1g-/- mice, as determined by qRT-PCR. Relative Expression indicates 
the expression of each marker in the presence of IVIg and relative to its expression in the absence of IVIg. Shown are the mean 
± SD of four independent experiments (untreated vs. IVIg-treated samples: *, p<0.05; **, p<0.01; ***, p<0.001; comparison 
between IVIg-treated samples: #, p<0.05; ##, p<0.01; ###, p<0.001). (B) LPS-induced release of IL-10 and TNFα from M2 BMDM 
untreated or treated with IVIg (24 hours). Shown are the mean ± SD of four independent experiments (*, p<0.05; **, p<0.01). 
IVIg promotes proinflammatory response in vivo.- To assess the in vivo relevance of the above in vitro data, 
we evaluated the influence of IVIg on three animal models of disease: a middle cerebral artery-occlusion 
stroke model and an LPS-induced sepsis-like mouse model, where tissue damage correlates with excessive 
proinflammatory responses (34), and a xenograft tumor model, where tumor and tumor-associated cells 
contribute to the establishment of an immunosuppressive environment (35). IVIg injection led to significant 
increases in the volume of the infarcted area in the stroke mouse model (Fig 4A), and diminished survival rates 
after injection of a lethal dose of LPS (Fig. 4B), thus implying that IVIg misbalances innate immune responses 
82
towards a more pro-inflammatory state. Along the same line, and regarding the xenograft tumor model, IVIg 
significantly reduced tumor volumes after 15 days (Fig. 4C). Altogether, data from the three assayed animal 
models revealed that IVIg exerts a global proinflammatory response in vivo. 
Inhibition of mouse tumor metastasis by IVIg is associated to changes in macrophage polarization and 
depends on Fcγ receptors.- Since tumor metastasis and progression are dependent on the tumor ability to 
alter macrophage polarization (5,36) and given the above described effects of IVIg, we hypothesized that 
IVIg might inhibit tumor growth and/or metastasis by skewing macrophage polarization via engagement of 
Fcγ receptors. In the MC38 colon cancer xenograft model, IVIg significantly reduced tumor volume in WT 
and Fcgr3-/- mice, but had no effect in Fcer1g-/- mice (Fig. 5A, B). Along the same line, IVIg significantly 
lowered B16F10 melanoma lung metastasis in WT mice, an inhibitory effect that was absent in Fcgr3-/- and 
Fcer1g-/- mice (Fig. 5C). Importantly, analysis of the tumor-associated CD11b+ myeloid cells from MC38 
tumor xenografts revealed a significantly increased expression of the M1 polarization-associated markers 
Cd11c, Ccr7 and Nos2 in tumor-bearing WT mice but not in Fcer1g -/- mice (Fig. 5D). Even more, the IVIg-
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Fig. 4. Effect of IVIg on different animal models: infarct 
outcome after permanent middle cerebral artery occlusion, LPS-
Induced Endotoxin Shock and subcutaneous tumors. (A) Infarct 
volume (left panel) and infarct areas (right panel) assessed by TTC 
staining 48 h after permanent MCAO in brain form IVIG-treated or 
untreated mice. The mean ± SEM is indicated. Date are pool from 
N=10 mice (*, p<0.05). (B) C57Bl/6 mice were pretreated i.p. with 
IVIG or PBS and one hour after injected i.p. with 350ug LPS. The 
survival was monitored during 7 days. Data represent mean of pool 
from N=20 mice. (C) Effect of i.v. injection of IVIg on the volume 
of tumors found after s.c. injection of BLM human melanoma 
cells in the lateral thoracic wall of BALB/c SCID mice. The mean 
± SEM is indicated. Date are pool from N=8 mice (*, p<0.05). 
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Fig. 5. IVIg inhibition of tumor progression requires macrophages and is dependent on Fcgr3 and Fcεr1γ . Tumor volume in 
PBS (CNT) or i.v. IVIg-treated (A) WT or (B) Fcgr3-/- and Fcer1g-/- C57BL/6 mice  s.c. injected with MC38 colon cancer cells in 
the lateral thoracic wall. Shown are the mean ± SEM (n=7; *, p<0.05). (C) Number of lung metastatic foci in PBS (-) or i.v. IVIg-
treated WT (n=6), Fcgr3-/- (n=6) and Fcer1g-/- (n=11) C57BL/6 mice i.v. injected with B16F10 melanoma cells. Shown are the mean 
± SEM (*, p<0.05). (D) Polarization marker expression in CD11b+ cells isolated from tumors in PBS (CNT) or IVIg-treated (24 
hours) WT and Fcer1g-/- mice s.c. injected with MC38 colon cancer cells. In all cases, the ratio of the expression level of each gene 
in tumor-associated CD11b+ in IVIg- vs. PBS-treated animals (IVIg/CNT) is represented (*, p<0.05). The comparison between the 
global expression of M1-specific markers in WT and Fcer1g -/- mice is also shown (*, p<0.05).  (E) Tumor volume in PBS (CNT) 
or i.v. IVIg-treated WT C57BL/6 mice s.c. injected with MC38 colon cancer cells in the lateral thoracic wall, either with or without 
clodronate liposome-mediated depletion of macrophages. Shown are the mean ± SEM (n=8) (CNT vs. IVIg-treated mice: *, p<0.05; 
**, p<0.01; CNT vs. CNT+Clodronate: #, p<0.05; ##, p<0.01; IVIg vs. IVIg+Clodronate: $, p<0.05). (F) Serum cytokine levels in 
WT mice PBS- (-) or IVIg-treated, either with or without clodronate liposome-mediated depletion of macrophages. Shown are the 
mean ± SD (n=8; *, p<0.05; **, p<0.01).
mediated global upregulation of M1-specific markers group seen in WT mice was completely abolished in 
Fcer1g -/- mice (Figure 5D). Therefore, and through engagement of activating Fcγ receptors, IVIg treatment 
impairs tumor progression (growth and metastasis) and influences the polarization of tumor-associated myeloid 
cells. The causal relationship between both effects was assessed by determining the ability of IVIg to inhibit 
tumor growth upon macrophage depletion. As shown in Figure 5E, clodronate liposome-mediated depletion 
of macrophages prevented the IVIg-promoted tumor growth reduction in the MC38 colon cancer model. In 
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fact, even the decrease in serum CCL2 caused by IVIg treatment was found to be macrophage-dependent (Fig. 
5F). Therefore, IVIg alters the polarization of macrophages, whose presence is absolutely required for IVIg to 
limit tumor growth. 
Discussion
The immunomodulatory action of IVIg has widened the range of pathologies for which IVIg therapy is either 
approved or has shown benefit (37,38). In line with its beneficial actions on inflammatory pathologies, we now 
show that IVIg impairs the effector functions of pro-inflammatory M1 macrophages. However, we also report 
the ability of IVIg to cause a M2-to-M1 phenotypic and functional Fc receptor-mediated polarization switch 
on human and murine macrophages in vitro and in vivo, thus illustrating that the IVIg immunomodulatory 
effects are dependent on the polarization state of the responding macrophages. 
Immunocomplexes have long been known to promote tumor cell killing in an FcγR-dependent manner, and 
to elicit potent inflammatory responses that underlie pathologies like systemic lupus erythematosus and 
rheumatoid arthritis(39). From this point of view, the pro-inflammatory and anti-tumor nature of the IVIg 
effect that we report is not unprecedented. Paradoxically, however, high doses of IgG (IVIg) exert beneficial 
effects on several autoimmune disorders by virtue of their potent anti-inflammatory activity (16,40). Attempts 
to explain this apparent contradiction have indicated that the active components within IVIg constitute a 
minor fraction of the preparation (e.g., immune complexes, sialylated-Fc IgG), thus explaining the large doses 
requirement (14). The results that we now present shed more light on this issue, since IVIg provokes different 
responses, either pro- or anti-inflammatory, depending on the polarization state of the target macrophage. 
Whereas IVIg improves inflammatory diseases through impairment of the functional activities of M1 pro-
inflammatory macrophages, the IVIg effects on M2 anti-inflammatory macrophages skews them towards the 
acquisition of the phenotypic and functional characteristics of M1/pro-inflammatory macrophages. These last 
effects are consistent with the pro-inflammatory actions exerted by immunoglobulins or immune complexes 
(19). Thus, considering the effects of IVIg on both types of macrophages, IVIg exhibits both pro-inflammatory 
and anti-inflammatory properties, and that the nature of its effects are dependent on the activation/polarization 
status of the target macrophages, as it enhances the pro-inflammatory activities of M2 macrophages and 
limits the pro-inflammatory actions of M1 macrophages. Therefore, IVIg appears as a potent and versatile 
immunomodulatory agent that tunes macrophage effector functions in an environment-dependent manner.
85
In the context of cancer, we have demonstrated that IVIg impairs tumor progression and metastasis in a Fc 
receptor- and macrophage-dependent manner, and that IVIg alters the expression of polarization markers in 
CD11b+ tumor-associated myeloid cells from WT but not Fcer1g -/- mice. The co-existence of autoimmune 
pathologies and cancer has previously provided evidences that IVIg therapy promotes regression of cancer 
in patients with chronic lymphatic leukemia, Kaposi´s sarcoma and melanoma (41). Given the importance of 
the polarization of tumor-associated macrophages for tumor progression and dissemination (36), our results 
establish a sequential link between the IVIg ability to modulate macrophage polarization and its anti-tumor 
effect, suggesting that the pro-inflammatory activities of IVIg might also be therapeutically useful in pathologies 
like cancer, where immunogenic and pro-inflammatory macrophage functions need to be promoted.    
Numerous molecular and cellular mechanisms have been proposed to explain the immunomodulatory activity 
of IVIg (19). Our results clearly establish macrophages as an absolute requirement for the anti-tumor effect 
of IVIg, since macrophage depletion abrogates the inhibition of tumor growth by IVIg. Moreover, in tumor-
bearing animals, IVIg inhibited the level of circulating Ccl2, whose tumor-dependent increase was significantly 
reduced upon clodronate-mediated macrophage depletion. This is of particular significance since CCL2 is 
known to promote M2 macrophage polarization (42,43) and CCL2-induced MCPIP1 inhibits proinflammatory 
cytokine production(44) and augments the expression of the M2-associated IL-10-driving cMaf transcription 
factor (26,45). The ability of IVIg to reduce CCL2 both in vivo (Figure 5) and in vitro (Figure 1A, B) might, 
therefore, contribute to lower the M2/anti-inflammatory environment seen in tumor-bearing animals, thus 
favoring the generation of anti-tumor responses. In this regard, others have also shown that IVIg decreases 
CCL2 levels in whole blood (46) and skin tissue (47). 
Besides monocytes/macrophages, cellular targets for IVIg include NK cells, T and B lymphocytes, granulocytes 
and endothelial cells (48). Our data also supports the idea that cells other than macrophages contribute to the 
pro-inflammatory activity of IVIg because the IVIg-induced increase in circulating TNFα in tumor-bearing 
animals is not eliminated upon macrophage depletion (Figure 5F). Since inhibition of tumor growth by IVIg 
is macrophage-dependent, it seems reasonable to conclude that the IVIg-enhanced levels of TNFα do not 
significantly participate to the anti-tumor action of IVIg. However, and given the TNFα functional activities, it 
could be hypothesized that IVIg-induced TNFα might explain the mild/adverse side effects occasionally seen 
during IVIg therapy.      
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Supplementary Figure 1
Kinetic analysis of representative M1- and M2-specific markers on IVIg-treated M2 macrophages. M2
macrophages were exposed to IVIg, and the expression level of the indicated M1 and M2 polarization markers was
determined by qRT-PCR after 6, 12 or 24 hours. Results are expressed as Relative Expression, which indicates the
expression of each marker in the presence of IVIg and relative to its expression in the absence of IVIg.
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Supplementary Figure 2
Effect of IVIg on ex vivo-isolated macrophages. (A) Thymic macrophages from two independent donors were
exposed to IVIg for 24 hours, and the expression level of the indicated polarization markers was determined by
qRT-PCR. Results are expressed as Relative Expression, which indicates the expression of each marker in the
presence of IVIg and relative to its expression in the absence of IVIg. (B) CD14+ TAM from the pleural fluid of a
metastatic breast adenocarcinoma were stimulated for 24 hours with 10 ng/ml LPS in the absence (-) or in the
presence (+) of IVIg, and supernatants assayed for TNFα and IL-10. Each determination was done in triplicate and
mean ± SD is indicated.
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IVIg-triggered intracellular signaling in human macrophages. (A) M2 macrophages were left untreated (-) or
exposed to IVIg for 15 minutes, and the phosphorylation state of the indicated signaling molecules was determined
using the Proteome Profiler® protein array (R&D Systems, Inc, USA), which detects the relative phosphorylation
levels of 46 intracellular serine/threonine/tyrosine kinases. Results are shown as the pixel density of each spot after
densitometric analysis of the blot (insert). Arrows indicate the kinases specifically mentioned in the text. (B) M2
macrophages were left untreated (-) or exposed to IVIg for 15 minutes, and the phosphorylation state of the
indicated molecules was determined by Western blot using specific antibodies. Where indicated, the level of
GAPDH, Akt and p38α was used as a loading control.
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IVIg-triggered intracellular signaling in human macrophages in the presence of Syk tyrosine kinase inhibitor
piceatannol . (A) M2 macrophages were left untreated (-) or exposed to IVIg for 15 minutes either in the absence
or presence of piceatannol, and the level of Syk phosphorylation and total protein state was determined by Western
blot. (B) M2 macrophages were left untreated (-) or exposed to IVIg for 15 minutes either in the absence or absence
of piceatannol, and the phosphorylation state of Syk, ERK1/2 and p38MAPK was determined by Western blot using
phosphorylation-specific antibodies. Where indicated, the level of Syk and GAPDH was used as a loading control.
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seroTonin anD M2 polariZaTion
Macrophage polarization is critically determined by the cytokine environment and dictates the range of effector 
functions of macrophages within a tissue (220). M1 and M2 macrophages exhibit different functions and, 
display opposite effects in some scenarios (220). Thus, the identification of specific markers that properly 
distinguish M1 and M2 macrophages should provide potentially useful therapeutic targets for pathologies 
where altered or deregulated macrophage polarization takes place. In the present work we demonstrate that 
5-HTR2B and 5-HTR7 serotonin receptors are preferentially expressed by in vitro generated M2(M-CSF) 
macrophages, and that two well-known populations of ex-vivo M2 macrophages, (Kupffer cells and Tumor 
Associated Macrophages, TAM) express 5-HTR2B at the mRNA and protein levels. Indeed, our results reveal 
that 5-HT modulates macrophage functions and phenotype by acting through both receptors. 5-HT skews 
macrophages towards an M2 phenotype by inducing a set of M2-marker genes and repressing the expression of 
several M1 markers. Even more, blockade of these two 5-HT receptors during the M-CSF-derived macrophage 
polarization  in vitro  partially impairs this process, further confirming that 5-HT contributes to the M-CSF-
mediated macrophage polarization.  
Detailed analysis of the M1 and M2 macrophage gene expression profiles revealed that 6 hour-treatment with 
5-HT, or with the 5-HTR2B agonist BW723C86, induces significant changes in the expression of a number 
of M1- and M2-specific genes, including MS4A7, TTYH2, ISG20, RGS2, OLFML2B, HMOX1, S1PR1 and 
NAMPT, thus confirming the involvement of 5-HTR2B in polarization towards an M2-like state. However, 
those experiments also revealed that 5-HT-mediated gene expression changes are mostly dependent on 5-HTR
7.
 
More specifically, our data showed that most of the transcriptional effects induced by 5-HT on macrophages 
are mediated by the 5-HTR
7
/PKA axis, since 5-HTR
7
 agonists or antagonists either reproduce or neutralize 
the majority of 5-HT-mediated changes. In this regard, it has been previously described that cAMP leads to 
an M2 polarization (25). Thus, GM-CSF-derived macrophages exposed to PDE inhibitors or cAMP inducers 
enhanced the expression of CD163, IL-10 and a number of wound healing-related markers (a function typically 
associated to M2 polarization) (221). Moreover, IL-10 expression is mainly controlled by CREB, whose 
activity is directly controlled by cAMP (2). Altogether, these observations confirm that 5-HT, via activation 
of the 5-HTR
7/
cAMP/PKA/CREB axis, and in combination with 5-HTR2B-mediated pathways, participates in 
shaping an M2-like polarization in macrophages. 
97
Of interest, it has been described that platelet-derived serotonin delays virus clearance in a model of hepatitis C 
viral infection (222). These observations might be partially in agreement with ours, since M1 (IFNγ-activated) 
macrophages could participate in virus clearance, and we have shown that serotonin skews macrophages 
polarization towards an M2-like state. However, we have also illustrated the existence of a link between 
5-HTR2B -initiated signals and the type I IFN signalling pathway. The observation of increased IFNB mRNA 
levels just two hours after BW723C86 treatment, and the subsequent induction of IFN-dependent genes 
(CXCL10, ETV7, IFIT1, IFIT2, RSAD), leads us to propose a role for 5-HTR2B in infectious pathologies and, 
therefore, its potential use as a therapeutic target. However, at present, it remains to be determined whether 
5-HT modifies the expression of IFN-target genes, or can directly promote IFN synthesis and release. Although 
preliminary ELISA experiments indicate that 5-HT is not able of triggering IFNβ released by it self, more 
extensive analysis are required to completely rule out this possibility. 
5-hT anD inFlaMMaTion
It has been reported that 5-HT modulates the cytokine profile in mononuclear cells, monocytes, monocyte-
derived dendritic cells and ex vivo isolated macrophages (Table 2). Of interest, many of those previous 
observations were done in serum-containing media, where 5-HT concentration is as high as 1-2 μM (223). 
In the majority of those cases, the levels of LPS-induced TNF-α were reduced upon stimulation with 5-HT. 
Nevertheless, the correlation between 5-HT stimulation and the levels of pro-inflammatory (IL-6 or IL-12) or 
anti-inflammatory cytokines (IL-10) remained unclear in those studies, and the variability in the reported data 
has been attributed to differences in cell type or signalling through distinct 5-HT receptors. We believe that the 
high level of 5-HT in serum, as well as the presence of serum factors that could modulate or synergize with 
5-HT, might have precluded an accurate determination of the influence of 5-HT. Therefore, in an attempt to 
avoid these potential artefacts, we decided to maintain macrophages in serum-free media for 48 hours before 
assaying the functional or transcriptional effects of 5-HT. 
In these conditions, we observed that a co-stimulation with 5-HT/LPS inhibits the LPS-stimulated TNFα and 
IL-12p40 production, but has no effect on IL-10, thus shifting the balance towards a less pro-inflammatory 
response. We also found that a 5-HT pre-treatment altered the LPS-induced cytokine response towards a 
diminished production of pro-inflammatory cytokines. In all cases, we have determined that the 5-HT-mediated 
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References Cell type Stimuli  LPS Cytokine effects Medium 
Life Sci. 48:2557, 1991 Human monocytes Serotonin Yes Decreased TNF-α 
Int. Immunol. 15: 233, 2003    PBMCs (whole blood ) Serotonin  
DOI (HTR2A/C agonist) Yes Decreased TNF-α  No effect on IL-10 RPMI+5% human serum 
J. Immunol. 172: 6011, 2004 Dendritic cell  
(GM-CSF + IL-4) Serotonin  DOI (HTR2A/C agonist) 
Agonists for HTR4 and HTR7 
Yes Decreased TNF-α and 
IL-12p70 
Enhaced IL-1 and IL-8 
RPMI + 10% FBS 
Psychiatry Res. 134:251, 2005. Whole blood Serotonin 
mCPP (HTR2C/B agonist,   
partial for HTR2A) 
Yes Decreased TNF-α and 
IL-6 with serotonin. 
Increased with mCPP 
Not specified 
Int. Immunol. 17: 599, 2005 Human monocytes (CD14+) Serotonin  
DOI (HTR2A/C agonist) 
HTR4 and HTR7 agonists  
Yes Decreased TNF-α 
(HTR4 and HTR7), 
Increased IL12p40 
(HTR4 and HTR7) 
and IL-1β, IL-6, IL-8 
by serotonin. 
HTR2 agonists did not 
modulate LPS-induced 
cytokine production 
RPMI + 10% FBS 
Clin. Exp. Immunol. 146: 354,  
2006 
Dendritic cell  
(GM-CSF + IL-4 ± Serotonin) Serotonin Inespecific agonist/antagonist  Yes Increased TNF-α, IL-10, IL-6, IL-8. RPMI +10% FBS 
J.Invest. Dermatol. 2007 Aug;
127(8):1947-55 
Human monocytes Serotonin Yes Increased TNF-α and 
IL-6 
No effect on IL-10 
No FBS for 1h during 
5HT stimulation and 
then RPMI 10% FBS 
Clin. Exp.Immunol. 150: 340, 
2007 
NR8383 (rat alveolar cell line)  
Human alveolar macrophages  
(purified by a 2h adherence step) 
Serotonin Yes (weak changes) 
Decreased TNF-α 
Increased IL-10 
RPMI + 5% FBS 
Rheumatol. Int. 28:1017, 2008. Human Synovial macrophages Serotonin No Increased PGE2  IMDM + insulin 
Int J Neuropsychopharmacol. 
12:525, 2009 
Peritoneal macrophages 
(thioglycollate) Venlafaxine (inhibitor of 5-HT re-uptake) Yes Decreased TNF-α and IL-6 RPMI + 10% FBS 
Arthritis Rheum 62:683, 2010 Human Synovial membrane Serotonin No No efects on IL-6 or 
TNF-α produccion RPMI + 10% FBS 
Am J Physiol Lung Cell Mol  
Physiol 299:L272, 2010. 
Murine Alveolar macrophages Serotonin No Increased CCL2 RPMI + 0.1% FBS 
Am. J. Pathol. 178:662, 2011 Murine Gut Dendritic cell Serotonin Yes Increased IL-12 
  
 
Table 2.  serotonin modulates cytokine profile in several mononuclear cells.
anti-inflammatory action is 5-HTR
7
-dependent, as pre-treatment with a 5-HTR
7
-specific antagonist reverted the 
5-HT-dependent inhibition, whereas 5-HTR2B modifiers had no effect on cytokine production. Therefore, the 
anti-inflammatory action of 5-HT in terms of cytokines production seems to be exclusively 5-HTR
7
-dependent. 
In line with our results on in vitro generated macrophages, it has been reported that 5-HT, via 5-HTR
7
, 
negatively regulates TNF-α secretion from mature MDDC  (186) and LPS-activated monocytes (185). Here 
we extend those observations to M2(M-CSF) macrophages. In the case of resolution-phase macrophages, a 
unique macrophage population is capable of secreting pro-inflammatory cytokines at early stages, and anti-
inflammatory cytokines later in the process (25). This particular switch is mediated by cAMP, which inhibits 
TNFα production without affecting IL-10 release (25). Of importance, as mentioned above, we have found a 
similar effect on the cytokine profile through activation of the 5-HT
7
-cAMP-PKA axis. Therefore, our results 
suggest that 5-HT might contribute to inflammation resolution by binding to 5-HT
7
, and that cAMP may be the 
key intracellular molecule that mediates the 5-HT-promoted inhibition of TNFα release. 
99
Regarding 5-HTR
7
, it has been reported that specific agonists of this receptor favour the release of IL-1β and 
IL-8 on both MDDC (186) and monocytes (185). Along this line, we have observed that macrophages pre-
treated with either 5-HT or BW723C86 up-regulate IL-1β mRNA, and that higher levels of LPS-induced IL-1β 
are released from 5-HT-treated macrophages. We postulate that, although IL-1β acts as a pro-inflammatory 
cytokine, its enhanced expression after 5-HT treatment might also exert an inhibitory feed-back activity, as 
it might increase the expression and activity of the 5-HT transport (SERT) (180) on platelets (224), thus 
facilitating 5-HT removal. 
Given the net anti-inflammatory action that 5-HT displays, and in line with the increase of  IL1B mRNA triggered 
by 5-HT, the induction of TREM-1 mRNA levels by 5-HT was also unexpected, because TREM-1 potentiates 
macrophage activation (225) and favours the production of TNFα, IL-6 and IL-8 by colon macrophages (226). 
However, soluble forms of TREM family members (sTREM) have been described (225), and whose generation 
has been explained by either alternative splicing (227) or metalloproteinase-processing of TREM extracellular 
domains (228). Little is known about sTREM-1 functions, but it is thought to negatively regulate TREM-1 
receptor signalling by neutralizing its ligands (225). In fact, it has been proposed that sTREM-1 levels correlate 
positively with IL-10 and negatively with IL-8 in chronic colitis patients (229). Therefore, we hypothesize 
that the enhanced levels of TREM1 mRNA observed after 5-HT treatment might give rise to sTREM-1, an 
hypothesis that we are currently testing. If so, the modulation of TNFα secretion by 5-HT could be partly 
mediated via sTREM-1. 
Altogether, our results extend previous findings on the anti-inflammatory capacity of 5-HT, and provide 
evidences that 5-HTR
7
 is responsible for the change in cytokine profile provoked by 5-HT on human 
macrophages. 
5-hT-inDuceD cell proliFeraTion 
5-HT regulates cell proliferation in various cell types, including hepatocytes (230) and tumor cells (231). 
On the other hand, macrophages are able to secrete several proliferative factors such as EGF (232), vascular 
endothelial growth factor (VEGF) (2, 233), platelet derived growth factor (PDGF), hepatocyte growth factor 
(HGF) (234) or TGF (2). Our results on the 5-HT-controlled gene profile in macrophages have identified 
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epiregulin (EREG), a member of the EGF family of growth factors (235), as a 5-HT-inducible factor, and 
suggest that it might contribute to the control of cell proliferation by 5-HT as we will discuss next. 
The link between 5-HT and cell proliferation has been known for a long time, and is more evident in organs like 
heart and liver, where 5-HT levels have a clear physiopathological influence.  The adult mammalian liver is a 
highly regenerative organ (230). It is capable of rapidly and effectively restoring loss of mass and rebuilding 
complex tissue structures, such as hepatic sinusoids and bile conducts, that are vital for normal liver function 
(236). Both liver regeneration and hepatocyte proliferation are regulated by 5-HT. TPH1-/- hepatectomized 
mice (where lack of TPH1 impairs the 5-HT synthesis in peripheral tissues) display a robust reduction of 
several markers associated to hepatocyte proliferation (237), suggesting that 5-HT is involved in the induction 
of liver regeneration. Of interest, the knock out of SERT in rats, where the 5-HT concentration in platelets is 
very low, showed that 5-HT derived from platelets might not be involved in the proliferative process of the liver 
regeneration (238), that might be exclusively mediated by enterochromaffin cell-derived 5-HT (238) or 5-HT 
from epithelial cells in the bile conduct (Cholangiocytes) (239).  Interestingly, activation of 5-HT2B improves 
animal survival in small liver grafts transplantations (240) and age-associated impairments in regenerative 
capacity (241), further illustrating the involvement of this receptor on 5-HT-promoted cell proliferation. 
We have found that 5-HT2B receptor is expressed on Kupffer cells, localized in liver sinusoids and continuously 
exposed to circulating serotonin in peripheral blood.  Kupffer cells play a key role in liver regeneration and 
repair through the secretion of numerous cytokines that participate in both processes (242). Therefore, it is 
temping to speculate that the presence of 5-HT2B on Kupffer cells might have an impact on liver regeneration. 
Such hypothesis would be supported by the fact that 5-HT and BW723C86 favour the in vitro maintenance of 
the M2 macrophage polarization state (which is characterized by its tissue-repair and cell growth- promoting 
properties), as well as by the 5-HT-induced production of the growth-promoting factor epiregulin. Thus, the 
role that both Kupffer cells and 5-HT play on liver regeneration (and therefore on hepatocyte proliferation) 
might be in part mediated by the 5-HT-inducible growth factor EREG. 
Also related to the link between serotonin and cell growth, the detection of 5-HT2B in immunosuppressive 
tumor-associated macrophages (TAMs) (2) suggests the contribution of serotonin to tumor development (fig. 
12). Besides the fact that serotonin may directly foster tumor cell proliferation in some cases (243-245), the 
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growth of murine colon cancer allografts is dependent on the 5-HT-mediated reduction in MMP12 levels by 
TAMs, that leads to enhanced angiogenesis (179). Our results are in concordance with these observations, 
since we have demonstrated that 5-HT, or BW723C86, promotes a down-regulation of MMP12 mRNA levels. 
Moreover, EREG is up-regulated upon 5-HT, BW723C86 or LP-12 (a specific 5-HT
7
 agonist) treatments in just 
two hours. EREG promotes tumor cell proliferation in several cancer models (235, 246), and EREG levels are 
induced in human patients with colitis-associated cancer (246). It has also been shown that monocyte-derived 
EREG has pro-tumoral effects (235). Therefore, it can be speculated that 5HT-induced EREG up-regulation can 
facilitate tumor cell proliferation and metastasis. Along the same line, the presence of sTREM-1, potentially 
induced by 5-HT in macrophages, correlates with a poor prognosis in patients with non-small cell lung cancer 
(247). Altogether, these observations might contribute to better define the involvement of M2 macrophages 
and serotonin in tumor progression, suggesting that the pro-tumoral actions of M2 macrophages might be 
explained, at least in part, by the increased expression of 5HT-induced factors such as EREG and TREM-1 
(fig. 12). 
Figure 12. Possible role of serotonin on macrophage-dependent tumor promotion.
Pathologies dependent on 5-HT2B, such as pulmonary arterial hypertension (PAH) or valvular heart disease 
(VHD), are associated with abnormal proliferation of vascular smooth muscle cells  (135) or valvular fibroblasts 
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(131), respectively. In line with the potential effect of 5-HT-induced epiregulin in liver regeneration and tumor 
promotion, epiregulin might be also involved in the proliferation of smooth muscle cells and fibroblasts that 
underlie both pathologies. Moreover, in the specific case of PAH, it has been described that 5-HT contributes 
to the pathogenesis through 5-HT2B in bone marrow-derived cells (140) (a group of cells that includes 
macrophages). Besides, several observations point to the possible link between PAH and IFN (248), as type 
II IFN-γ, type I IFN-α and IFN-β activate pulmonary vascular cells to release the vasoconstrictor and pro-
mitogen hormone endothelin-1 (ET-1), that enhances PAH (248). In addition, a positive correlation has been 
established between raised levels of CXCL10 (IP-10) and PAH in patients with systemic sclerosis (249) and, 
in fact, IFN-β1–treated multiple sclerosis patients develop PAH (250, 251). Our gene expression results have 
revealed that stimulation of 5-HT2B with the specific agonist BW723C86 enhanced the mRNA levels of IFNB 
and, moreover, the levels of several IFN-dependent genes, including CXCL10. Therefore, we can speculate 
that macrophages might play an important role in the development of PAH, as stimulation of 5-HT2B might lead 
to enhanced levels of both EREG (that could promote vascular proliferation) and IFNβ/CXCL10 (that might 
exacerbate PAH development). Consequently, our gene expression data have allowed the definition of a link 
between 5-HT and IFN that might be of pathological significance in the case of PAH (fig.13). 
Figure 13. Possible role of serotonin on macrophage-dependent PAH.
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In summary, given the implication of 5-HT in the abnormal cell proliferation that takes place in the 
aforementioned pathologies, we can hypothesize that the 5-HT-inducible growth factor epiregulin might lie at 
the basis of the deleterious cellular proliferation seen in PAH and other 5-HT-associated pathologies.
Serotonin and Wound Healing
M2 macrophages play an important role in wound healing. In this process, platelets and serotonin are well-
defined players (236), so it is tempting to speculate that serotonin released from platelets might directly 
modulate macrophage functions during wound healing. Wound healing is a highly complex and coordinated 
process that can be separated in four distinct phases after tissue injury:
1. Coagulation and homeostasis.
2. Inflammation.
3. Fibro-proliferative process (can eventually be resolved over several weeks or months)
4. Full restorative regeneration of functional tissue.
At initial stages, platelet aggregation at the damaged tissue leads to the release of 5-HT, which then contributes 
to homeostasis due to its vasoactive properties (236). Rapidly, in the following steps, macrophages orchestrate 
the inflammation process by producing high doses of pro-inflammatory cytokines in response to potentially 
damaging exogenous or altered endogenous products (236). Subsequently, and taking our results into 
account, platelet-derived serotonin might act on macrophages to switch their cytokine profile, thus reducing 
the production of pro-inflammatory cytokines (such as TNFα and IL12p40). If so, this event could break 
the balance towards an anti-inflammatory condition, and would lead to a serotonin-mediated inflammation 
resolution. 
In parallel, 5-HT would also stimulate EREG secretion, thus favouring fibroblast and endothelial cell 
proliferation for restoring tissue integrity and functionality. At a later step, the activation of the serotonin 
transport (SERT) by IL-1β, itself an 5HT-inducible cytokine, could represent a mechanism to remove serotonin 
from the serum and to help recovering tissue homeostasis (fig14).  
Altogether, our data demonstrate that 5-HT2B and 5-HT7 are crucial receptors that mediate the skewing effect of 
serotonin on human macrophage polarization, and might also regulate the serotonin-dependent pro-proliferative 
and tissue-repair activity of macrophages during physiological and pathological processes.   
104
ivig anD Macrophages polariZaTion
The immunomodulatory action of IVIg has widened the range of pathologies for which IVIg therapy is either 
approved or has shown benefit (194, 195). Due to its beneficial actions on inflammatory pathologies and its 
ability to limit tumor metastasis (202, 203), we hypothesized that IVIg might also exert its therapeutic action 
through modulation of the macrophage polarization state, whose M2-skewing contributes to physiological 
(inflammation resolution) and pathological (tumor progression and metastasis) processes. We have demonstrated 
that IVIg, via activating Fc receptors, causes an overt M2-to-M1 phenotypic and functional polarization switch 
in human and murine macrophage both in vitro and in vivo. Besides, in murine tumor models, we showed that 
IVIg treatment reduces tumor progression and metastasis, and alters the expression of polarization markers 
in CD11b+ tumor-associated myeloid cells. Given the importance of tumor-associated macrophages for 
tumor progression and dissemination (252), our results establish a sequential link between the IVIg ability to 
modulate macrophage polarization and its anti-tumor effect, suggesting that the pro-inflammatory activities of 
IVIg might have therapeutic relevance.   
Figure 14. Possible role of serotonin and macrophages in wound healing.
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The beneficial effects that, by virtue of their anti-inflammatory activity, high doses of IVIg exert on several 
autoimmune disorders (253, 254), are in concordance with our finding that IVIg-treated M1-macrophages 
exhibit lower LPS-stimulated production of pro-inflammatory cytokines. This indicates that IVIg exert anti-
inflammatory actions within a pro-inflammatory context. However, since IVIg was not able to overtly alter the 
expression of polarization-associated genes, the effect of IVIg on M1 macrophages cannot be really defined as 
a switch in the macrophage polarization state. 
A different picture emerged when analysing the influence of IVIg on M2 macrophages. IVIg administration to 
M2-macrophages led, in fact, to opposite results. In this anti-inflammatory (and hence pro-tumoral) context, 
IVIg exhibited pro-inflammatory and anti-tumoral actions, as it modulated not only the cytokine profile 
(enhancing pro-inflammatory and reducing anti-inflammatory cytokine release), but also the balance of M1 
and M2 polarization markers: whereas IVIg turns off M1 macrophage functional activities, it promotes an M2-
to-M1 polarization switch at the transcriptomic and functional level. In essence, and considering the somewhat 
opposite effects of IVIg on both types of macrophages, it appears that IVIg is capable of exerting both pro-
inflammatory and anti-inflammatory properties, and that the nature of its effects is critically dependent on 
the activation/polarization status of the target macrophages (enhancing pro-inflammatory activities of M2 
macrophages and limiting the pro-inflammatory activity of M1 macrophages).
ivig in TuMor proMoTion anD MeTasTasis    
Tumors are not just a mass of genetically abnormal proliferating cells, but  are now considered as a 
heterogeneous and structurally complex tissue (255). Malignant tumor cells recruit a variety of cell types, 
including fibroblasts, immune inflammatory cells, and endothelial cells, through the production and secretion of 
stimulatory growth factors, chemokines and cytokines (256). This assortment of cells and molecules comprises 
the tumor microenvironment. At later states of the tumor development, anti-tumor immunity within the tumor 
microenvironment can be suppressed by a variety of tumor infiltrating leukocytes, including regulatory T cells 
(Treg) (257), myeloid-derived suppressor cells (MDSC) and M2-macrophages (252, 258).  The mechanisms 
employed by both malignant cancer cells and the immune cell types to suppress effective immunity include 
secretion of cytokines such as TGFβ and IL-10 (252), that promote a Th2 immune response, less effective 
against tumor cells (259). 
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Macrophage plasticity opens the possibility of manipulating tumor-associated immunosuppressive M2 
macrophages to become immuno-stimulatory M1-like macrophages (2). Several strategies that combine 
chemotherapy with specific antibodies (e.g. anti-IL-10 (103), anti-CD40 (260)) synergize in promoting anti-
tumoral effects and are associated with re-polarization of the infiltrating tumor-associated macrophages. 
These macrophage re-polarization would be able to, at least partially, change the tumor microenvironment by 
secreting pro-inflammatory cytokines and chemokines and promote the triggering of a Th1, and therefore anti-
tumoral, type of immune response. Thus, re-programming immunosuppressive myeloid cells (in combination 
with other therapies) constitutes a good strategy against tumor development, and IVIg represents an attractive 
tool for such a purpose.  
The co-existence of autoimmune pathologies and cancer has provided evidences that IVIg therapy promotes 
regression of cancer in patients with chronic lymphatic leukemia, Kaposi´s sarcoma and melanoma (203). 
These findings, together with the effect of IVIg on tumor metastasis in murine cancer models, have led to 
the proposal of IVIg as a potential anti-metastatic agent (203). This anti-metastatic effect has been explained 
by others by either direct effects on endothelial cells (inhibition of NFκB activation) (261), actions on innate 
immune cells like cell cycle arrest (262), induction of IL-12 secretion (263) or inhibition of MMP9 mRNA 
expression (264). Our results point to “modulation of macrophage polarization” as an additional mechanism to 
explain the IVIg´s ability to limit tumor growth and metastasis.
Macrophages are essential cells for tumor progression as they secrete pro-metastatic and pro-angiogenic 
cytokines, chemokines and growth factors into the microenvironment (fig.15).  In the present work we have 
demonstrated that IVIg is capable of switching M2 pro-tumoral macrophages into M1 anti-tumoral macrophages, 
thus favouring the pro-inflammatory actions necessary to confront tumor growing and metastasis (fig.15). We 
have also demonstrated that the anti-tumoral effect of IVIg is exclusively mediated by macrophages. 
Moreover, the detailed analysis of the genetic profile that governs the IVIg-evoked M2-to-M1 polarization 
process revealed that IVIg induces a remarkable decrease in several M2-polarization markers that are 
expressed by TAMs, such as CD209 (67), FOLR2 (65) and HTR2B. Our group has previously reported that 
DC-SIGN triggers macrophage IL-10 production upon interaction with DC-SIGN ligands (e.g., CD15) on 
tumor cells (67). Therefore, we can hypothesize that the IVIg-evoked decrease of DC-SIGN could reduce 
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IL-10 levels in the tumor microenvironment and, therefore, limit the immunosuppressive status of the tumor 
tissue.  Regarding the potential correlation with serotonin, we have observed that IVIg promotes a decrease 
on HTR2B mRNA levels. Thus, we can also speculate the serotonin-driven pro-tumoral effects (e.g., secretion 
of epiregulin, inhibition of IL12p40 and TNFα) would be limited in the presence of IVIg. Interestingly, we 
also observed that M1-marker genes, such as INHBA (71), EGLN3 (72) or MMP12, were induced in M2 
macrophages upon IVIg treatment. Activin A (INHBA) exerts multiple actions, including cancer cell growth 
arrest and M1-polarization. Thus, higher levels of activin A (and EGLN3, which has been described to be 
activin A-dependent (72)) in the tumor microenvironment could help in skewing macrophages towards the M1 
anti-tumoral status. Finally, MMP12 up-regulation by IVIg would also result in inhibition of angiogenesis and 
subsequent reduction of tumor growth and metastasis, since this metalloproteinase has been directly involved 
in the production of the potent anti-angiogenic molecule angiostatin (265).
Figure 15. Possible role of IVIg and macrophages anti-tumoral actions.
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Altogether, our results indicate that IVIg could be considered as a potential immunotherapy agent against 
tumor promotion and metastasis, as it triggers anti-tumoral actions by switching the phenotype and effector 
functions of TAMs into an anti-tumoral polarization state.
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CONCLUSIONS
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1. The serotonin (5-HT) receptors 5-HTR2B and 5-HTR7 are preferentially expressed by in vitro M-CSF-
derived macrophages. 
2. The receptor 5-HTR2B has been identified on human macrophages in vivo, including Kupffer cells and 
Tumor Associated Macrophages (TAM).
3. 5-HT is able to modulate macrophage polarization towards to an M2-like phenotype through both 5-HTR2B 
and 5-HTR
7
.
4. 5-HT and the 5-HTR2B specific agonist BW723C86 modulate the gene expression profile of M-CSF-
conditioned (M2) macrophages.
5. 5-HT modifies the macrophage gene expression profile mostly through the 5-HTR
7
/cAMP/PKA axis.  
6. Activation of 5-HTR2B by BW723C86 regulates the expression of type I IFN-regulated genes. 
7. 5-HT inhibits the LPS-induced secretion of pro-inflammatory cytokines from macrophages via ligation of 
5-HTR
7
.
8. IVIg reduces the LPS-induced secretion of pro-inflammatory cytokines from M1 macrophages without 
significantly affecting the transcriptomic polarization state.
9. IVIg switches the phenotypic and functional polarization of human and murine M2 macrophages towards 
the acquisition of an M1-like state. 
10. The IVIg-induced M2-to-M1 polarization switch is partly CD16-dependent in human macrophages, and 
Fc receptor-mediated in murine macrophages. 
11. IVIg exerts an anti-tumoral activity in murine models of cancer, an effect that is dependent on macrophages
12. IVIg treatment triggers an increase in pro-inflammatory gene markers in intra-tumoral macrophages, as 
well as a change in the basal level of cytokines in the peripheral blood of tumor-bearing animals.
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